From f2e2be178c5eff96acc1a65711ee1ff0b3b8d801 Mon Sep 17 00:00:00 2001
From: Ryan Whaley <whaleyr@pharmgkb.org>
Date: Mon, 11 Mar 2024 12:55:18 -0700
Subject: [PATCH] feat(pharmcat): add FDA PGx association recommendations

- add FDA PGx Assocation recommendation data
- add new DataSourceType class to group recommendation datas
- rename recommendation data files to accommodate two FDA data types
---
 .../org/pharmgkb/pharmcat/BaseConfig.java     |   7 +-
 .../java/org/pharmgkb/pharmcat/Pipeline.java  |   6 +-
 .../pharmcat/reporter/MessageHelper.java      |  13 +-
 .../reporter/PgkbGuidelineCollection.java     |   7 +-
 .../pharmcat/reporter/ReportContext.java      |  25 +-
 .../pharmcat/reporter/format/HtmlFormat.java  |  24 +-
 .../reporter/format/html/Recommendation.java  |  62 +-
 .../pharmcat/reporter/format/html/Report.java |   8 +-
 .../reporter/handlebars/ReportHelpers.java    |  15 +-
 .../pharmcat/reporter/model/DataSource.java   |   2 +-
 .../reporter/model/DataSourceType.java        |  87 +++
 .../pharmcat/reporter/model/ObjectType.java   |  38 +
 .../reporter/model/pgkb/DosingGuideline.java  |  23 +-
 .../reporter/model/pgkb/GuidelinePackage.java |  19 +-
 .../reporter/model/result/DrugReport.java     |  15 +-
 .../model/result/GuidelineReport.java         |  14 +-
 .../pharmgkb/pharmcat/util/DataManager.java   |  25 +-
 ...Annotation__and_CYP2C9_CYP4F2_VKORC1.json} |   1 +
 ...CPIC_Guideline_Annotation__and_IFNL3.json} |   1 +
 ...deline_Annotation_abacavir_and_HLA-B.json} |   3 +-
 ...ine_Annotation_allopurinol_and_HLA-B.json} |   3 +-
 ..._streptomycin_tobramycin_and_MT-RNR1.json} |   3 +-
 ...ion_amitriptyline_and_CYP2C19_CYP2D6.json} |   3 +-
 ...ine_Annotation_atazanavir_and_UGT1A1.json} |   3 +-
 ...ne_Annotation_atomoxetine_and_CYP2D6.json} |   3 +-
 ..._Annotation_atorvastatin_and_SLCO1B1.json} |   3 +-
 ...otation_azathioprine_and_NUDT15_TPMT.json} |   3 +-
 ...ine_Annotation_capecitabine_and_DPYD.json} |   3 +-
 ...tation_carbamazepine_and_HLA-A_HLA-B.json} |   3 +-
 ...ofen_ibuprofen_lornoxicam_and_CYP2C9.json} |   3 +-
 ..._citalopram_escitalopram_and_CYP2C19.json} |   3 +-
 ...tion_clomipramine_and_CYP2C19_CYP2D6.json} |   3 +-
 ...e_Annotation_clopidogrel_and_CYP2C19.json} |   3 +-
 ...deline_Annotation_codeine_and_CYP2D6.json} |   3 +-
 ..._tafenoquine_toluidine_blue_and_G6PD.json} |   3 +-
 ...ane_succinylcholine_and_CACNA1S_RYR1.json} |   3 +-
 ...ne_Annotation_desipramine_and_CYP2D6.json} |   3 +-
 ...notation_dexlansoprazole_and_CYP2C19.json} |   3 +-
 ...nnotation_doxepin_and_CYP2C19_CYP2D6.json} |   3 +-
 ...line_Annotation_efavirenz_and_CYP2B6.json} |   3 +-
 ...ine_Annotation_fluorouracil_and_DPYD.json} |   3 +-
 ...ation_fluvastatin_and_CYP2C9_SLCO1B1.json} |   3 +-
 ...ne_Annotation_fluvoxamine_and_CYP2D6.json} |   3 +-
 ...phenytoin_phenytoin_and_CYP2C9_HLA-B.json} |   3 +-
 ...ne_Annotation_hydrocodone_and_CYP2D6.json} |   3 +-
 ...tation_imipramine_and_CYP2C19_CYP2D6.json} |   3 +-
 ...deline_Annotation_ivacaftor_and_CFTR.json} |   3 +-
 ..._omeprazole_pantoprazole_and_CYP2C19.json} |   3 +-
 ...ne_Annotation_lovastatin_and_SLCO1B1.json} |   3 +-
 ...line_Annotation_meloxicam_and_CYP2C9.json} |   3 +-
 ...ation_mercaptopurine_and_NUDT15_TPMT.json} |   3 +-
 ...e_Annotation_nitrofurantoin_and_G6PD.json} |   3 +-
 ..._Annotation_nortriptyline_and_CYP2D6.json} |   3 +-
 ...ne_Annotation_ondansetron_and_CYP2D6.json} |   3 +-
 ...e_Annotation_oxcarbazepine_and_HLA-B.json} |   3 +-
 ...ine_Annotation_paroxetine_and_CYP2D6.json} |   3 +-
 ...line_Annotation_piroxicam_and_CYP2C9.json} |   3 +-
 ..._Annotation_pitavastatin_and_SLCO1B1.json} |   3 +-
 ...e_Annotation_pravastatin_and_SLCO1B1.json} |   3 +-
 ...eline_Annotation_primaquine_and_G6PD.json} |   3 +-
 ...ation_rosuvastatin_and_ABCG2_SLCO1B1.json} |   3 +-
 ...tation_sertraline_and_CYP2B6_CYP2C19.json} |   3 +-
 ...e_Annotation_simvastatin_and_SLCO1B1.json} |   3 +-
 ...ine_Annotation_tacrolimus_and_CYP3A5.json} |   3 +-
 ...line_Annotation_tamoxifen_and_CYP2D6.json} |   3 +-
 ...line_Annotation_tenoxicam_and_CYP2C9.json} |   3 +-
 ...notation_thioguanine_and_NUDT15_TPMT.json} |   3 +-
 ...eline_Annotation_tramadol_and_CYP2D6.json} |   3 +-
 ...tion_trimipramine_and_CYP2C19_CYP2D6.json} |   3 +-
 ...ne_Annotation_tropisetron_and_CYP2D6.json} |   3 +-
 ...ne_Annotation_venlafaxine_and_CYP2D6.json} |   3 +-
 ..._Annotation_voriconazole_and_CYP2C19.json} |   3 +-
 ...e_Annotation_vortioxetine_and_CYP2D6.json} |   3 +-
 ...deline_Annotation_abacavir_and_HLA-B.json} |   3 +-
 ..._Annotation_acenocoumarol_and_VKORC1.json} |   3 +-
 ...ine_Annotation_allopurinol_and_ABCG2.json} |   3 +-
 ...ine_Annotation_allopurinol_and_HLA-B.json} |   3 +-
 ..._Annotation_amitriptyline_and_CYP2D6.json} |   3 +-
 ...e_Annotation_aripiprazole_and_CYP2D6.json} |   3 +-
 ...ne_Annotation_atomoxetine_and_CYP2D6.json} |   3 +-
 ..._Annotation_atorvastatin_and_SLCO1B1.json} |   3 +-
 ...e_Annotation_azathioprine_and_NUDT15.json} |   3 +-
 ...ine_Annotation_azathioprine_and_TPMT.json} |   3 +-
 ..._Annotation_brexpiprazole_and_CYP2D6.json} |   3 +-
 ...ine_Annotation_capecitabine_and_DPYD.json} |   3 +-
 ...e_Annotation_carbamazepine_and_HLA-A.json} |   3 +-
 ...e_Annotation_carbamazepine_and_HLA-B.json} |   3 +-
 ...ne_Annotation_citalopram_and_CYP2C19.json} |   3 +-
 ..._Annotation_clomipramine_and_CYP2C19.json} |   3 +-
 ...e_Annotation_clomipramine_and_CYP2D6.json} |   3 +-
 ...e_Annotation_clopidogrel_and_CYP2C19.json} |   3 +-
 ...deline_Annotation_codeine_and_CYP2D6.json} |   3 +-
 ...deline_Annotation_doxepin_and_CYP2D6.json} |   3 +-
 ...line_Annotation_efavirenz_and_CYP2B6.json} |   3 +-
 ...ine_Annotation_eliglustat_and_CYP2D6.json} |   3 +-
 ..._Annotation_escitalopram_and_CYP2C19.json} |   3 +-
 ...ine_Annotation_flecainide_and_CYP2D6.json} |   3 +-
 ..._Annotation_flucloxacillin_and_HLA-B.json} |   3 +-
 ...line_Annotation_flucytosine_and_DPYD.json} |   3 +-
 ...ine_Annotation_fluorouracil_and_DPYD.json} |   3 +-
 ...ne_Annotation_haloperidol_and_CYP2D6.json} |   3 +-
 ...ntraceptives_for_systemic_use_and_F5.json} |   3 +-
 ...ne_Annotation_imipramine_and_CYP2C19.json} |   3 +-
 ...ine_Annotation_imipramine_and_CYP2D6.json} |   3 +-
 ...ine_Annotation_irinotecan_and_UGT1A1.json} |   3 +-
 ...ine_Annotation_lamotrigine_and_HLA-B.json} |   3 +-
 ..._Annotation_lansoprazole_and_CYP2C19.json} |   3 +-
 ...Annotation_mercaptopurine_and_NUDT15.json} |   3 +-
 ...e_Annotation_mercaptopurine_and_TPMT.json} |   3 +-
 ...ine_Annotation_metoprolol_and_CYP2D6.json} |   3 +-
 ..._Annotation_nortriptyline_and_CYP2D6.json} |   3 +-
 ...ne_Annotation_omeprazole_and_CYP2C19.json} |   3 +-
 ...e_Annotation_oxcarbazepine_and_HLA-B.json} |   3 +-
 ..._Annotation_pantoprazole_and_CYP2C19.json} |   3 +-
 ...ine_Annotation_paroxetine_and_CYP2D6.json} |   3 +-
 ..._Annotation_phenprocoumon_and_VKORC1.json} |   3 +-
 ...line_Annotation_phenytoin_and_CYP2C9.json} |   3 +-
 ...eline_Annotation_phenytoin_and_HLA-B.json} |   3 +-
 ...eline_Annotation_pimozide_and_CYP2D6.json} |   3 +-
 ...ne_Annotation_propafenone_and_CYP2D6.json} |   3 +-
 ...ine_Annotation_quetiapine_and_CYP3A4.json} |   3 +-
 ...ne_Annotation_risperidone_and_CYP2D6.json} |   3 +-
 ...ne_Annotation_sertraline_and_CYP2C19.json} |   3 +-
 ...e_Annotation_simvastatin_and_SLCO1B1.json} |   3 +-
 ...line_Annotation_siponimod_and_CYP2C9.json} |   3 +-
 ...ine_Annotation_tacrolimus_and_CYP3A5.json} |   3 +-
 ...line_Annotation_tamoxifen_and_CYP2D6.json} |   3 +-
 ...uideline_Annotation_tegafur_and_DPYD.json} |   3 +-
 ...ne_Annotation_thioguanine_and_NUDT15.json} |   3 +-
 ...line_Annotation_thioguanine_and_TPMT.json} |   3 +-
 ...eline_Annotation_tramadol_and_CYP2D6.json} |   3 +-
 ...ne_Annotation_venlafaxine_and_CYP2D6.json} |   3 +-
 ..._Annotation_voriconazole_and_CYP2C19.json} |   3 +-
 ...eline_Annotation_warfarin_and_CYP2C9.json} |   3 +-
 ...eline_Annotation_warfarin_and_VKORC1.json} |   3 +-
 ...Annotation_zuclopenthixol_and_CYP2D6.json} |   3 +-
 ...bic_acid_(vitamin_C),_plain_and_G6PD.json} |   3 +-
 ..._Label_Annotation_abacavir_and_HLA-B.json} |   3 +-
 ...l_Annotation_abrocitinib_and_CYP2C19.json} |   3 +-
 ...caffeine___dihydrocodeine_and_CYP2D6.json} |   3 +-
 ...bel_Annotation_allopurinol_and_HLA-B.json} |   3 +-
 ...l_Annotation_aripiprazole_and_CYP2D6.json} |   3 +-
 ...ion_aripiprazole_lauroxil_and_CYP2D6.json} |   3 +-
 ...icaine___epinephrine_and_CYB5R3_G6PD.json} |   3 +-
 ...el_Annotation_atomoxetine_and_CYP2D6.json} |   3 +-
 ...otation_azathioprine_and_NUDT15_TPMT.json} |   3 +-
 ...bel_Annotation_belinostat_and_UGT1A1.json} |   3 +-
 ...ation_belzutifan_and_CYP2C19_UGT2B17.json} |   3 +-
 ..._Annotation_brexpiprazole_and_CYP2D6.json} |   3 +-
 ..._Annotation_brivaracetam_and_CYP2C19.json} |   3 +-
 ...bel_Annotation_capecitabine_and_DPYD.json} |   3 +-
 ...l_Annotation_carbamazepine_and_HLA-B.json} |   3 +-
 ..._Annotation_carisoprodol_and_CYP2C19.json} |   3 +-
 ...notation_ceftriaxone_and_CYB5R3_G6PD.json} |   3 +-
 ...abel_Annotation_celecoxib_and_CYP2C9.json} |   3 +-
 ...bel_Annotation_cevimeline_and_CYP2D6.json} |   3 +-
 ...abel_Annotation_chloroquine_and_G6PD.json} |   3 +-
 ...l_Annotation_chlorpropamide_and_G6PD.json} |   3 +-
 ...el_Annotation_citalopram_and_CYP2C19.json} |   3 +-
 ...abel_Annotation_clobazam_and_CYP2C19.json} |   3 +-
 ...l_Annotation_clopidogrel_and_CYP2C19.json} |   3 +-
 ...abel_Annotation_clozapine_and_CYP2D6.json} |   3 +-
 ..._Label_Annotation_codeine_and_CYP2D6.json} |   3 +-
 ...notation_desflurane_and_CACNA1S_RYR1.json} |   3 +-
 ...notation_deutetrabenazine_and_CYP2D6.json} |   3 +-
 ...tromethorphan___quinidine_and_CYP2D6.json} |   3 +-
 ...__bupropion_hydrochloride_and_CYP2D6.json} |   3 +-
 ...bel_Annotation_dronabinol_and_CYP2C9.json} |   3 +-
 ...bel_Annotation_eliglustat_and_CYP2D6.json} |   3 +-
 ...el_Annotation_erdafitinib_and_CYP2C9.json} |   3 +-
 ...bel_Annotation_fluorouracil_and_DPYD.json} |   3 +-
 ...l_Annotation_flurbiprofen_and_CYP2C9.json} |   3 +-
 ...osphenytoin_and_CYP2C19_CYP2C9_HLA-B.json} |   3 +-
 ...abel_Annotation_gefitinib_and_CYP2D6.json} |   3 +-
 ...abel_Annotation_glimepiride_and_G6PD.json} |   3 +-
 ..._Label_Annotation_glipizide_and_G6PD.json} |   3 +-
 ..._Label_Annotation_glyburide_and_G6PD.json} |   3 +-
 ...notation_hydroxychloroquine_and_G6PD.json} |   3 +-
 ...el_Annotation_iloperidone_and_CYP2D6.json} |   3 +-
 ...bel_Annotation_irinotecan_and_UGT1A1.json} |   3 +-
 ...notation_isoflurane_and_CACNA1S_RYR1.json} |   3 +-
 ..._Label_Annotation_ivacaftor_and_CFTR.json} |   3 +-
 ...abel_Annotation_lesinurad_and_CYP2C9.json} |   3 +-
 ...on_lidocaine_and_tetracaine_and_G6PD.json} |   3 +-
 ...bel_Annotation_lofexidine_and_CYP2D6.json} |   3 +-
 ...abel_Annotation_meclizine_and_CYP2D6.json} |   3 +-
 ...abel_Annotation_meloxicam_and_CYP2C9.json} |   3 +-
 ...abel_Annotation_mepivacaine_and_G6PD.json} |   3 +-
 ...ation_mercaptopurine_and_NUDT15_TPMT.json} |   3 +-
 ...l_Annotation_methylene_blue_and_G6PD.json} |   3 +-
 ...Annotation_metoclopramide_and_CYP2D6.json} |   3 +-
 ...A_Label_Annotation_moviprep_and_G6PD.json} |   3 +-
 ...l_Annotation_nalidixic_acid_and_G6PD.json} |   3 +-
 ...el_Annotation_oliceridine_and_CYP2D6.json} |   3 +-
 ...l_Annotation_oxcarbazepine_and_HLA-B.json} |   3 +-
 ..._and_tetracaine_and_BCHE_CYB5R3_G6PD.json} |   3 +-
 ..._Annotation_pantoprazole_and_CYP2C19.json} |   3 +-
 ...abel_Annotation_pegloticase_and_G6PD.json} |   3 +-
 ...n_phenytoin_and_CYP2C19_CYP2C9_HLA-B.json} |   3 +-
 ...Label_Annotation_pimozide_and_CYP2D6.json} |   3 +-
 ...abel_Annotation_piroxicam_and_CYP2C9.json} |   3 +-
 ...bel_Annotation_pitolisant_and_CYP2D6.json} |   3 +-
 ...Label_Annotation_primaquine_and_G6PD.json} |   3 +-
 ...abel_Annotation_rasburicase_and_G6PD.json} |   3 +-
 ...ion_sacituzumab_govitecan_and_UGT1A1.json} |   3 +-
 ...otation_sevoflurane_and_CACNA1S_RYR1.json} |   3 +-
 ...abel_Annotation_siponimod_and_CYP2C9.json} |   3 +-
 ...ation_sodium_nitrite_and_CYB5R3_G6PD.json} |   3 +-
 ...uccinylcholine_and_BCHE_CACNA1S_RYR1.json} |   3 +-
 ...notation_sulfasalazine_and_G6PD_NAT2.json} |   3 +-
 ...abel_Annotation_tafenoquine_and_G6PD.json} |   3 +-
 ...bel_Annotation_tamsulosin_and_CYP2D6.json} |   3 +-
 ..._Annotation_tetrabenazine_and_CYP2D6.json} |   3 +-
 ...notation_thioguanine_and_NUDT15_TPMT.json} |   3 +-
 ...l_Annotation_thioridazine_and_CYP2D6.json} |   3 +-
 ...Label_Annotation_tolazamide_and_G6PD.json} |   3 +-
 ...abel_Annotation_tolbutamide_and_G6PD.json} |   3 +-
 ...Label_Annotation_tramadol_and_CYP2D6.json} |   3 +-
 ...el_Annotation_valbenazine_and_CYP2D6.json} |   3 +-
 ...l_Annotation_vortioxetine_and_CYP2D6.json} |   3 +-
 ...arfarin_and_CYP2C9_PROC_PROS1_VKORC1.json} |   3 +-
 ...DA_PGx_Association_abacavir_and_HLA-B.json |  53 ++
 ...x_Association_abrocitinib_and_CYP2C19.json |  77 ++
 ...PGx_Association_allopurinol_and_HLA-B.json |  53 ++
 ..._Association_amitriptyline_and_CYP2D6.json | 413 ++++++++++
 ..._PGx_Association_amoxapine_and_CYP2D6.json | 413 ++++++++++
 ...Gx_Association_amphetamine_and_CYP2D6.json |  53 ++
 ...x_Association_aripiprazole_and_CYP2D6.json |  53 ++
 ...tion_aripiprazole_lauroxil_and_CYP2D6.json |  53 ++
 ...Gx_Association_atomoxetine_and_CYP2D6.json |  53 ++
 ..._Association_atorvastatin_and_SLCO1B1.json |  53 ++
 ...x_Association_avatrombopag_and_CYP2C9.json | 125 +++
 ...ociation_azathioprine_and_NUDT15_TPMT.json | 709 ++++++++++++++++++
 ...PGx_Association_belinostat_and_UGT1A1.json |  53 ++
 ...iation_belzutifan_and_CYP2C19_UGT2B17.json |  82 ++
 ..._Association_brexpiprazole_and_CYP2D6.json |  53 ++
 ..._Association_brivaracetam_and_CYP2C19.json | 125 +++
 ...PGx_Association_capecitabine_and_DPYD.json | 125 +++
 ...x_Association_carbamazepine_and_HLA-A.json |  53 ++
 ...x_Association_carbamazepine_and_HLA-B.json |  53 ++
 ..._Association_carisoprodol_and_CYP2C19.json |  77 ++
 ...PGx_Association_carvedilol_and_CYP2D6.json |  53 ++
 ..._PGx_Association_celecoxib_and_CYP2C9.json | 104 +++
 ...PGx_Association_cevimeline_and_CYP2D6.json |  53 ++
 ...Gx_Association_citalopram_and_CYP2C19.json |  77 ++
 ..._PGx_Association_clobazam_and_CYP2C19.json | 125 +++
 ...x_Association_clomipramine_and_CYP2D6.json | 437 +++++++++++
 ...x_Association_clopidogrel_and_CYP2C19.json | 125 +++
 ..._PGx_Association_clozapine_and_CYP2D6.json |  53 ++
 ...DA_PGx_Association_codeine_and_CYP2D6.json |  53 ++
 ...Gx_Association_darifenacin_and_CYP2D6.json |  53 ++
 ...Gx_Association_desipramine_and_CYP2D6.json | 413 ++++++++++
 ...sociation_deutetrabenazine_and_CYP2D6.json |  53 ++
 ...sociation_dexlansoprazole_and_CYP2C19.json | 125 +++
 ..._PGx_Association_diazepam_and_CYP2C19.json |  77 ++
 ...x_Association_dolutegravir_and_UGT1A1.json |  53 ++
 ..._PGx_Association_donepezil_and_CYP2D6.json | 317 ++++++++
 ...A_PGx_Association_doxepin_and_CYP2C19.json | 125 +++
 ...DA_PGx_Association_doxepin_and_CYP2D6.json | 413 ++++++++++
 ...PGx_Association_dronabinol_and_CYP2C9.json | 125 +++
 ..._PGx_Association_efavirenz_and_CYP2B6.json |  53 ++
 ..._PGx_Association_elagolix_and_SLCO1B1.json |  53 ++
 ...PGx_Association_eliglustat_and_CYP2D6.json | 533 +++++++++++++
 ...Gx_Association_erdafitinib_and_CYP2C9.json |  77 ++
 ..._Association_escitalopram_and_CYP2C19.json | 149 ++++
 ..._Association_esomeprazole_and_CYP2C19.json |  77 ++
 ...x_Association_fesoterodine_and_CYP2D6.json |  53 ++
 ...x_Association_flibanserin_and_CYP2C19.json |  77 ++
 ...PGx_Association_fluorouracil_and_DPYD.json | 125 +++
 ...x_Association_flurbiprofen_and_CYP2C9.json | 104 +++
 ...Gx_Association_fluvoxamine_and_CYP2D6.json |  53 ++
 ...x_Association_fosphenytoin_and_CYP2C9.json | 125 +++
 ...Gx_Association_fosphenytoin_and_HLA-B.json |  53 ++
 ...Gx_Association_galantamine_and_CYP2D6.json |  53 ++
 ..._PGx_Association_gefitinib_and_CYP2D6.json |  53 ++
 ..._PGx_Association_ibuprofen_and_CYP2C9.json |  77 ++
 ...Gx_Association_iloperidone_and_CYP2D6.json |  53 ++
 ...PGx_Association_imipramine_and_CYP2D6.json | 413 ++++++++++
 ...PGx_Association_irinotecan_and_UGT1A1.json |  77 ++
 ..._Association_lansoprazole_and_CYP2C19.json |  77 ++
 ...PGx_Association_lofexidine_and_CYP2D6.json |  53 ++
 ...Gx_Association_mavacamten_and_CYP2C19.json | 125 +++
 ..._PGx_Association_meclizine_and_CYP2D6.json | 413 ++++++++++
 ..._PGx_Association_meloxicam_and_CYP2C9.json | 104 +++
 ...iation_mercaptopurine_and_NUDT15_TPMT.json | 709 ++++++++++++++++++
 ...Association_metoclopramide_and_CYP2D6.json |  53 ++
 ...PGx_Association_metoprolol_and_CYP2D6.json |  53 ++
 ...PGx_Association_mirabegron_and_CYP2D6.json |  53 ++
 ...Gx_Association_nateglinide_and_CYP2C9.json |  77 ++
 ..._PGx_Association_nebivolol_and_CYP2D6.json |  53 ++
 ..._PGx_Association_nilotinib_and_UGT1A1.json |  53 ++
 ..._Association_nortriptyline_and_CYP2D6.json | 413 ++++++++++
 ...Gx_Association_oliceridine_and_CYP2D6.json |  53 ++
 ...Gx_Association_omeprazole_and_CYP2C19.json | 125 +++
 ...x_Association_oxcarbazepine_and_HLA-B.json |  53 ++
 ..._Association_pantoprazole_and_CYP2C19.json | 125 +++
 ...PGx_Association_paroxetine_and_CYP2D6.json | 413 ++++++++++
 ...A_PGx_Association_pazopanib_and_HLA-B.json |  53 ++
 ..._PGx_Association_pazopanib_and_UGT1A1.json |  53 ++
 ...x_Association_perphenazine_and_CYP2D6.json |  53 ++
 ..._PGx_Association_phenytoin_and_CYP2C9.json | 125 +++
 ...A_PGx_Association_phenytoin_and_HLA-B.json |  53 ++
 ...A_PGx_Association_pimozide_and_CYP2D6.json |  77 ++
 ..._PGx_Association_piroxicam_and_CYP2C9.json | 125 +++
 ...PGx_Association_pitolisant_and_CYP2D6.json |  53 ++
 ...Gx_Association_propafenone_and_CYP2D6.json |  53 ++
 ...Gx_Association_propranolol_and_CYP2D6.json |  53 ++
 ..._Association_protriptyline_and_CYP2D6.json |  53 ++
 ...x_Association_rabeprazole_and_CYP2C19.json |  77 ++
 ...Gx_Association_raltegravir_and_UGT1A1.json |  53 ++
 ...Gx_Association_risperidone_and_CYP2D6.json |  53 ++
 ..._Association_rosuvastatin_and_SLCO1B1.json |  53 ++
 ...tion_sacituzumab_govitecan_and_UGT1A1.json |  53 ++
 ...x_Association_simvastatin_and_SLCO1B1.json | 101 +++
 ..._PGx_Association_siponimod_and_CYP2C9.json | 125 +++
 ...PGx_Association_tacrolimus_and_CYP3A5.json | 101 +++
 ..._PGx_Association_tamoxifen_and_CYP2D6.json | 149 ++++
 ...PGx_Association_tamsulosin_and_CYP2D6.json |  53 ++
 ..._Association_tetrabenazine_and_CYP2D6.json |  53 ++
 ...sociation_thioguanine_and_NUDT15_TPMT.json | 709 ++++++++++++++++++
 ...x_Association_thioridazine_and_CYP2D6.json |  53 ++
 ...Gx_Association_tolterodine_and_CYP2D6.json |  53 ++
 ...A_PGx_Association_tramadol_and_CYP2D6.json | 293 ++++++++
 ...x_Association_trimipramine_and_CYP2D6.json | 413 ++++++++++
 ...Gx_Association_valbenazine_and_CYP2D6.json |  53 ++
 ...Gx_Association_venlafaxine_and_CYP2D6.json |  53 ++
 ...PGx_Association_viloxazine_and_CYP2D6.json |  53 ++
 ..._Association_voriconazole_and_CYP2C19.json | 125 +++
 ...x_Association_vortioxetine_and_CYP2D6.json |  53 ++
 ...A_PGx_Association_warfarin_and_CYP2C9.json | 125 +++
 ...A_PGx_Association_warfarin_and_VKORC1.json |  77 ++
 .../org/pharmgkb/pharmcat/reporter/report.hbs |   2 +-
 .../org/pharmgkb/pharmcat/Cacna1sTest.java    |   9 +-
 .../java/org/pharmgkb/pharmcat/DpydTest.java  |  25 +-
 .../org/pharmgkb/pharmcat/PipelineTest.java   | 195 ++---
 .../pharmgkb/pharmcat/PipelineWrapper.java    |  27 +-
 .../java/org/pharmgkb/pharmcat/Ryr1Test.java  |   5 +-
 .../pharmgkb/pharmcat/SyntheticBatchTest.java |  47 +-
 .../org/pharmgkb/pharmcat/ToxicGenesTest.java |  15 +-
 339 files changed, 15368 insertions(+), 463 deletions(-)
 create mode 100644 src/main/java/org/pharmgkb/pharmcat/reporter/model/DataSourceType.java
 create mode 100644 src/main/java/org/pharmgkb/pharmcat/reporter/model/ObjectType.java
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_warfarin_and_CYP2C9_CYP4F2_VKORC1.json => CPIC_Guideline_Annotation__and_CYP2C9_CYP4F2_VKORC1.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_peginterferon_alfa_2a_peginterferon_alfa_2b_ribavirin_and_IFNL3.json => CPIC_Guideline_Annotation__and_IFNL3.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_abacavir_and_HLA_B.json => CPIC_Guideline_Annotation_abacavir_and_HLA-B.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_allopurinol_and_HLA_B.json => CPIC_Guideline_Annotation_allopurinol_and_HLA-B.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_amikacin_gentamicin_kanamycin_paromomycin_plazomicin_streptomycin_tobramycin_and_MT_RNR1.json => CPIC_Guideline_Annotation_amikacin_gentamicin_kanamycin_paromomycin_plazomicin_streptomycin_tobramycin_and_MT-RNR1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_amitriptyline_and_CYP2C19_CYP2D6.json => CPIC_Guideline_Annotation_amitriptyline_and_CYP2C19_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_atazanavir_and_UGT1A1.json => CPIC_Guideline_Annotation_atazanavir_and_UGT1A1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_atomoxetine_and_CYP2D6.json => CPIC_Guideline_Annotation_atomoxetine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_atorvastatin_and_SLCO1B1.json => CPIC_Guideline_Annotation_atorvastatin_and_SLCO1B1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_azathioprine_and_NUDT15_TPMT.json => CPIC_Guideline_Annotation_azathioprine_and_NUDT15_TPMT.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_capecitabine_and_DPYD.json => CPIC_Guideline_Annotation_capecitabine_and_DPYD.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_carbamazepine_and_HLA_A_HLA_B.json => CPIC_Guideline_Annotation_carbamazepine_and_HLA-A_HLA-B.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_celecoxib_flurbiprofen_ibuprofen_lornoxicam_and_CYP2C9.json => CPIC_Guideline_Annotation_celecoxib_flurbiprofen_ibuprofen_lornoxicam_and_CYP2C9.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_citalopram_escitalopram_and_CYP2C19.json => CPIC_Guideline_Annotation_citalopram_escitalopram_and_CYP2C19.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_clomipramine_and_CYP2C19_CYP2D6.json => CPIC_Guideline_Annotation_clomipramine_and_CYP2C19_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_clopidogrel_and_CYP2C19.json => CPIC_Guideline_Annotation_clopidogrel_and_CYP2C19.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_codeine_and_CYP2D6.json => CPIC_Guideline_Annotation_codeine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_dapsone_methylene_blue_pegloticase_rasburicase_tafenoquine_toluidine_blue_and_G6PD.json => CPIC_Guideline_Annotation_dapsone_methylene_blue_pegloticase_rasburicase_tafenoquine_toluidine_blue_and_G6PD.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_succinylcholine_and_CACNA1S_RYR1.json => CPIC_Guideline_Annotation_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_succinylcholine_and_CACNA1S_RYR1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_desipramine_and_CYP2D6.json => CPIC_Guideline_Annotation_desipramine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_dexlansoprazole_and_CYP2C19.json => CPIC_Guideline_Annotation_dexlansoprazole_and_CYP2C19.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_doxepin_and_CYP2C19_CYP2D6.json => CPIC_Guideline_Annotation_doxepin_and_CYP2C19_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_efavirenz_and_CYP2B6.json => CPIC_Guideline_Annotation_efavirenz_and_CYP2B6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_fluorouracil_and_DPYD.json => CPIC_Guideline_Annotation_fluorouracil_and_DPYD.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_fluvastatin_and_CYP2C9_SLCO1B1.json => CPIC_Guideline_Annotation_fluvastatin_and_CYP2C9_SLCO1B1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_fluvoxamine_and_CYP2D6.json => CPIC_Guideline_Annotation_fluvoxamine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_fosphenytoin_phenytoin_and_CYP2C9_HLA_B.json => CPIC_Guideline_Annotation_fosphenytoin_phenytoin_and_CYP2C9_HLA-B.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_hydrocodone_and_CYP2D6.json => CPIC_Guideline_Annotation_hydrocodone_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_imipramine_and_CYP2C19_CYP2D6.json => CPIC_Guideline_Annotation_imipramine_and_CYP2C19_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_ivacaftor_and_CFTR.json => CPIC_Guideline_Annotation_ivacaftor_and_CFTR.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_lansoprazole_omeprazole_pantoprazole_and_CYP2C19.json => CPIC_Guideline_Annotation_lansoprazole_omeprazole_pantoprazole_and_CYP2C19.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_lovastatin_and_SLCO1B1.json => CPIC_Guideline_Annotation_lovastatin_and_SLCO1B1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_meloxicam_and_CYP2C9.json => CPIC_Guideline_Annotation_meloxicam_and_CYP2C9.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_mercaptopurine_and_NUDT15_TPMT.json => CPIC_Guideline_Annotation_mercaptopurine_and_NUDT15_TPMT.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_nitrofurantoin_and_G6PD.json => CPIC_Guideline_Annotation_nitrofurantoin_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_nortriptyline_and_CYP2D6.json => CPIC_Guideline_Annotation_nortriptyline_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_ondansetron_and_CYP2D6.json => CPIC_Guideline_Annotation_ondansetron_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_oxcarbazepine_and_HLA_B.json => CPIC_Guideline_Annotation_oxcarbazepine_and_HLA-B.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_paroxetine_and_CYP2D6.json => CPIC_Guideline_Annotation_paroxetine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_piroxicam_and_CYP2C9.json => CPIC_Guideline_Annotation_piroxicam_and_CYP2C9.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_pitavastatin_and_SLCO1B1.json => CPIC_Guideline_Annotation_pitavastatin_and_SLCO1B1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_pravastatin_and_SLCO1B1.json => CPIC_Guideline_Annotation_pravastatin_and_SLCO1B1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_primaquine_and_G6PD.json => CPIC_Guideline_Annotation_primaquine_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_rosuvastatin_and_ABCG2_SLCO1B1.json => CPIC_Guideline_Annotation_rosuvastatin_and_ABCG2_SLCO1B1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_sertraline_and_CYP2B6_CYP2C19.json => CPIC_Guideline_Annotation_sertraline_and_CYP2B6_CYP2C19.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_simvastatin_and_SLCO1B1.json => CPIC_Guideline_Annotation_simvastatin_and_SLCO1B1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_tacrolimus_and_CYP3A5.json => CPIC_Guideline_Annotation_tacrolimus_and_CYP3A5.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_tamoxifen_and_CYP2D6.json => CPIC_Guideline_Annotation_tamoxifen_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_tenoxicam_and_CYP2C9.json => CPIC_Guideline_Annotation_tenoxicam_and_CYP2C9.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_thioguanine_and_NUDT15_TPMT.json => CPIC_Guideline_Annotation_thioguanine_and_NUDT15_TPMT.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_tramadol_and_CYP2D6.json => CPIC_Guideline_Annotation_tramadol_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_trimipramine_and_CYP2C19_CYP2D6.json => CPIC_Guideline_Annotation_trimipramine_and_CYP2C19_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_tropisetron_and_CYP2D6.json => CPIC_Guideline_Annotation_tropisetron_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_venlafaxine_and_CYP2D6.json => CPIC_Guideline_Annotation_venlafaxine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_voriconazole_and_CYP2C19.json => CPIC_Guideline_Annotation_voriconazole_and_CYP2C19.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{CPIC_vortioxetine_and_CYP2D6.json => CPIC_Guideline_Annotation_vortioxetine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_abacavir_and_HLA_B.json => DPWG_Guideline_Annotation_abacavir_and_HLA-B.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_acenocoumarol_and_VKORC1.json => DPWG_Guideline_Annotation_acenocoumarol_and_VKORC1.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_allopurinol_and_ABCG2.json => DPWG_Guideline_Annotation_allopurinol_and_ABCG2.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_allopurinol_and_HLA_B.json => DPWG_Guideline_Annotation_allopurinol_and_HLA-B.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_amitriptyline_and_CYP2D6.json => DPWG_Guideline_Annotation_amitriptyline_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_aripiprazole_and_CYP2D6.json => DPWG_Guideline_Annotation_aripiprazole_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_atomoxetine_and_CYP2D6.json => DPWG_Guideline_Annotation_atomoxetine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_atorvastatin_and_SLCO1B1.json => DPWG_Guideline_Annotation_atorvastatin_and_SLCO1B1.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_azathioprine_and_NUDT15.json => DPWG_Guideline_Annotation_azathioprine_and_NUDT15.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_azathioprine_and_TPMT.json => DPWG_Guideline_Annotation_azathioprine_and_TPMT.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_brexpiprazole_and_CYP2D6.json => DPWG_Guideline_Annotation_brexpiprazole_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_capecitabine_and_DPYD.json => DPWG_Guideline_Annotation_capecitabine_and_DPYD.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_carbamazepine_and_HLA_A.json => DPWG_Guideline_Annotation_carbamazepine_and_HLA-A.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_carbamazepine_and_HLA_B.json => DPWG_Guideline_Annotation_carbamazepine_and_HLA-B.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_citalopram_and_CYP2C19.json => DPWG_Guideline_Annotation_citalopram_and_CYP2C19.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_clomipramine_and_CYP2C19.json => DPWG_Guideline_Annotation_clomipramine_and_CYP2C19.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_clomipramine_and_CYP2D6.json => DPWG_Guideline_Annotation_clomipramine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_clopidogrel_and_CYP2C19.json => DPWG_Guideline_Annotation_clopidogrel_and_CYP2C19.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_codeine_and_CYP2D6.json => DPWG_Guideline_Annotation_codeine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_doxepin_and_CYP2D6.json => DPWG_Guideline_Annotation_doxepin_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_efavirenz_and_CYP2B6.json => DPWG_Guideline_Annotation_efavirenz_and_CYP2B6.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_eliglustat_and_CYP2D6.json => DPWG_Guideline_Annotation_eliglustat_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_escitalopram_and_CYP2C19.json => DPWG_Guideline_Annotation_escitalopram_and_CYP2C19.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_flecainide_and_CYP2D6.json => DPWG_Guideline_Annotation_flecainide_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_flucloxacillin_and_HLA_B.json => DPWG_Guideline_Annotation_flucloxacillin_and_HLA-B.json} (95%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_flucytosine_and_DPYD.json => DPWG_Guideline_Annotation_flucytosine_and_DPYD.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_fluorouracil_and_DPYD.json => DPWG_Guideline_Annotation_fluorouracil_and_DPYD.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_haloperidol_and_CYP2D6.json => DPWG_Guideline_Annotation_haloperidol_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_hormonal_contraceptives_for_systemic_use_and_F5.json => DPWG_Guideline_Annotation_hormonal_contraceptives_for_systemic_use_and_F5.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_imipramine_and_CYP2C19.json => DPWG_Guideline_Annotation_imipramine_and_CYP2C19.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_imipramine_and_CYP2D6.json => DPWG_Guideline_Annotation_imipramine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_irinotecan_and_UGT1A1.json => DPWG_Guideline_Annotation_irinotecan_and_UGT1A1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_lamotrigine_and_HLA_B.json => DPWG_Guideline_Annotation_lamotrigine_and_HLA-B.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_lansoprazole_and_CYP2C19.json => DPWG_Guideline_Annotation_lansoprazole_and_CYP2C19.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_mercaptopurine_and_NUDT15.json => DPWG_Guideline_Annotation_mercaptopurine_and_NUDT15.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_mercaptopurine_and_TPMT.json => DPWG_Guideline_Annotation_mercaptopurine_and_TPMT.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_metoprolol_and_CYP2D6.json => DPWG_Guideline_Annotation_metoprolol_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_nortriptyline_and_CYP2D6.json => DPWG_Guideline_Annotation_nortriptyline_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_omeprazole_and_CYP2C19.json => DPWG_Guideline_Annotation_omeprazole_and_CYP2C19.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_oxcarbazepine_and_HLA_B.json => DPWG_Guideline_Annotation_oxcarbazepine_and_HLA-B.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_pantoprazole_and_CYP2C19.json => DPWG_Guideline_Annotation_pantoprazole_and_CYP2C19.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_paroxetine_and_CYP2D6.json => DPWG_Guideline_Annotation_paroxetine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_phenprocoumon_and_VKORC1.json => DPWG_Guideline_Annotation_phenprocoumon_and_VKORC1.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_phenytoin_and_CYP2C9.json => DPWG_Guideline_Annotation_phenytoin_and_CYP2C9.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_phenytoin_and_HLA_B.json => DPWG_Guideline_Annotation_phenytoin_and_HLA-B.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_pimozide_and_CYP2D6.json => DPWG_Guideline_Annotation_pimozide_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_propafenone_and_CYP2D6.json => DPWG_Guideline_Annotation_propafenone_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_quetiapine_and_CYP3A4.json => DPWG_Guideline_Annotation_quetiapine_and_CYP3A4.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_risperidone_and_CYP2D6.json => DPWG_Guideline_Annotation_risperidone_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_sertraline_and_CYP2C19.json => DPWG_Guideline_Annotation_sertraline_and_CYP2C19.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_simvastatin_and_SLCO1B1.json => DPWG_Guideline_Annotation_simvastatin_and_SLCO1B1.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_siponimod_and_CYP2C9.json => DPWG_Guideline_Annotation_siponimod_and_CYP2C9.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_tacrolimus_and_CYP3A5.json => DPWG_Guideline_Annotation_tacrolimus_and_CYP3A5.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_tamoxifen_and_CYP2D6.json => DPWG_Guideline_Annotation_tamoxifen_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_tegafur_and_DPYD.json => DPWG_Guideline_Annotation_tegafur_and_DPYD.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_thioguanine_and_NUDT15.json => DPWG_Guideline_Annotation_thioguanine_and_NUDT15.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_thioguanine_and_TPMT.json => DPWG_Guideline_Annotation_thioguanine_and_TPMT.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_tramadol_and_CYP2D6.json => DPWG_Guideline_Annotation_tramadol_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_venlafaxine_and_CYP2D6.json => DPWG_Guideline_Annotation_venlafaxine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_voriconazole_and_CYP2C19.json => DPWG_Guideline_Annotation_voriconazole_and_CYP2C19.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_warfarin_and_CYP2C9.json => DPWG_Guideline_Annotation_warfarin_and_CYP2C9.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_warfarin_and_VKORC1.json => DPWG_Guideline_Annotation_warfarin_and_VKORC1.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{DPWG_zuclopenthixol_and_CYP2D6.json => DPWG_Guideline_Annotation_zuclopenthixol_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_Ascorbic_acid_vitamin_C_combinations_Ascorbic_acid_vitamin_C_plain_sodium_ascorbate_and_G6PD.json => FDA_Label_Annotation_Ascorbic_acid_(vitamin_C),_plain_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_abacavir_and_HLA_B.json => FDA_Label_Annotation_abacavir_and_HLA-B.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_abrocitinib_and_CYP2C19.json => FDA_Label_Annotation_abrocitinib_and_CYP2C19.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_acetaminophen_caffeine_dihydrocodeine_and_CYP2D6.json => FDA_Label_Annotation_acetaminophen___caffeine___dihydrocodeine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_allopurinol_and_HLA_B.json => FDA_Label_Annotation_allopurinol_and_HLA-B.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_aripiprazole_and_CYP2D6.json => FDA_Label_Annotation_aripiprazole_and_CYP2D6.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_aripiprazole_lauroxil_and_CYP2D6.json => FDA_Label_Annotation_aripiprazole_lauroxil_and_CYP2D6.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_articaine_epinephrine_and_CYB5R3_G6PD.json => FDA_Label_Annotation_articaine___epinephrine_and_CYB5R3_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_atomoxetine_and_CYP2D6.json => FDA_Label_Annotation_atomoxetine_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_azathioprine_and_NUDT15_TPMT.json => FDA_Label_Annotation_azathioprine_and_NUDT15_TPMT.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_belinostat_and_UGT1A1.json => FDA_Label_Annotation_belinostat_and_UGT1A1.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_belzutifan_and_CYP2C19_UGT2B17.json => FDA_Label_Annotation_belzutifan_and_CYP2C19_UGT2B17.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_brexpiprazole_and_CYP2D6.json => FDA_Label_Annotation_brexpiprazole_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_brivaracetam_and_CYP2C19.json => FDA_Label_Annotation_brivaracetam_and_CYP2C19.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_capecitabine_and_DPYD.json => FDA_Label_Annotation_capecitabine_and_DPYD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_carbamazepine_and_HLA_B.json => FDA_Label_Annotation_carbamazepine_and_HLA-B.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_carisoprodol_and_CYP2C19.json => FDA_Label_Annotation_carisoprodol_and_CYP2C19.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_ceftriaxone_and_CYB5R3_G6PD.json => FDA_Label_Annotation_ceftriaxone_and_CYB5R3_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_celecoxib_and_CYP2C9.json => FDA_Label_Annotation_celecoxib_and_CYP2C9.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_cevimeline_and_CYP2D6.json => FDA_Label_Annotation_cevimeline_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_chloroquine_and_G6PD.json => FDA_Label_Annotation_chloroquine_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_chlorpropamide_and_G6PD.json => FDA_Label_Annotation_chlorpropamide_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_citalopram_and_CYP2C19.json => FDA_Label_Annotation_citalopram_and_CYP2C19.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_clobazam_and_CYP2C19.json => FDA_Label_Annotation_clobazam_and_CYP2C19.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_clopidogrel_and_CYP2C19.json => FDA_Label_Annotation_clopidogrel_and_CYP2C19.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_clozapine_and_CYP2D6.json => FDA_Label_Annotation_clozapine_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_codeine_and_CYP2D6.json => FDA_Label_Annotation_codeine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_desflurane_and_CACNA1S_RYR1.json => FDA_Label_Annotation_desflurane_and_CACNA1S_RYR1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_deutetrabenazine_and_CYP2D6.json => FDA_Label_Annotation_deutetrabenazine_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_dextromethorphan_quinidine_and_CYP2D6.json => FDA_Label_Annotation_dextromethorphan___quinidine_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_dextromethorphan_hydrobromide_bupropion_hydrochloride_and_CYP2D6.json => FDA_Label_Annotation_dextromethorphan_hydrobromide___bupropion_hydrochloride_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_dronabinol_and_CYP2C9.json => FDA_Label_Annotation_dronabinol_and_CYP2C9.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_eliglustat_and_CYP2D6.json => FDA_Label_Annotation_eliglustat_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_erdafitinib_and_CYP2C9.json => FDA_Label_Annotation_erdafitinib_and_CYP2C9.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_fluorouracil_and_DPYD.json => FDA_Label_Annotation_fluorouracil_and_DPYD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_flurbiprofen_and_CYP2C9.json => FDA_Label_Annotation_flurbiprofen_and_CYP2C9.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_fosphenytoin_and_CYP2C19_CYP2C9_HLA_B.json => FDA_Label_Annotation_fosphenytoin_and_CYP2C19_CYP2C9_HLA-B.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_gefitinib_and_CYP2D6.json => FDA_Label_Annotation_gefitinib_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_glimepiride_and_G6PD.json => FDA_Label_Annotation_glimepiride_and_G6PD.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_glipizide_and_G6PD.json => FDA_Label_Annotation_glipizide_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_glyburide_and_G6PD.json => FDA_Label_Annotation_glyburide_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_hydroxychloroquine_and_G6PD.json => FDA_Label_Annotation_hydroxychloroquine_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_iloperidone_and_CYP2D6.json => FDA_Label_Annotation_iloperidone_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_irinotecan_and_UGT1A1.json => FDA_Label_Annotation_irinotecan_and_UGT1A1.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_isoflurane_and_CACNA1S_RYR1.json => FDA_Label_Annotation_isoflurane_and_CACNA1S_RYR1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_ivacaftor_and_CFTR.json => FDA_Label_Annotation_ivacaftor_and_CFTR.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_lesinurad_and_CYP2C9.json => FDA_Label_Annotation_lesinurad_and_CYP2C9.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_lidocaine_and_tetracaine_and_G6PD.json => FDA_Label_Annotation_lidocaine_and_tetracaine_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_lofexidine_and_CYP2D6.json => FDA_Label_Annotation_lofexidine_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_meclizine_and_CYP2D6.json => FDA_Label_Annotation_meclizine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_meloxicam_and_CYP2C9.json => FDA_Label_Annotation_meloxicam_and_CYP2C9.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_mepivacaine_and_G6PD.json => FDA_Label_Annotation_mepivacaine_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_mercaptopurine_and_NUDT15_TPMT.json => FDA_Label_Annotation_mercaptopurine_and_NUDT15_TPMT.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_methylene_blue_and_G6PD.json => FDA_Label_Annotation_methylene_blue_and_G6PD.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_metoclopramide_and_CYP2D6.json => FDA_Label_Annotation_metoclopramide_and_CYP2D6.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_moviprep_and_G6PD.json => FDA_Label_Annotation_moviprep_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_nalidixic_acid_and_G6PD.json => FDA_Label_Annotation_nalidixic_acid_and_G6PD.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_oliceridine_and_CYP2D6.json => FDA_Label_Annotation_oliceridine_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_oxcarbazepine_and_HLA_B.json => FDA_Label_Annotation_oxcarbazepine_and_HLA-B.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_oxymetazoline_and_tetracaine_and_BCHE_CYB5R3_G6PD.json => FDA_Label_Annotation_oxymetazoline_and_tetracaine_and_BCHE_CYB5R3_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_pantoprazole_and_CYP2C19.json => FDA_Label_Annotation_pantoprazole_and_CYP2C19.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_pegloticase_and_G6PD.json => FDA_Label_Annotation_pegloticase_and_G6PD.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_phenytoin_and_CYP2C19_CYP2C9_HLA_B.json => FDA_Label_Annotation_phenytoin_and_CYP2C19_CYP2C9_HLA-B.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_pimozide_and_CYP2D6.json => FDA_Label_Annotation_pimozide_and_CYP2D6.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_piroxicam_and_CYP2C9.json => FDA_Label_Annotation_piroxicam_and_CYP2C9.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_pitolisant_and_CYP2D6.json => FDA_Label_Annotation_pitolisant_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_primaquine_and_G6PD.json => FDA_Label_Annotation_primaquine_and_G6PD.json} (97%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_rasburicase_and_G6PD.json => FDA_Label_Annotation_rasburicase_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_sacituzumab_govitecan_and_UGT1A1.json => FDA_Label_Annotation_sacituzumab_govitecan_and_UGT1A1.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_sevoflurane_and_CACNA1S_RYR1.json => FDA_Label_Annotation_sevoflurane_and_CACNA1S_RYR1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_siponimod_and_CYP2C9.json => FDA_Label_Annotation_siponimod_and_CYP2C9.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_sodium_nitrite_and_CYB5R3_G6PD.json => FDA_Label_Annotation_sodium_nitrite_and_CYB5R3_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_succinylcholine_and_BCHE_CACNA1S_RYR1.json => FDA_Label_Annotation_succinylcholine_and_BCHE_CACNA1S_RYR1.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_sulfasalazine_and_G6PD_NAT2.json => FDA_Label_Annotation_sulfasalazine_and_G6PD_NAT2.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_tafenoquine_and_G6PD.json => FDA_Label_Annotation_tafenoquine_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_tamsulosin_and_CYP2D6.json => FDA_Label_Annotation_tamsulosin_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_tetrabenazine_and_CYP2D6.json => FDA_Label_Annotation_tetrabenazine_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_thioguanine_and_NUDT15_TPMT.json => FDA_Label_Annotation_thioguanine_and_NUDT15_TPMT.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_thioridazine_and_CYP2D6.json => FDA_Label_Annotation_thioridazine_and_CYP2D6.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_tolazamide_and_G6PD.json => FDA_Label_Annotation_tolazamide_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_tolbutamide_and_G6PD.json => FDA_Label_Annotation_tolbutamide_and_G6PD.json} (98%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_tramadol_and_CYP2D6.json => FDA_Label_Annotation_tramadol_and_CYP2D6.json} (99%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_valbenazine_and_CYP2D6.json => FDA_Label_Annotation_valbenazine_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_vortioxetine_and_CYP2D6.json => FDA_Label_Annotation_vortioxetine_and_CYP2D6.json} (96%)
 rename src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/{FDA_warfarin_and_CYP2C9_PROC_PROS1_VKORC1.json => FDA_Label_Annotation_warfarin_and_CYP2C9_PROC_PROS1_VKORC1.json} (99%)
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_abacavir_and_HLA-B.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_abrocitinib_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_allopurinol_and_HLA-B.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_amitriptyline_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_amoxapine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_amphetamine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_aripiprazole_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_aripiprazole_lauroxil_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_atomoxetine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_atorvastatin_and_SLCO1B1.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_avatrombopag_and_CYP2C9.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_azathioprine_and_NUDT15_TPMT.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_belinostat_and_UGT1A1.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_belzutifan_and_CYP2C19_UGT2B17.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_brexpiprazole_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_brivaracetam_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_capecitabine_and_DPYD.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carbamazepine_and_HLA-A.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carbamazepine_and_HLA-B.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carisoprodol_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carvedilol_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_celecoxib_and_CYP2C9.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_cevimeline_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_citalopram_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clobazam_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clomipramine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clopidogrel_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clozapine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_codeine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_darifenacin_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_desipramine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_deutetrabenazine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_dexlansoprazole_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_diazepam_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_dolutegravir_and_UGT1A1.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_donepezil_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_doxepin_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_doxepin_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_dronabinol_and_CYP2C9.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_efavirenz_and_CYP2B6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_elagolix_and_SLCO1B1.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_eliglustat_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_erdafitinib_and_CYP2C9.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_escitalopram_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_esomeprazole_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fesoterodine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_flibanserin_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fluorouracil_and_DPYD.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_flurbiprofen_and_CYP2C9.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fluvoxamine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fosphenytoin_and_CYP2C9.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fosphenytoin_and_HLA-B.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_galantamine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_gefitinib_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_ibuprofen_and_CYP2C9.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_iloperidone_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_imipramine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_irinotecan_and_UGT1A1.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_lansoprazole_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_lofexidine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_mavacamten_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_meclizine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_meloxicam_and_CYP2C9.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_mercaptopurine_and_NUDT15_TPMT.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_metoclopramide_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_metoprolol_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_mirabegron_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nateglinide_and_CYP2C9.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nebivolol_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nilotinib_and_UGT1A1.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nortriptyline_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_oliceridine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_omeprazole_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_oxcarbazepine_and_HLA-B.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pantoprazole_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_paroxetine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pazopanib_and_HLA-B.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pazopanib_and_UGT1A1.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_perphenazine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_phenytoin_and_CYP2C9.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_phenytoin_and_HLA-B.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pimozide_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_piroxicam_and_CYP2C9.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pitolisant_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_propafenone_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_propranolol_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_protriptyline_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_rabeprazole_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_raltegravir_and_UGT1A1.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_risperidone_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_rosuvastatin_and_SLCO1B1.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_sacituzumab_govitecan_and_UGT1A1.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_simvastatin_and_SLCO1B1.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_siponimod_and_CYP2C9.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tacrolimus_and_CYP3A5.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tamoxifen_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tamsulosin_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tetrabenazine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_thioguanine_and_NUDT15_TPMT.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_thioridazine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tolterodine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tramadol_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_trimipramine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_valbenazine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_venlafaxine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_viloxazine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_voriconazole_and_CYP2C19.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_vortioxetine_and_CYP2D6.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_warfarin_and_CYP2C9.json
 create mode 100644 src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_warfarin_and_VKORC1.json

diff --git a/src/main/java/org/pharmgkb/pharmcat/BaseConfig.java b/src/main/java/org/pharmgkb/pharmcat/BaseConfig.java
index c641c6276..9bbb76bc8 100644
--- a/src/main/java/org/pharmgkb/pharmcat/BaseConfig.java
+++ b/src/main/java/org/pharmgkb/pharmcat/BaseConfig.java
@@ -14,7 +14,7 @@
 import org.apache.commons.io.FilenameUtils;
 import org.apache.commons.lang3.StringUtils;
 import org.pharmgkb.common.util.CliHelper;
-import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
 
 
 /**
@@ -40,7 +40,7 @@ public class BaseConfig {
   boolean runReporter = true;
   String reporterTitle;
   boolean reporterCompact = true;
-  List<DataSource> reporterSources;
+  List<DataSourceType> reporterSources;
   boolean reporterJson;
   boolean reporterHtml = true;
   Path outputDir;
@@ -93,7 +93,6 @@ public class BaseConfig {
       topCandidateOnly = !cliHelper.hasOption("ma");
 
       if (cliHelper.hasOption("research")) {
-        //noinspection UnstableApiUsage
         List<String> types = sf_commaSplitter.splitToStream(Objects.requireNonNull(cliHelper.getValue("research")))
             .map(String::toLowerCase)
             .collect(Collectors.toList());
@@ -134,7 +133,7 @@ public class BaseConfig {
         reporterSources = new ArrayList<>();
         for (String src : sf_commaSplitter.splitToList(Objects.requireNonNull(cliHelper.getValue("rs")))) {
           try {
-            reporterSources.add(DataSource.valueOf(src.toUpperCase()));
+            reporterSources.add(DataSourceType.valueOf(src));
           } catch (IllegalArgumentException ex) {
             throw new ReportableException("Unknown source: " + src);
           }
diff --git a/src/main/java/org/pharmgkb/pharmcat/Pipeline.java b/src/main/java/org/pharmgkb/pharmcat/Pipeline.java
index 494e939db..a1c8d73e2 100644
--- a/src/main/java/org/pharmgkb/pharmcat/Pipeline.java
+++ b/src/main/java/org/pharmgkb/pharmcat/Pipeline.java
@@ -23,7 +23,7 @@
 import org.pharmgkb.pharmcat.reporter.ReportContext;
 import org.pharmgkb.pharmcat.reporter.format.HtmlFormat;
 import org.pharmgkb.pharmcat.reporter.format.JsonFormat;
-import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
 
 
 /**
@@ -64,7 +64,7 @@ public enum Mode {
   private Path m_reporterInputFile;
   private String m_reporterTitle;
   private boolean m_reporterCompact;
-  private List<DataSource> m_reporterSources;
+  private List<DataSourceType> m_reporterSources;
   private Path m_reporterJsonFile;
   private Path m_reporterHtmlFile;
   private ReportContext m_reportContext;
@@ -83,7 +83,7 @@ public Pipeline(Env env,
       boolean topCandidateOnly, boolean callCyp2d6, boolean findCombinations, boolean matcherHtml,
       boolean runPhenotyper, @Nullable Path phenotyperInputFile, @Nullable Path phenotyperOutsideCallsFile,
       boolean runReporter, @Nullable Path reporterInputFile, @Nullable String reporterTitle,
-      @Nullable List<DataSource> reporterSources, boolean reporterCompact, boolean reporterJson, boolean reporterHtml,
+      @Nullable List<DataSourceType> reporterSources, boolean reporterCompact, boolean reporterJson, boolean reporterHtml,
       @Nullable Path outputDir, @Nullable String baseFilename, boolean deleteIntermediateFiles,
       Mode mode, @Nullable String displayCount, boolean verbose) throws ReportableException {
     m_env = env;
diff --git a/src/main/java/org/pharmgkb/pharmcat/reporter/MessageHelper.java b/src/main/java/org/pharmgkb/pharmcat/reporter/MessageHelper.java
index f357788f1..8adfe4e95 100644
--- a/src/main/java/org/pharmgkb/pharmcat/reporter/MessageHelper.java
+++ b/src/main/java/org/pharmgkb/pharmcat/reporter/MessageHelper.java
@@ -17,6 +17,7 @@
 import org.checkerframework.checker.nullness.qual.Nullable;
 import org.pharmgkb.common.util.PathUtils;
 import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
 import org.pharmgkb.pharmcat.reporter.model.MatchLogic;
 import org.pharmgkb.pharmcat.reporter.model.MessageAnnotation;
 import org.pharmgkb.pharmcat.reporter.model.VariantReport;
@@ -153,11 +154,11 @@ else if (!StringUtils.isBlank(match.getVariant()) &&
    * @param drugReport a {@link DrugReport} to add message annotations to
    * @param reportContext the report context to pull related information from
    */
-  public void addMatchingMessagesTo(DrugReport drugReport, ReportContext reportContext, DataSource source) {
+  public void addMatchingMessagesTo(DrugReport drugReport, ReportContext reportContext, DataSourceType source) {
     Collection<MessageAnnotation> allMessages = m_drugMap.get(drugReport.getName()).stream()
-        .filter((ma) -> allowedForSource(ma, source))
+        .filter((ma) -> allowedForSource(ma, source.getDataSource()))
         .toList();
-    if (allMessages.size() == 0) {
+    if (allMessages.isEmpty()) {
       return;
     }
     List<MessageAnnotation> reportAsGenotype = new ArrayList<>();
@@ -165,13 +166,13 @@ public void addMatchingMessagesTo(DrugReport drugReport, ReportContext reportCon
       if (messageAnnotation.getExceptionType().equals(MessageAnnotation.TYPE_REPORT_AS_GENOTYPE)) {
         reportAsGenotype.add(messageAnnotation);
       } else {
-        if (matchDrugReport(messageAnnotation, reportContext, source)) {
+        if (matchDrugReport(messageAnnotation, reportContext, source.getDataSource())) {
           drugReport.addMessage(messageAnnotation);
         }
       }
     }
 
-    if (reportAsGenotype.size() > 0) {
+    if (!reportAsGenotype.isEmpty()) {
       for (MessageAnnotation msgAnn : reportAsGenotype) {
         String geneSymbol = msgAnn.getMatches().getGene();
         String genotype = null;
@@ -179,7 +180,7 @@ public void addMatchingMessagesTo(DrugReport drugReport, ReportContext reportCon
           if (geneSymbol == null || guidelineReport.getGenes().contains(geneSymbol)) {
             for (AnnotationReport annotationReport : guidelineReport.getAnnotations()) {
               if (genotype == null) {
-                genotype = computeGenotype(msgAnn, reportContext, source);
+                genotype = computeGenotype(msgAnn, reportContext, source.getDataSource());
               }
               annotationReport.addHighlightedVariant(genotype);
             }
diff --git a/src/main/java/org/pharmgkb/pharmcat/reporter/PgkbGuidelineCollection.java b/src/main/java/org/pharmgkb/pharmcat/reporter/PgkbGuidelineCollection.java
index b347e12f1..d7c8a580f 100644
--- a/src/main/java/org/pharmgkb/pharmcat/reporter/PgkbGuidelineCollection.java
+++ b/src/main/java/org/pharmgkb/pharmcat/reporter/PgkbGuidelineCollection.java
@@ -17,6 +17,7 @@
 import com.google.common.collect.TreeMultimap;
 import org.pharmgkb.common.util.PathUtils;
 import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
 import org.pharmgkb.pharmcat.reporter.model.pgkb.AccessionObject;
 import org.pharmgkb.pharmcat.reporter.model.pgkb.GuidelinePackage;
 import org.pharmgkb.pharmcat.util.DataSerializer;
@@ -41,7 +42,7 @@ public PgkbGuidelineCollection(Path dir) throws IOException {
         stream.filter(f -> f.getFileName().toString().endsWith(".json"))
             .forEach(annotationFiles::add);
     }}
-    if (annotationFiles.size() == 0) {
+    if (annotationFiles.isEmpty()) {
       throw new IOException("Cannot find annotations");
     }
 
@@ -60,9 +61,9 @@ public List<GuidelinePackage> getGuidelinePackages() {
     return f_guidelinePackages;
   }
 
-  public List<GuidelinePackage> findGuidelinePackages(String chemicalName, DataSource source) {
+  public List<GuidelinePackage> findGuidelinePackages(String chemicalName, DataSourceType source) {
     return f_guidelineMap.get(chemicalName).stream()
-        .filter(p -> p.getGuideline().getSource().equalsIgnoreCase(source.getPharmgkbName()))
+        .filter(p -> p.isDataSourceType(source))
         .collect(Collectors.toList());
   }
 
diff --git a/src/main/java/org/pharmgkb/pharmcat/reporter/ReportContext.java b/src/main/java/org/pharmgkb/pharmcat/reporter/ReportContext.java
index 2f0a47db3..34c4463eb 100644
--- a/src/main/java/org/pharmgkb/pharmcat/reporter/ReportContext.java
+++ b/src/main/java/org/pharmgkb/pharmcat/reporter/ReportContext.java
@@ -10,13 +10,14 @@
 import java.util.Set;
 import java.util.SortedMap;
 import java.util.TreeMap;
-import com.google.common.collect.ImmutableList;
 import com.google.gson.annotations.Expose;
 import com.google.gson.annotations.SerializedName;
 import org.checkerframework.checker.nullness.qual.Nullable;
 import org.pharmgkb.pharmcat.Env;
 import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
 import org.pharmgkb.pharmcat.reporter.model.MessageAnnotation;
+import org.pharmgkb.pharmcat.reporter.model.ObjectType;
 import org.pharmgkb.pharmcat.reporter.model.pgkb.GuidelinePackage;
 import org.pharmgkb.pharmcat.reporter.model.result.DrugReport;
 import org.pharmgkb.pharmcat.reporter.model.result.GeneReport;
@@ -30,8 +31,6 @@
  * @author Ryan Whaley
  */
 public class ReportContext {
-  private static final List<DataSource> DRUG_REPORT_SOURCES = ImmutableList.of(DataSource.CPIC, DataSource.DPWG, DataSource.FDA);
-
   @Expose
   @SerializedName("title")
   private final String f_title;
@@ -52,7 +51,7 @@ public class ReportContext {
   private final SortedMap<DataSource, SortedMap<String, GeneReport>> m_geneReports;
   @Expose
   @SerializedName("drugs")
-  private final SortedMap<DataSource, SortedMap<String, DrugReport>> m_drugReports = new TreeMap<>();
+  private final SortedMap<DataSourceType, SortedMap<String, DrugReport>> m_drugReports = new TreeMap<>();
   @Expose
   @SerializedName("messages")
   private final List<MessageAnnotation> f_messages = new ArrayList<>();
@@ -70,12 +69,12 @@ public ReportContext(Env env, SortedMap<DataSource, SortedMap<String, GeneReport
     m_cpicVersion = validateVersions(env.getDrugs(), DataSource.CPIC);
     m_dpwgVersion = validateVersions(env.getDrugs(), DataSource.DPWG);
 
-    for (DataSource dataSource : DRUG_REPORT_SOURCES) {
-      Map<String, DrugReport> drugReports = m_drugReports.computeIfAbsent(dataSource, (s) -> new TreeMap<>());
+    for (DataSourceType dataSourceType : DataSourceType.listValidDataSourceTypes()) {
+      Map<String, DrugReport> drugReports = m_drugReports.computeIfAbsent(dataSourceType, (s) -> new TreeMap<>());
       // go through all drugs, we iterate this way because one guideline may have multiple chemicals/drugs
       for (String drugName : env.getDrugs().getGuidelineMap().keys()) {
-        List<GuidelinePackage> guidelinePackages = env.getDrugs().findGuidelinePackages(drugName, dataSource);
-        if (guidelinePackages != null && guidelinePackages.size() > 0) {
+        List<GuidelinePackage> guidelinePackages = env.getDrugs().findGuidelinePackages(drugName, dataSourceType);
+        if (guidelinePackages != null && !guidelinePackages.isEmpty()) {
           DrugReport newDrugReport = new DrugReport(drugName, guidelinePackages, this);
           drugReports.put(drugName.toLowerCase(), newDrugReport);
         }
@@ -89,13 +88,13 @@ public ReportContext(Env env, SortedMap<DataSource, SortedMap<String, GeneReport
         .flatMap((m) -> m.values().stream())
         .forEach(messageHelper::addMatchingMessagesTo);
     // to drug reports
-    for (DataSource source : m_drugReports.keySet()) {
+    for (DataSourceType source : m_drugReports.keySet()) {
       for (DrugReport drugReport : m_drugReports.get(source).values()) {
         messageHelper.addMatchingMessagesTo(drugReport, this, source);
 
         // add a message for any gene that has missing data
         drugReport.getRelatedGeneSymbols().stream()
-            .map((s) -> getGeneReport(source, s))
+            .map((s) -> getGeneReport(source.getDataSource(), s))
             .filter((gr) -> gr != null && !gr.isOutsideCall() && gr.isMissingVariants() && !gr.isNoData())
             .forEach((gr) -> drugReport.addMessage(new MessageAnnotation(MessageAnnotation.TYPE_NOTE,
                 "missing-variants",
@@ -150,7 +149,7 @@ private String validateVersions(PgkbGuidelineCollection guidelineCollection, Dat
    *
    * @return a map of {@link DrugReport} objects
    */
-  public Map<DataSource, SortedMap<String, DrugReport>> getDrugReports() {
+  public Map<DataSourceType, SortedMap<String, DrugReport>> getDrugReports() {
     return m_drugReports;
   }
 
@@ -168,8 +167,8 @@ public List<DrugReport> getDrugReports(String drug) {
         .toList();
   }
 
-  public @Nullable DrugReport getDrugReport(DataSource source, String drug) {
-    return m_drugReports.get(source).get(drug);
+  public @Nullable DrugReport getDrugReport(DataSource source, ObjectType type, String drug) {
+    return m_drugReports.get(new DataSourceType(source, type)).get(drug);
   }
 
   public List<GeneReport> getGeneReports(String gene) {
diff --git a/src/main/java/org/pharmgkb/pharmcat/reporter/format/HtmlFormat.java b/src/main/java/org/pharmgkb/pharmcat/reporter/format/HtmlFormat.java
index 1df5caa75..fa1b41be9 100644
--- a/src/main/java/org/pharmgkb/pharmcat/reporter/format/HtmlFormat.java
+++ b/src/main/java/org/pharmgkb/pharmcat/reporter/format/HtmlFormat.java
@@ -15,11 +15,12 @@
 import java.util.SortedSet;
 import java.util.TreeMap;
 import java.util.TreeSet;
+import java.util.stream.Collectors;
 import com.github.jknack.handlebars.Handlebars;
 import com.github.jknack.handlebars.helper.StringHelpers;
 import com.github.jknack.handlebars.io.ClassPathTemplateLoader;
 import com.google.common.collect.HashMultimap;
-import com.google.common.collect.Lists;
+import com.google.common.collect.ImmutableSet;
 import com.google.common.collect.Multimap;
 import com.google.common.collect.SortedSetMultimap;
 import com.google.common.collect.TreeMultimap;
@@ -30,6 +31,7 @@
 import org.pharmgkb.pharmcat.reporter.format.html.Recommendation;
 import org.pharmgkb.pharmcat.reporter.handlebars.ReportHelpers;
 import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
 import org.pharmgkb.pharmcat.reporter.model.MessageAnnotation;
 import org.pharmgkb.pharmcat.reporter.model.result.CallSource;
 import org.pharmgkb.pharmcat.reporter.model.result.DrugLink;
@@ -48,7 +50,8 @@ public class HtmlFormat extends AbstractFormat {
   private static final String sf_templatePrefix = "/org/pharmgkb/pharmcat/reporter";
   private static final String sf_handlebarTemplateName = "report";
   private static final boolean sf_compact_drugs = false;
-  private List<DataSource> m_sources = Lists.newArrayList(DataSource.CPIC, DataSource.DPWG, DataSource.FDA);
+  private Set<DataSource> m_geneSources = ImmutableSet.of(DataSource.CPIC, DataSource.DPWG);
+  private List<DataSourceType> m_sources = DataSourceType.listValidDataSourceTypes();
   private boolean m_compact;
   private final boolean f_testMode;
 
@@ -63,8 +66,17 @@ public HtmlFormat(Path outputPath, Env env, boolean testMode) {
     f_testMode = testMode;
   }
 
-  public HtmlFormat sources(List<DataSource> sources) {
+  public HtmlFormat sources(List<DataSourceType> sources) {
     if (sources != null) {
+      m_geneSources = sources.stream()
+          .map((t) -> {
+            if (t.getDataSource() == DataSource.DPWG) {
+              return DataSource.DPWG;
+            } else {
+              return DataSource.CPIC;
+            }
+          })
+          .collect(Collectors.toSet());
       m_sources = sources;
     }
     return this;
@@ -122,7 +134,7 @@ private Map<String,Object> compile(ReportContext reportContext) {
     SortedSetMultimap<String, GeneReport> geneReportMap = TreeMultimap.create();
     Map<String, Map<String, String>> functionMap = new HashMap<>();
     for (DataSource source : new TreeSet<>(reportContext.getGeneReports().keySet())) {
-      if (!m_sources.contains(source)) {
+      if (!m_geneSources.contains(source)) {
         continue;
       }
       for (GeneReport geneReport : reportContext.getGeneReports().get(source).values()) {
@@ -151,7 +163,7 @@ private Map<String,Object> compile(ReportContext reportContext) {
         }
 
         // skip gene reports that aren't related to any drugs
-        if (geneReport.getRelatedDrugs().size() == 0) {
+        if (geneReport.getRelatedDrugs().isEmpty()) {
           continue;
         }
 
@@ -225,7 +237,7 @@ private Map<String,Object> compile(ReportContext reportContext) {
 
     // Section II: Prescribing Recommendations
     SortedMap<String, Recommendation> recommendationMap = new TreeMap<>();
-    for (DataSource source : reportContext.getDrugReports().keySet()) {
+    for (DataSourceType source : reportContext.getDrugReports().keySet()) {
       if (!m_sources.contains(source)) {
         continue;
       }
diff --git a/src/main/java/org/pharmgkb/pharmcat/reporter/format/html/Recommendation.java b/src/main/java/org/pharmgkb/pharmcat/reporter/format/html/Recommendation.java
index 2251c8fb3..08454c7e5 100644
--- a/src/main/java/org/pharmgkb/pharmcat/reporter/format/html/Recommendation.java
+++ b/src/main/java/org/pharmgkb/pharmcat/reporter/format/html/Recommendation.java
@@ -12,7 +12,9 @@
 import org.pharmgkb.pharmcat.reporter.MessageHelper;
 import org.pharmgkb.pharmcat.reporter.caller.LowestFunctionGeneCaller;
 import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
 import org.pharmgkb.pharmcat.reporter.model.MessageAnnotation;
+import org.pharmgkb.pharmcat.reporter.model.ObjectType;
 import org.pharmgkb.pharmcat.reporter.model.cpic.Publication;
 import org.pharmgkb.pharmcat.reporter.model.result.AnnotationReport;
 import org.pharmgkb.pharmcat.reporter.model.result.Diplotype;
@@ -33,6 +35,7 @@ public class Recommendation implements Comparable<Recommendation> {
   private Report m_cpicReport;
   private Report m_dpwgReport;
   private Report m_fdaReport;
+  private Report m_fdaPgxAssocReport;
   private boolean m_hasInferred;
   private boolean m_hasDpydInferred;
   private final Set<MessageAnnotation> m_messages = new LinkedHashSet<>();
@@ -46,31 +49,36 @@ public Recommendation(Env env, String drug) {
   }
 
 
-  public void addReport(DataSource source, DrugReport report) {
+  public void addReport(DataSourceType source, DrugReport report) {
     Preconditions.checkArgument(m_drug.equals(report.getName()));
+    Preconditions.checkNotNull(source);
 
-    switch (source) {
-      case CPIC -> {
-        if (m_cpicReport != null) {
-          throw new IllegalStateException("Multiple drug reports for " + report.getName() + " from " +
-              source.getDisplayName());
-        }
-        m_cpicReport = new Report(source, report);
+    if (source.getDataSource() == DataSource.CPIC && source.getObjectType() == ObjectType.GUIDELINE) {
+      if (m_cpicReport != null) {
+        throw new IllegalStateException("Multiple drug reports for " + report.getName() + " from " + source);
       }
-      case DPWG -> {
-        if (m_dpwgReport != null) {
-          throw new IllegalStateException("Multiple drug reports for " + report.getName() + " from " +
-              source.getDisplayName());
-        }
-        m_dpwgReport = new Report(source, report);
+      m_cpicReport = new Report(source, report);
+    }
+    else if (source.getDataSource() == DataSource.DPWG && source.getObjectType() == ObjectType.GUIDELINE) {
+      if (m_dpwgReport != null) {
+        throw new IllegalStateException("Multiple drug reports for " + report.getName() + " from " + source);
       }
-      case FDA -> {
-        if (m_fdaReport != null) {
-          throw new IllegalStateException("Multiple drug reports for " + report.getName() + " from " +
-              source.getDisplayName());
-        }
-        m_fdaReport = new Report(source, report);
+      m_dpwgReport = new Report(source, report);
+    }
+    else if (source.getDataSource() == DataSource.FDA && source.getObjectType() == ObjectType.LABEL) {
+      if (m_fdaReport != null) {
+        throw new IllegalStateException("Multiple drug reports for " + report.getName() + " from " + source);
       }
+      m_fdaReport = new Report(source, report);
+    }
+    else if (source.getDataSource() == DataSource.FDA && source.getObjectType() == ObjectType.ASSOCIATION) {
+      if (m_fdaPgxAssocReport != null) {
+        throw new IllegalStateException("Multiple drug reports for " + report.getName() + " from " + source);
+      }
+      m_fdaPgxAssocReport = new Report(source, report);
+    }
+    else {
+      throw new RuntimeException("Source not supported: " + source);
     }
 
     boolean callMultiMatch = false;
@@ -95,7 +103,7 @@ public void addReport(DataSource source, DrugReport report) {
         for (Genotype genotype : annotation.getGenotypes()) {
           for (Diplotype diplotype : genotype.getDiplotypes()) {
             if (!scoreMultimatch && diplotype.getLookupKeys().size() > 1) {
-              GenePhenotype gp = m_env.getPhenotype(diplotype.getGene(), source);
+              GenePhenotype gp = m_env.getPhenotype(diplotype.getGene(), source.getDataSource());
               scoreMultimatch = gp != null && gp.isMatchedByActivityScore();
             }
             if (diplotype.getOutsidePhenotypeMismatch() != null ||
@@ -105,7 +113,7 @@ public void addReport(DataSource source, DrugReport report) {
           }
           if (scoreMultimatch || genotype.getDiplotypes().stream().anyMatch((d) -> {
             if (d.getLookupKeys().size() > 1) {
-              GenePhenotype gp = m_env.getPhenotype(d.getGene(), source);
+              GenePhenotype gp = m_env.getPhenotype(d.getGene(), source.getDataSource());
               return gp != null && gp.isMatchedByActivityScore();
             }
             return false;
@@ -169,7 +177,8 @@ public String getDrug() {
   public boolean isMatched() {
     return (m_cpicReport != null && m_cpicReport.isMatched()) ||
         (m_dpwgReport != null && m_dpwgReport.isMatched()) ||
-        (m_fdaReport != null && m_fdaReport.isMatched());
+        (m_fdaReport != null && m_fdaReport.isMatched()) ||
+        (m_fdaPgxAssocReport != null && m_fdaPgxAssocReport.isMatched());
   }
 
 
@@ -184,6 +193,9 @@ public List<Report> getReports() {
     if (m_fdaReport != null) {
       reports.add(m_fdaReport);
     }
+    if (m_fdaPgxAssocReport != null) {
+      reports.add(m_fdaPgxAssocReport);
+    }
     return reports;
   }
 
@@ -199,6 +211,10 @@ public Report getFdaReport() {
     return m_fdaReport;
   }
 
+  public Report getFdaPgxAssocReport() {
+    return m_fdaPgxAssocReport;
+  }
+
   public boolean isHasInferred() {
     return m_hasInferred;
   }
diff --git a/src/main/java/org/pharmgkb/pharmcat/reporter/format/html/Report.java b/src/main/java/org/pharmgkb/pharmcat/reporter/format/html/Report.java
index deb41aa7c..f5efbb271 100644
--- a/src/main/java/org/pharmgkb/pharmcat/reporter/format/html/Report.java
+++ b/src/main/java/org/pharmgkb/pharmcat/reporter/format/html/Report.java
@@ -5,7 +5,7 @@
 import java.util.TreeSet;
 import java.util.stream.Collectors;
 import org.checkerframework.checker.nullness.qual.Nullable;
-import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
 import org.pharmgkb.pharmcat.reporter.model.result.Diplotype;
 import org.pharmgkb.pharmcat.reporter.model.result.DrugReport;
 import org.pharmgkb.pharmcat.reporter.model.result.GeneReport;
@@ -21,7 +21,7 @@
  */
 public class Report {
   private final String m_id;
-  private final DataSource m_source;
+  private final DataSourceType m_source;
   private final boolean m_matched;
   private final List<String> m_urls;
   private SortedSet<GuidelineReport> m_guidelines;
@@ -32,7 +32,7 @@ public class Report {
   private boolean m_unmatchedDpydInferred;
 
 
-  public Report(DataSource source, DrugReport drugReport) {
+  public Report(DataSourceType source, DrugReport drugReport) {
     m_id = drugReport.getId();
     m_source = source;
     m_matched = drugReport.isMatched();
@@ -73,7 +73,7 @@ public String getId() {
     return m_id;
   }
 
-  public DataSource getSource() {
+  public DataSourceType getSource() {
     return m_source;
   }
 
diff --git a/src/main/java/org/pharmgkb/pharmcat/reporter/handlebars/ReportHelpers.java b/src/main/java/org/pharmgkb/pharmcat/reporter/handlebars/ReportHelpers.java
index 29af94ca7..de468e528 100644
--- a/src/main/java/org/pharmgkb/pharmcat/reporter/handlebars/ReportHelpers.java
+++ b/src/main/java/org/pharmgkb/pharmcat/reporter/handlebars/ReportHelpers.java
@@ -19,6 +19,7 @@
 import org.pharmgkb.pharmcat.reporter.TextConstants;
 import org.pharmgkb.pharmcat.reporter.format.html.Report;
 import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
 import org.pharmgkb.pharmcat.reporter.model.MessageAnnotation;
 import org.pharmgkb.pharmcat.reporter.model.VariantReport;
 import org.pharmgkb.pharmcat.reporter.model.cpic.Publication;
@@ -237,16 +238,14 @@ public static String gsPhenotype(Diplotype diplotype) {
   }
 
 
-  public static String rxAnnotationClass(DataSource source, String drug) {
-    StringBuilder builder = new StringBuilder();
-    builder.append(source.name().toLowerCase());
-    builder.append("-");
-    builder.append(sanitizeCssSelector(drug));
-    return builder.toString();
+  public static String rxAnnotationClass(DataSourceType source, String drug) {
+    return source.toCompactString() +
+        "-" +
+        sanitizeCssSelector(drug);
   }
 
-  public static boolean rxIsCpicWarfarin(String drug, DataSource source) {
-    return drug.equals("warfarin") && source == DataSource.CPIC;
+  public static boolean rxIsCpicWarfarin(String drug, DataSourceType source) {
+    return drug.equals("warfarin") && source.getDataSource() == DataSource.CPIC;
   }
 
   public static boolean rxDpydInferred(Genotype genotype) {
diff --git a/src/main/java/org/pharmgkb/pharmcat/reporter/model/DataSource.java b/src/main/java/org/pharmgkb/pharmcat/reporter/model/DataSource.java
index 9659742bb..cd9e8b486 100644
--- a/src/main/java/org/pharmgkb/pharmcat/reporter/model/DataSource.java
+++ b/src/main/java/org/pharmgkb/pharmcat/reporter/model/DataSource.java
@@ -8,7 +8,7 @@ public enum DataSource {
   // NOTE: we want to indicate that the Dutch (DPWG) data comes through PharmGKB annotations so we add it to the display
   DPWG("PharmGKB-DPWG", "DPWG"),
   PHARMGKB("PharmGKB", "PharmGKB"),
-  FDA("FDA Drug Label", "FDA"),
+  FDA("FDA", "FDA"),
   UNKNOWN("Unknown", "Unknown");
 
   private final String displayName;
diff --git a/src/main/java/org/pharmgkb/pharmcat/reporter/model/DataSourceType.java b/src/main/java/org/pharmgkb/pharmcat/reporter/model/DataSourceType.java
new file mode 100644
index 000000000..d4b68232c
--- /dev/null
+++ b/src/main/java/org/pharmgkb/pharmcat/reporter/model/DataSourceType.java
@@ -0,0 +1,87 @@
+package org.pharmgkb.pharmcat.reporter.model;
+
+import java.util.List;
+import com.google.common.collect.ImmutableList;
+import org.apache.commons.lang3.StringUtils;
+import org.apache.commons.lang3.builder.CompareToBuilder;
+
+
+/**
+ * This class combines DataSource and ObjectType into one object that can be compared or used for reporting. Source and
+ * Type are used individually elsewhere in this code so that's why we keep them as atomic elements.
+ */
+public class DataSourceType implements Comparable<DataSourceType> {
+  private final DataSource m_dataSource;
+  private final ObjectType m_objectType;
+
+  public static List<DataSourceType> listValidDataSourceTypes() {
+    return ImmutableList.of(
+        new DataSourceType(DataSource.CPIC, ObjectType.GUIDELINE),
+        new DataSourceType(DataSource.DPWG, ObjectType.GUIDELINE),
+        new DataSourceType(DataSource.FDA, ObjectType.LABEL),
+        new DataSourceType(DataSource.FDA, ObjectType.ASSOCIATION)
+    );
+  }
+
+  public DataSourceType(DataSource source, ObjectType objectType) {
+    m_dataSource = source;
+    m_objectType = objectType;
+  }
+
+  /**
+   * Convenience method for looking up the value based on a string
+   * @param text a string that starts with a data source and ends with an object type
+   * @return a new {@link DataSourceType} that matches the given text
+   * @throws RuntimeException if no match is found for the source OR the type
+   */
+  public static DataSourceType valueOf(String text) {
+    if (StringUtils.isBlank(text)) {
+      return null;
+    }
+    String[] tokens = text.split("\\s", 2);
+    return new DataSourceType(
+        DataSource.valueOf(tokens[0].toUpperCase()),
+        ObjectType.valueOf(tokens[1].toUpperCase()));
+  }
+
+  public DataSource getDataSource() {
+    return m_dataSource;
+  }
+
+  public ObjectType getObjectType() {
+    return m_objectType;
+  }
+
+  /**
+   * Gets a user-friendly string to describe this value, safe for user-facing output
+   */
+  public String toString() {
+    return m_dataSource.getDisplayName() + " " + m_objectType.getDisplayName();
+  }
+
+  /**
+   * Gets a string with no spaces and all lower-case to describe this value that is useful for keys or non-user-facing
+   * content.
+   */
+  public String toCompactString() {
+    return m_dataSource.name().toLowerCase() + "-" + m_objectType.name().toLowerCase();
+  }
+
+  public boolean equals(Object o) {
+    if (o == null) {
+      return false;
+    }
+    if (!(o instanceof DataSourceType otherDst)) {
+      return false;
+    }
+    return m_dataSource == otherDst.getDataSource() && m_objectType.equals(otherDst.getObjectType());
+  }
+
+  @Override
+  public int compareTo(DataSourceType o) {
+    return new CompareToBuilder()
+        .append(this.m_dataSource, o.getDataSource())
+        .append(this.m_objectType, o.getObjectType())
+        .toComparison();
+  }
+}
diff --git a/src/main/java/org/pharmgkb/pharmcat/reporter/model/ObjectType.java b/src/main/java/org/pharmgkb/pharmcat/reporter/model/ObjectType.java
new file mode 100644
index 000000000..643fd272b
--- /dev/null
+++ b/src/main/java/org/pharmgkb/pharmcat/reporter/model/ObjectType.java
@@ -0,0 +1,38 @@
+package org.pharmgkb.pharmcat.reporter.model;
+
+/**
+ * Analogues of PharmGKB object types that are used in the Reporter
+ */
+public enum ObjectType {
+  GUIDELINE("Guideline Annotation"),
+  LABEL("Label Annotation"),
+  ASSOCIATION("PGx Association");
+
+  private final String displayName;
+
+  ObjectType(String displayName) {
+    this.displayName = displayName;
+  }
+
+  /**
+   * The text to use in all user-facing output
+   */
+  public String getDisplayName() {
+    return this.displayName;
+  }
+
+  /**
+   * Look up an {@link ObjectType} value based on either the name or displayName
+   * @param value a name string of an object type
+   * @return an {@link ObjectType} that matches the name
+   * @throws RuntimeException if no matching type value is found
+   */
+  public static ObjectType find(String value) {
+    for (ObjectType objectType : values()) {
+      if (objectType.getDisplayName().equalsIgnoreCase(value) || objectType.name().equalsIgnoreCase(value)) {
+        return objectType;
+      }
+    }
+    throw new RuntimeException("Invalid objectType: " + value);
+  }
+}
diff --git a/src/main/java/org/pharmgkb/pharmcat/reporter/model/pgkb/DosingGuideline.java b/src/main/java/org/pharmgkb/pharmcat/reporter/model/pgkb/DosingGuideline.java
index 9dcc0686b..79b7dbbe7 100644
--- a/src/main/java/org/pharmgkb/pharmcat/reporter/model/pgkb/DosingGuideline.java
+++ b/src/main/java/org/pharmgkb/pharmcat/reporter/model/pgkb/DosingGuideline.java
@@ -1,18 +1,12 @@
 package org.pharmgkb.pharmcat.reporter.model.pgkb;
 
 import java.util.ArrayList;
-import java.util.Comparator;
 import java.util.List;
-import java.util.Optional;
-import java.util.Set;
-import java.util.TreeSet;
 import com.google.gson.annotations.Expose;
 import com.google.gson.annotations.SerializedName;
-import org.pharmgkb.pharmcat.reporter.TextConstants;
-import org.pharmgkb.pharmcat.reporter.model.result.Diplotype;
-import org.pharmgkb.pharmcat.reporter.model.result.Genotype;
-
-import static org.pharmgkb.pharmcat.reporter.TextConstants.GENOTYPE_DELIMITER;
+import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
+import org.pharmgkb.pharmcat.reporter.model.ObjectType;
 
 
 /**
@@ -26,6 +20,9 @@ public class DosingGuideline {
   @SerializedName("name")
   private String name;
   @Expose
+  @SerializedName("objCls")
+  private String objCls;
+  @Expose
   @SerializedName("source")
   private String source;
   @Expose
@@ -57,6 +54,14 @@ public String getSource() {
     return source;
   }
 
+  public String getObjCls() {
+    return objCls;
+  }
+
+  public DataSourceType getDataSourceType() {
+    return new DataSourceType(DataSource.valueOf(getSource()), ObjectType.find(getObjCls()));
+  }
+
   public Integer getVersion() {
     return m_version;
   }
diff --git a/src/main/java/org/pharmgkb/pharmcat/reporter/model/pgkb/GuidelinePackage.java b/src/main/java/org/pharmgkb/pharmcat/reporter/model/pgkb/GuidelinePackage.java
index 3f2ce174f..321a78c2f 100644
--- a/src/main/java/org/pharmgkb/pharmcat/reporter/model/pgkb/GuidelinePackage.java
+++ b/src/main/java/org/pharmgkb/pharmcat/reporter/model/pgkb/GuidelinePackage.java
@@ -6,6 +6,7 @@
 import java.util.stream.Collectors;
 import com.google.gson.annotations.Expose;
 import com.google.gson.annotations.SerializedName;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
 import org.pharmgkb.pharmcat.reporter.model.cpic.Publication;
 
 
@@ -73,10 +74,26 @@ public String getVersion() {
   }
 
 
+  public boolean isDataSourceType(DataSourceType dataSourceType) {
+    return guideline != null && guideline.getDataSourceType().equals(dataSourceType);
+  }
+
   @Override
   public String toString() {
     if (guideline != null) {
-      return guideline.getName();
+      String chemicals = recommendations.stream()
+          .flatMap((r) -> r.getRelatedChemicals().stream())
+          .map(AccessionObject::getName)
+          .distinct()
+          .sorted()
+          .collect(Collectors.joining("_"));
+      return String.format(
+          "%s_%s_%s_and_%s.json",
+          guideline.getSource(),
+          guideline.getObjCls(),
+          chemicals,
+          guideline.getRelatedGenes().stream().map(AccessionObject::getSymbol).collect(Collectors.joining("_"))
+      ).replaceAll("[\\s\\/]", "_");
     }
     else {
       return super.toString();
diff --git a/src/main/java/org/pharmgkb/pharmcat/reporter/model/result/DrugReport.java b/src/main/java/org/pharmgkb/pharmcat/reporter/model/result/DrugReport.java
index 7848f5590..1566ff286 100644
--- a/src/main/java/org/pharmgkb/pharmcat/reporter/model/result/DrugReport.java
+++ b/src/main/java/org/pharmgkb/pharmcat/reporter/model/result/DrugReport.java
@@ -15,7 +15,9 @@
 import org.pharmgkb.common.util.ComparisonChain;
 import org.pharmgkb.pharmcat.reporter.ReportContext;
 import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
 import org.pharmgkb.pharmcat.reporter.model.MessageAnnotation;
+import org.pharmgkb.pharmcat.reporter.model.ObjectType;
 import org.pharmgkb.pharmcat.reporter.model.cpic.Publication;
 import org.pharmgkb.pharmcat.reporter.model.pgkb.GuidelinePackage;
 
@@ -37,7 +39,7 @@ public class DrugReport implements Comparable<DrugReport> {
   private String m_id;
   @Expose
   @SerializedName("source")
-  private DataSource m_source;
+  private DataSourceType m_source;
   @Expose
   @SerializedName("version")
   private String m_version;
@@ -72,7 +74,10 @@ public DrugReport(String name, List<GuidelinePackage> guidelinePackages, ReportC
 
     // DPWG drug can have multiple guideline reports
     for (GuidelinePackage guidelinePackage : guidelinePackages) {
-      m_source = DataSource.valueOf(guidelinePackage.getGuideline().getSource());
+      m_source = new DataSourceType(
+          DataSource.valueOf(guidelinePackage.getGuideline().getSource()),
+          ObjectType.find(guidelinePackage.getGuideline().getObjCls())
+      );
       m_urls.add(guidelinePackage.getGuideline().getUrl());
       if (guidelinePackage.getCitations() != null) {
         m_citations.addAll(guidelinePackage.getCitations());
@@ -100,7 +105,7 @@ public String getId() {
     return m_id;
   }
 
-  public DataSource getSource() {
+  public DataSourceType getSource() {
     return m_source;
   }
 
@@ -122,7 +127,7 @@ public Collection<String> getRelatedGeneSymbols() {
   }
 
   public boolean isMatched() {
-    return (m_source == DataSource.CPIC && sf_notApplicableMatches.contains(m_id))
+    return (m_source.getDataSource() == DataSource.CPIC && sf_notApplicableMatches.contains(m_id))
         || m_guidelines.stream().anyMatch(GuidelineReport::isMatched);
   }
 
@@ -201,7 +206,7 @@ public SortedSet<GuidelineReport> getGuidelines() {
 
   public void addGuideline(GuidelineReport guidelineReport) {
     if (guidelineReport != null) {
-      Preconditions.checkArgument(guidelineReport.getSource() == m_source, "Sources do not match");
+      Preconditions.checkArgument(guidelineReport.getSource().equals(m_source), "Sources do not match");
       m_guidelines.add(guidelineReport);
     }
   }
diff --git a/src/main/java/org/pharmgkb/pharmcat/reporter/model/result/GuidelineReport.java b/src/main/java/org/pharmgkb/pharmcat/reporter/model/result/GuidelineReport.java
index 82c0dc227..0119446b4 100644
--- a/src/main/java/org/pharmgkb/pharmcat/reporter/model/result/GuidelineReport.java
+++ b/src/main/java/org/pharmgkb/pharmcat/reporter/model/result/GuidelineReport.java
@@ -12,6 +12,8 @@
 import org.pharmgkb.common.util.ComparisonChain;
 import org.pharmgkb.pharmcat.reporter.ReportContext;
 import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
+import org.pharmgkb.pharmcat.reporter.model.ObjectType;
 import org.pharmgkb.pharmcat.reporter.model.pgkb.GuidelinePackage;
 import org.pharmgkb.pharmcat.reporter.model.pgkb.RecommendationAnnotation;
 
@@ -26,7 +28,7 @@ public class GuidelineReport implements Comparable<GuidelineReport> {
 
   @Expose
   @SerializedName("source")
-  private DataSource m_source;
+  private DataSourceType m_source;
   @Expose
   @SerializedName("version")
   private String m_version;
@@ -54,7 +56,9 @@ private GuidelineReport() {
   public GuidelineReport(GuidelinePackage guidelinePackage, ReportContext reportContext, String drugName) {
     m_id = guidelinePackage.getGuideline().getId();
     m_name = guidelinePackage.getGuideline().getName();
-    m_source = DataSource.valueOf(guidelinePackage.getGuideline().getSource());
+    m_source = new DataSourceType(
+        DataSource.valueOf(guidelinePackage.getGuideline().getSource()),
+        ObjectType.find(guidelinePackage.getGuideline().getObjCls()));
     m_version = guidelinePackage.getVersion();
     m_url = guidelinePackage.getGuideline().getUrl();
     initializeGenes(guidelinePackage.getGenes(), reportContext);
@@ -64,7 +68,7 @@ public GuidelineReport(GuidelinePackage guidelinePackage, ReportContext reportCo
   private void initializeGenes(Collection<String> genes, ReportContext reportContext) {
     // link guideline report to gene report
     for (String geneSymbol : genes) {
-      GeneReport geneReport = reportContext.getGeneReport(m_source, geneSymbol);
+      GeneReport geneReport = reportContext.getGeneReport(m_source.getDataSource(), geneSymbol);
       if (geneReport == null) {
         continue;
       }
@@ -90,7 +94,7 @@ public String getName() {
     return m_name;
   }
 
-  public DataSource getSource() {
+  public DataSourceType getSource() {
     return m_source;
   }
 
@@ -147,7 +151,7 @@ private void matchAnnotations(GuidelinePackage guidelinePackage, String drugName
           .filter(rec -> rec.matchesGenotype(genotype))
           .forEach(rec -> matchedGenotypes.put(rec, genotype));
     }
-    if (drugName.equals("warfarin") && m_source == DataSource.CPIC) {
+    if (drugName.equals("warfarin") && m_source.getDataSource() == DataSource.CPIC) {
       AnnotationReport ann = AnnotationReport.forWarfarin(m_recommendationGenotypes);
       m_recommendationGenotypes.forEach(ann::addGenotype);
       m_annotationReports.add(ann);
diff --git a/src/main/java/org/pharmgkb/pharmcat/util/DataManager.java b/src/main/java/org/pharmgkb/pharmcat/util/DataManager.java
index 42d01a1ef..61fd339dc 100644
--- a/src/main/java/org/pharmgkb/pharmcat/util/DataManager.java
+++ b/src/main/java/org/pharmgkb/pharmcat/util/DataManager.java
@@ -20,14 +20,11 @@
 import java.util.TreeMap;
 import java.util.TreeSet;
 import java.util.concurrent.atomic.AtomicInteger;
-import java.util.regex.Matcher;
-import java.util.regex.Pattern;
 import java.util.stream.Collectors;
 import java.util.stream.Stream;
 import com.google.common.base.Charsets;
 import com.google.common.base.Preconditions;
 import org.apache.commons.io.FileUtils;
-import org.apache.commons.io.FilenameUtils;
 import org.pharmgkb.common.util.CliHelper;
 import org.pharmgkb.common.util.PathUtils;
 import org.pharmgkb.pharmcat.definition.DefinitionReader;
@@ -224,8 +221,6 @@ public static void main(String[] args) {
     }
   }
 
-  private static final Pattern GUIDELINE_FILENAME_PATTERN = Pattern.compile("^Annotation_of_(.+)_(Guideline|Label)_for_(.+)$");
-
   private void transformGuidelines(Path downloadDir, Path guidelinesDir) throws IOException {
     if (!Files.exists(guidelinesDir)) {
       Files.createDirectories(guidelinesDir);
@@ -235,19 +230,13 @@ private void transformGuidelines(Path downloadDir, Path guidelinesDir) throws IO
     try (Stream<Path> stream = Files.list(downloadDir.resolve("guidelines"))) {
       stream.forEach((file) -> {
         try {
-          String origFilename = FilenameUtils.getName(file.toString());
-          Matcher m = GUIDELINE_FILENAME_PATTERN.matcher(origFilename);
-          if (m.matches()) {
-            String dataSource = m.group(1);
-            String annotationName = m.group(3);
-            String filename = dataSource + "_" + annotationName;
-            count.incrementAndGet();
-            try (Reader reader = Files.newBufferedReader(file)) {
-              GuidelinePackage guidelinePackage = DataSerializer.GSON.fromJson(reader, GuidelinePackage.class);
-              guidelinePackage.getCitations().forEach(Publication::normalize);
-              try (Writer writer = Files.newBufferedWriter(guidelinesDir.resolve(filename))) {
-                DataSerializer.GSON.toJson(guidelinePackage, writer);
-              }
+          count.incrementAndGet();
+          try (Reader reader = Files.newBufferedReader(file)) {
+            GuidelinePackage guidelinePackage = DataSerializer.GSON.fromJson(reader, GuidelinePackage.class);
+            guidelinePackage.getCitations().forEach(Publication::normalize);
+
+            try (Writer writer = Files.newBufferedWriter(guidelinesDir.resolve(guidelinePackage.toString()))) {
+              DataSerializer.GSON.toJson(guidelinePackage, writer);
             }
           }
         } catch (IOException ex) {
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_warfarin_and_CYP2C9_CYP4F2_VKORC1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation__and_CYP2C9_CYP4F2_VKORC1.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_warfarin_and_CYP2C9_CYP4F2_VKORC1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation__and_CYP2C9_CYP4F2_VKORC1.json
index 18630b119..645686678 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_warfarin_and_CYP2C9_CYP4F2_VKORC1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation__and_CYP2C9_CYP4F2_VKORC1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104949",
     "name": "Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 43,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104949",
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_peginterferon_alfa_2a_peginterferon_alfa_2b_ribavirin_and_IFNL3.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation__and_IFNL3.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_peginterferon_alfa_2a_peginterferon_alfa_2b_ribavirin_and_IFNL3.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation__and_IFNL3.json
index 626e05b5e..1b9e75897 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_peginterferon_alfa_2a_peginterferon_alfa_2b_ribavirin_and_IFNL3.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation__and_IFNL3.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166110235",
     "name": "Annotation of CPIC Guideline for peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and IFNL3",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 47,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166110235",
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_abacavir_and_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_abacavir_and_HLA-B.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_abacavir_and_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_abacavir_and_HLA-B.json
index be0db1493..7e5fbfde5 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_abacavir_and_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_abacavir_and_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104997",
     "name": "Annotation of CPIC Guideline for abacavir and HLA-B",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 48,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104997",
@@ -119,5 +120,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374459"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_allopurinol_and_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_allopurinol_and_HLA-B.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_allopurinol_and_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_allopurinol_and_HLA-B.json
index 2949c8b6d..c314da24e 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_allopurinol_and_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_allopurinol_and_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166105003",
     "name": "Annotation of CPIC Guideline for allopurinol and HLA-B",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 42,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166105003",
@@ -122,5 +123,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564416"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_amikacin_gentamicin_kanamycin_paromomycin_plazomicin_streptomycin_tobramycin_and_MT_RNR1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_amikacin_gentamicin_kanamycin_paromomycin_plazomicin_streptomycin_tobramycin_and_MT-RNR1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_amikacin_gentamicin_kanamycin_paromomycin_plazomicin_streptomycin_tobramycin_and_MT_RNR1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_amikacin_gentamicin_kanamycin_paromomycin_plazomicin_streptomycin_tobramycin_and_MT-RNR1.json
index d07d35043..0cb1323b1 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_amikacin_gentamicin_kanamycin_paromomycin_plazomicin_streptomycin_tobramycin_and_MT_RNR1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_amikacin_gentamicin_kanamycin_paromomycin_plazomicin_streptomycin_tobramycin_and_MT-RNR1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166229081",
     "name": "Annotation of CPIC Guideline for amikacin, gentamicin, kanamycin, paromomycin, plazomicin, streptomycin, tobramycin and MT-RNR1",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 5,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166229081",
@@ -685,5 +686,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613315"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_amitriptyline_and_CYP2C19_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_amitriptyline_and_CYP2C19_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_amitriptyline_and_CYP2C19_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_amitriptyline_and_CYP2C19_CYP2D6.json
index e4d123e71..d19a1aa65 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_amitriptyline_and_CYP2C19_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_amitriptyline_and_CYP2C19_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166105006",
     "name": "Annotation of CPIC Guideline for amitriptyline and CYP2C19, CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 58,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166105006",
@@ -6684,5 +6685,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_atazanavir_and_UGT1A1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_atazanavir_and_UGT1A1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_atazanavir_and_UGT1A1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_atazanavir_and_UGT1A1.json
index 3d26f028a..b1162b350 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_atazanavir_and_UGT1A1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_atazanavir_and_UGT1A1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166128738",
     "name": "Annotation of CPIC Guideline for atazanavir and UGT1A1",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 50,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166128738",
@@ -166,5 +167,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785051"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_atomoxetine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_atomoxetine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_atomoxetine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_atomoxetine_and_CYP2D6.json
index 81f6b6fba..acb382b8c 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_atomoxetine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_atomoxetine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166181885",
     "name": "Annotation of CPIC Guideline for atomoxetine and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 12,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166181885",
@@ -1346,5 +1347,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612570"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_atorvastatin_and_SLCO1B1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_atorvastatin_and_SLCO1B1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_atorvastatin_and_SLCO1B1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_atorvastatin_and_SLCO1B1.json
index 885998885..6e093a882 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_atorvastatin_and_SLCO1B1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_atorvastatin_and_SLCO1B1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166262221",
     "name": "Annotation of CPIC Guideline for atorvastatin and SLCO1B1",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 5,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166262221",
@@ -229,5 +230,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_azathioprine_and_NUDT15_TPMT.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_azathioprine_and_NUDT15_TPMT.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_azathioprine_and_NUDT15_TPMT.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_azathioprine_and_NUDT15_TPMT.json
index 214bfc111..45d4d42ee 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_azathioprine_and_NUDT15_TPMT.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_azathioprine_and_NUDT15_TPMT.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104933",
     "name": "Annotation of CPIC Guideline for azathioprine and NUDT15, TPMT",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 52,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104933",
@@ -1181,5 +1182,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098761"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_capecitabine_and_DPYD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_capecitabine_and_DPYD.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_capecitabine_and_DPYD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_capecitabine_and_DPYD.json
index f22768aa4..73a519fbc 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_capecitabine_and_DPYD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_capecitabine_and_DPYD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166109594",
     "name": "Annotation of CPIC Guideline for capecitabine and DPYD",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 58,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166109594",
@@ -206,5 +207,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831181"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_carbamazepine_and_HLA_A_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_carbamazepine_and_HLA-A_HLA-B.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_carbamazepine_and_HLA_A_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_carbamazepine_and_HLA-A_HLA-B.json
index 0c69d061e..735bddc11 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_carbamazepine_and_HLA_A_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_carbamazepine_and_HLA-A_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166105008",
     "name": "Annotation of CPIC Guideline for carbamazepine and HLA-A, HLA-B",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 51,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166105008",
@@ -817,5 +818,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748365"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_celecoxib_flurbiprofen_ibuprofen_lornoxicam_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_celecoxib_flurbiprofen_ibuprofen_lornoxicam_and_CYP2C9.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_celecoxib_flurbiprofen_ibuprofen_lornoxicam_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_celecoxib_flurbiprofen_ibuprofen_lornoxicam_and_CYP2C9.json
index a57cafa19..8b165f9d3 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_celecoxib_flurbiprofen_ibuprofen_lornoxicam_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_celecoxib_flurbiprofen_ibuprofen_lornoxicam_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166191841",
     "name": "Annotation of CPIC Guideline for celecoxib, flurbiprofen, ibuprofen, lornoxicam and CYP2C9",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 10,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166191841",
@@ -754,5 +755,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080882"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_citalopram_escitalopram_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_citalopram_escitalopram_and_CYP2C19.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_citalopram_escitalopram_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_citalopram_escitalopram_and_CYP2C19.json
index 14828b948..7f3953fb8 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_citalopram_escitalopram_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_citalopram_escitalopram_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166127638",
     "name": "Annotation of CPIC Guideline for citalopram, escitalopram and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 48,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166127638",
@@ -547,5 +548,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_clomipramine_and_CYP2C19_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_clomipramine_and_CYP2C19_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_clomipramine_and_CYP2C19_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_clomipramine_and_CYP2C19_CYP2D6.json
index d83f86567..d9b43d261 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_clomipramine_and_CYP2C19_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_clomipramine_and_CYP2C19_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166105007",
     "name": "Annotation of CPIC Guideline for clomipramine and CYP2C19, CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 44,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166105007",
@@ -6684,5 +6685,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_clopidogrel_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_clopidogrel_and_CYP2C19.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_clopidogrel_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_clopidogrel_and_CYP2C19.json
index e9a1e977d..974a518ef 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_clopidogrel_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_clopidogrel_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104948",
     "name": "Annotation of CPIC Guideline for clopidogrel and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 47,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104948",
@@ -786,5 +787,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234301"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_codeine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_codeine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_codeine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_codeine_and_CYP2D6.json
index 0e74518ca..eb486d96b 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_codeine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_codeine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104996",
     "name": "Annotation of CPIC Guideline for codeine and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 65,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104996",
@@ -758,5 +759,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289963"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_dapsone_methylene_blue_pegloticase_rasburicase_tafenoquine_toluidine_blue_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_dapsone_methylene_blue_pegloticase_rasburicase_tafenoquine_toluidine_blue_and_G6PD.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_dapsone_methylene_blue_pegloticase_rasburicase_tafenoquine_toluidine_blue_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_dapsone_methylene_blue_pegloticase_rasburicase_tafenoquine_toluidine_blue_and_G6PD.json
index 6a3de29e8..0b71d2f43 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_dapsone_methylene_blue_pegloticase_rasburicase_tafenoquine_toluidine_blue_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_dapsone_methylene_blue_pegloticase_rasburicase_tafenoquine_toluidine_blue_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166119846",
     "name": "Annotation of CPIC Guideline for dapsone, methylene blue, pegloticase, rasburicase, tafenoquine, toluidine blue and G6PD",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 45,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166119846",
@@ -960,5 +961,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111801"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_succinylcholine_and_CACNA1S_RYR1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_succinylcholine_and_CACNA1S_RYR1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_succinylcholine_and_CACNA1S_RYR1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_succinylcholine_and_CACNA1S_RYR1.json
index c4887b333..6a9c45f40 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_succinylcholine_and_CACNA1S_RYR1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_desflurane_enflurane_halothane_isoflurane_methoxyflurane_sevoflurane_succinylcholine_and_CACNA1S_RYR1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166303941",
     "name": "Annotation of CPIC Guideline for desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, succinylcholine and CACNA1S, RYR1",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 2,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166303941",
@@ -1764,5 +1765,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513720"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_desipramine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_desipramine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_desipramine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_desipramine_and_CYP2D6.json
index afb60ee63..8f5c0e0c7 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_desipramine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_desipramine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166105002",
     "name": "Annotation of CPIC Guideline for desipramine and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 44,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166105002",
@@ -730,5 +731,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_dexlansoprazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_dexlansoprazole_and_CYP2C19.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_dexlansoprazole_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_dexlansoprazole_and_CYP2C19.json
index 3ae5e72e5..cac93f393 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_dexlansoprazole_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_dexlansoprazole_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166219301",
     "name": "Annotation of CPIC Guideline for dexlansoprazole and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 7,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166219301",
@@ -286,5 +287,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868475"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_doxepin_and_CYP2C19_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_doxepin_and_CYP2C19_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_doxepin_and_CYP2C19_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_doxepin_and_CYP2C19_CYP2D6.json
index 637df32e1..7b5f952a6 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_doxepin_and_CYP2C19_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_doxepin_and_CYP2C19_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166105000",
     "name": "Annotation of CPIC Guideline for doxepin and CYP2C19, CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 46,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166105000",
@@ -6684,5 +6685,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_efavirenz_and_CYP2B6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_efavirenz_and_CYP2B6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_efavirenz_and_CYP2B6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_efavirenz_and_CYP2B6.json
index a151ac2fc..f1230a80c 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_efavirenz_and_CYP2B6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_efavirenz_and_CYP2B6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182603",
     "name": "Annotation of CPIC Guideline for efavirenz and CYP2B6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 9,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182603",
@@ -225,5 +226,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739160"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_fluorouracil_and_DPYD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_fluorouracil_and_DPYD.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_fluorouracil_and_DPYD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_fluorouracil_and_DPYD.json
index 2d6967c65..1e061ac79 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_fluorouracil_and_DPYD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_fluorouracil_and_DPYD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166122686",
     "name": "Annotation of CPIC Guideline for fluorouracil and DPYD",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 48,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166122686",
@@ -206,5 +207,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831181"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_fluvastatin_and_CYP2C9_SLCO1B1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_fluvastatin_and_CYP2C9_SLCO1B1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_fluvastatin_and_CYP2C9_SLCO1B1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_fluvastatin_and_CYP2C9_SLCO1B1.json
index ad9e37e62..912358d85 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_fluvastatin_and_CYP2C9_SLCO1B1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_fluvastatin_and_CYP2C9_SLCO1B1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166262341",
     "name": "Annotation of CPIC Guideline for fluvastatin and CYP2C9, SLCO1B1",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 6,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166262341",
@@ -1548,5 +1549,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_fluvoxamine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_fluvoxamine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_fluvoxamine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_fluvoxamine_and_CYP2D6.json
index 21ea034cc..11868a449 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_fluvoxamine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_fluvoxamine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166127637",
     "name": "Annotation of CPIC Guideline for fluvoxamine and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 49,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166127637",
@@ -740,5 +741,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_fosphenytoin_phenytoin_and_CYP2C9_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_fosphenytoin_phenytoin_and_CYP2C9_HLA-B.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_fosphenytoin_phenytoin_and_CYP2C9_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_fosphenytoin_phenytoin_and_CYP2C9_HLA-B.json
index 7f4b2d57f..0c5d27661 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_fosphenytoin_phenytoin_and_CYP2C9_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_fosphenytoin_phenytoin_and_CYP2C9_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166122806",
     "name": "Annotation of CPIC Guideline for fosphenytoin, phenytoin and CYP2C9, HLA-B",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 51,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166122806",
@@ -2557,5 +2558,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206662"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_hydrocodone_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_hydrocodone_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_hydrocodone_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_hydrocodone_and_CYP2D6.json
index bbaaa1754..90376a009 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_hydrocodone_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_hydrocodone_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166228121",
     "name": "Annotation of CPIC Guideline for hydrocodone and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 6,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166228121",
@@ -717,5 +718,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249478"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_imipramine_and_CYP2C19_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_imipramine_and_CYP2C19_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_imipramine_and_CYP2C19_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_imipramine_and_CYP2C19_CYP2D6.json
index a8a5c286a..2ea26c516 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_imipramine_and_CYP2C19_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_imipramine_and_CYP2C19_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104999",
     "name": "Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 47,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104999",
@@ -6684,5 +6685,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_ivacaftor_and_CFTR.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_ivacaftor_and_CFTR.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_ivacaftor_and_CFTR.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_ivacaftor_and_CFTR.json
index ab35293c4..8029e1063 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_ivacaftor_and_CFTR.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_ivacaftor_and_CFTR.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166114461",
     "name": "Annotation of CPIC Guideline for ivacaftor and CFTR",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 61,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166114461",
@@ -101,5 +102,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4026598"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_lansoprazole_omeprazole_pantoprazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_lansoprazole_omeprazole_pantoprazole_and_CYP2C19.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_lansoprazole_omeprazole_pantoprazole_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_lansoprazole_omeprazole_pantoprazole_and_CYP2C19.json
index 35cf57d82..4a611b646 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_lansoprazole_omeprazole_pantoprazole_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_lansoprazole_omeprazole_pantoprazole_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166219103",
     "name": "Annotation of CPIC Guideline for lansoprazole, omeprazole, pantoprazole and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 7,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166219103",
@@ -760,5 +761,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868475"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_lovastatin_and_SLCO1B1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_lovastatin_and_SLCO1B1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_lovastatin_and_SLCO1B1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_lovastatin_and_SLCO1B1.json
index 7e85edefa..34f2f5263 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_lovastatin_and_SLCO1B1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_lovastatin_and_SLCO1B1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166262241",
     "name": "Annotation of CPIC Guideline for lovastatin and SLCO1B1",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 5,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166262241",
@@ -229,5 +230,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_meloxicam_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_meloxicam_and_CYP2C9.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_meloxicam_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_meloxicam_and_CYP2C9.json
index b4b1e0cd9..5299f27e1 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_meloxicam_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_meloxicam_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166192301",
     "name": "Annotation of CPIC Guideline for meloxicam and CYP2C9",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 9,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166192301",
@@ -217,5 +218,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080882"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_mercaptopurine_and_NUDT15_TPMT.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_mercaptopurine_and_NUDT15_TPMT.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_mercaptopurine_and_NUDT15_TPMT.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_mercaptopurine_and_NUDT15_TPMT.json
index c66ffdbd9..fc35c136f 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_mercaptopurine_and_NUDT15_TPMT.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_mercaptopurine_and_NUDT15_TPMT.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104945",
     "name": "Annotation of CPIC Guideline for mercaptopurine and NUDT15, TPMT",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 46,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104945",
@@ -1181,5 +1182,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098761"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_nitrofurantoin_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_nitrofurantoin_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_nitrofurantoin_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_nitrofurantoin_and_G6PD.json
index 8f0e49b9b..af9983984 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_nitrofurantoin_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_nitrofurantoin_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166279721",
     "name": "Annotation of CPIC Guideline for nitrofurantoin and G6PD",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 1,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166279721",
@@ -169,5 +170,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_nortriptyline_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_nortriptyline_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_nortriptyline_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_nortriptyline_and_CYP2D6.json
index 2a74acd29..27e482e71 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_nortriptyline_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_nortriptyline_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104998",
     "name": "Annotation of CPIC Guideline for nortriptyline and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 54,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104998",
@@ -730,5 +731,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_ondansetron_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_ondansetron_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_ondansetron_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_ondansetron_and_CYP2D6.json
index 948f19297..640158059 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_ondansetron_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_ondansetron_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166161954",
     "name": "Annotation of CPIC Guideline for ondansetron and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166161954",
@@ -707,5 +708,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479760"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_oxcarbazepine_and_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_oxcarbazepine_and_HLA-B.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_oxcarbazepine_and_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_oxcarbazepine_and_HLA-B.json
index 456888480..bacc80f16 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_oxcarbazepine_and_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_oxcarbazepine_and_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166176623",
     "name": "Annotation of CPIC Guideline for oxcarbazepine and HLA-B",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 18,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166176623",
@@ -164,5 +165,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847474"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_paroxetine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_paroxetine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_paroxetine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_paroxetine_and_CYP2D6.json
index 1a5d4590d..5b73a57e1 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_paroxetine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_paroxetine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166127636",
     "name": "Annotation of CPIC Guideline for paroxetine and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 50,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166127636",
@@ -740,5 +741,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_piroxicam_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_piroxicam_and_CYP2C9.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_piroxicam_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_piroxicam_and_CYP2C9.json
index 77818f86d..85382875c 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_piroxicam_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_piroxicam_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166192321",
     "name": "Annotation of CPIC Guideline for piroxicam and CYP2C9",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 8,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166192321",
@@ -217,5 +218,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080882"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_pitavastatin_and_SLCO1B1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_pitavastatin_and_SLCO1B1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_pitavastatin_and_SLCO1B1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_pitavastatin_and_SLCO1B1.json
index 6fef6d584..90864d650 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_pitavastatin_and_SLCO1B1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_pitavastatin_and_SLCO1B1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166262261",
     "name": "Annotation of CPIC Guideline for pitavastatin and SLCO1B1",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 6,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166262261",
@@ -229,5 +230,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_pravastatin_and_SLCO1B1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_pravastatin_and_SLCO1B1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_pravastatin_and_SLCO1B1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_pravastatin_and_SLCO1B1.json
index 75d25e4f8..ac71a043b 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_pravastatin_and_SLCO1B1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_pravastatin_and_SLCO1B1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166262281",
     "name": "Annotation of CPIC Guideline for pravastatin and SLCO1B1",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 4,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166262281",
@@ -229,5 +230,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_primaquine_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_primaquine_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_primaquine_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_primaquine_and_G6PD.json
index d53b807bd..48fdb1c51 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_primaquine_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_primaquine_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166279621",
     "name": "Annotation of CPIC Guideline for primaquine and G6PD",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 1,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166279621",
@@ -192,5 +193,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/36049896"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_rosuvastatin_and_ABCG2_SLCO1B1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_rosuvastatin_and_ABCG2_SLCO1B1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_rosuvastatin_and_ABCG2_SLCO1B1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_rosuvastatin_and_ABCG2_SLCO1B1.json
index 7be0d3865..7296a1e93 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_rosuvastatin_and_ABCG2_SLCO1B1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_rosuvastatin_and_ABCG2_SLCO1B1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166262321",
     "name": "Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 4,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166262321",
@@ -897,5 +898,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035072"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_sertraline_and_CYP2B6_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_sertraline_and_CYP2B6_CYP2C19.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_sertraline_and_CYP2B6_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_sertraline_and_CYP2B6_CYP2C19.json
index d6a8c1629..5efe02512 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_sertraline_and_CYP2B6_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_sertraline_and_CYP2B6_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166127639",
     "name": "Annotation of CPIC Guideline for sertraline and CYP2B6, CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 48,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166127639",
@@ -2005,5 +2006,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512908"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_simvastatin_and_SLCO1B1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_simvastatin_and_SLCO1B1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_simvastatin_and_SLCO1B1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_simvastatin_and_SLCO1B1.json
index 55622c68e..c233dc6cc 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_simvastatin_and_SLCO1B1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_simvastatin_and_SLCO1B1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166105005",
     "name": "Annotation of CPIC Guideline for simvastatin and SLCO1B1",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 52,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166105005",
@@ -278,5 +279,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384438"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tacrolimus_and_CYP3A5.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tacrolimus_and_CYP3A5.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tacrolimus_and_CYP3A5.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tacrolimus_and_CYP3A5.json
index 8ef94bd13..49f4e4eaa 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tacrolimus_and_CYP3A5.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tacrolimus_and_CYP3A5.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166124619",
     "name": "Annotation of CPIC Guideline for tacrolimus and CYP3A5",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 38,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166124619",
@@ -195,5 +196,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481158"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tamoxifen_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tamoxifen_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tamoxifen_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tamoxifen_and_CYP2D6.json
index 9d3b64fe4..a175cafd8 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tamoxifen_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tamoxifen_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166176068",
     "name": "Annotation of CPIC Guideline for tamoxifen and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 12,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166176068",
@@ -711,5 +712,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931215"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tenoxicam_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tenoxicam_and_CYP2C9.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tenoxicam_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tenoxicam_and_CYP2C9.json
index 17771ccda..df4d41ab5 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tenoxicam_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tenoxicam_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166192341",
     "name": "Annotation of CPIC Guideline for tenoxicam and CYP2C9",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 8,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166192341",
@@ -217,5 +218,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080882"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_thioguanine_and_NUDT15_TPMT.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_thioguanine_and_NUDT15_TPMT.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_thioguanine_and_NUDT15_TPMT.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_thioguanine_and_NUDT15_TPMT.json
index 59f204ad4..998a7c460 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_thioguanine_and_NUDT15_TPMT.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_thioguanine_and_NUDT15_TPMT.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104965",
     "name": "Annotation of CPIC Guideline for thioguanine and NUDT15, TPMT",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 45,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104965",
@@ -1181,5 +1182,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098761"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tramadol_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tramadol_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tramadol_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tramadol_and_CYP2D6.json
index 056ca05fb..9a0fc7b5e 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tramadol_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tramadol_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166228101",
     "name": "Annotation of CPIC Guideline for tramadol and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 6,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166228101",
@@ -717,5 +718,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249478"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_trimipramine_and_CYP2C19_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_trimipramine_and_CYP2C19_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_trimipramine_and_CYP2C19_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_trimipramine_and_CYP2C19_CYP2D6.json
index 7114dd801..7849f35e8 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_trimipramine_and_CYP2C19_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_trimipramine_and_CYP2C19_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166105001",
     "name": "Annotation of CPIC Guideline for trimipramine and CYP2C19, CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 50,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166105001",
@@ -6684,5 +6685,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689226"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tropisetron_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tropisetron_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tropisetron_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tropisetron_and_CYP2D6.json
index f607ac70a..39a91352f 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_tropisetron_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_tropisetron_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166161955",
     "name": "Annotation of CPIC Guideline for tropisetron and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 33,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166161955",
@@ -707,5 +708,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479760"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_venlafaxine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_venlafaxine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_venlafaxine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_venlafaxine_and_CYP2D6.json
index f6e3d02fe..8dcb9d41c 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_venlafaxine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_venlafaxine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166288201",
     "name": "Annotation of CPIC Guideline for venlafaxine and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 2,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166288201",
@@ -714,5 +715,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/37032427"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_voriconazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_voriconazole_and_CYP2C19.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_voriconazole_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_voriconazole_and_CYP2C19.json
index e299bd06b..45fb54ab9 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_voriconazole_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_voriconazole_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166161537",
     "name": "Annotation of CPIC Guideline for voriconazole and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 38,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166161537",
@@ -511,5 +512,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474211"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_vortioxetine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_vortioxetine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_vortioxetine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_vortioxetine_and_CYP2D6.json
index 0300ab6ae..293345b4f 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_vortioxetine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/CPIC_Guideline_Annotation_vortioxetine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166288221",
     "name": "Annotation of CPIC Guideline for vortioxetine and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "CPIC",
     "version": 1,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166288221",
@@ -714,5 +715,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/37032427"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_abacavir_and_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_abacavir_and_HLA-B.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_abacavir_and_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_abacavir_and_HLA-B.json
index 4c7285d01..e6f1fd692 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_abacavir_and_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_abacavir_and_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104991",
     "name": "Annotation of DPWG Guideline for abacavir and HLA-B",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 35,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104991",
@@ -77,5 +78,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_acenocoumarol_and_VKORC1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_acenocoumarol_and_VKORC1.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_acenocoumarol_and_VKORC1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_acenocoumarol_and_VKORC1.json
index 5388f0cc5..9aeacb639 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_acenocoumarol_and_VKORC1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_acenocoumarol_and_VKORC1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104938",
     "name": "Annotation of DPWG Guideline for acenocoumarol and VKORC1",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 37,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104938",
@@ -135,5 +136,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_allopurinol_and_ABCG2.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_allopurinol_and_ABCG2.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_allopurinol_and_ABCG2.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_allopurinol_and_ABCG2.json
index 30bb0fb73..9202437d3 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_allopurinol_and_ABCG2.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_allopurinol_and_ABCG2.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166264961",
     "name": "Annotation of DPWG Guideline for allopurinol and ABCG2",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 13,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166264961",
@@ -136,5 +137,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10853275"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_allopurinol_and_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_allopurinol_and_HLA-B.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_allopurinol_and_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_allopurinol_and_HLA-B.json
index 6eba6da6d..808eab529 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_allopurinol_and_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_allopurinol_and_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166265141",
     "name": "Annotation of DPWG Guideline for allopurinol and HLA-B",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 6,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166265141",
@@ -78,5 +79,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10853275"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_amitriptyline_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_amitriptyline_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_amitriptyline_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_amitriptyline_and_CYP2D6.json
index cfe983e3b..ed238678e 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_amitriptyline_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_amitriptyline_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104982",
     "name": "Annotation of DPWG Guideline for amitriptyline and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104982",
@@ -570,5 +571,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_aripiprazole_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_aripiprazole_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_aripiprazole_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_aripiprazole_and_CYP2D6.json
index 21d4fa03f..500d225cc 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_aripiprazole_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_aripiprazole_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104937",
     "name": "Annotation of DPWG Guideline for aripiprazole and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 41,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104937",
@@ -594,5 +595,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_atomoxetine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_atomoxetine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_atomoxetine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_atomoxetine_and_CYP2D6.json
index 9915ff366..14154a8c1 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_atomoxetine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_atomoxetine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104989",
     "name": "Annotation of DPWG Guideline for atomoxetine and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 33,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104989",
@@ -594,5 +595,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_atorvastatin_and_SLCO1B1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_atorvastatin_and_SLCO1B1.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_atorvastatin_and_SLCO1B1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_atorvastatin_and_SLCO1B1.json
index 44279032e..454b65cc2 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_atorvastatin_and_SLCO1B1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_atorvastatin_and_SLCO1B1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182843",
     "name": "Annotation of DPWG Guideline for atorvastatin and SLCO1B1",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 11,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182843",
@@ -111,5 +112,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_azathioprine_and_NUDT15.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_azathioprine_and_NUDT15.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_azathioprine_and_NUDT15.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_azathioprine_and_NUDT15.json
index 500bdbb7a..9323651d5 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_azathioprine_and_NUDT15.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_azathioprine_and_NUDT15.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166184614",
     "name": "Annotation of DPWG Guideline for azathioprine and NUDT15",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 9,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166184614",
@@ -111,5 +112,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_azathioprine_and_TPMT.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_azathioprine_and_TPMT.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_azathioprine_and_TPMT.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_azathioprine_and_TPMT.json
index 913d21e74..fa9aff820 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_azathioprine_and_TPMT.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_azathioprine_and_TPMT.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104934",
     "name": "Annotation of DPWG Guideline for azathioprine and TPMT",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 33,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104934",
@@ -135,5 +136,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_brexpiprazole_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_brexpiprazole_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_brexpiprazole_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_brexpiprazole_and_CYP2D6.json
index a5c3cee0e..c856a7720 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_brexpiprazole_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_brexpiprazole_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166184527",
     "name": "Annotation of DPWG Guideline for brexpiprazole and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 11,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166184527",
@@ -571,5 +572,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/37002327"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_capecitabine_and_DPYD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_capecitabine_and_DPYD.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_capecitabine_and_DPYD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_capecitabine_and_DPYD.json
index c47280dc6..13366ea72 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_capecitabine_and_DPYD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_capecitabine_and_DPYD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104963",
     "name": "Annotation of DPWG Guideline for capecitabine and DPYD",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104963",
@@ -246,5 +247,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_carbamazepine_and_HLA_A.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_carbamazepine_and_HLA-A.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_carbamazepine_and_HLA_A.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_carbamazepine_and_HLA-A.json
index 68f88d92f..d0d67a58d 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_carbamazepine_and_HLA_A.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_carbamazepine_and_HLA-A.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166265161",
     "name": "Annotation of DPWG Guideline for carbamazepine and HLA-A",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 10,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166265161",
@@ -53,5 +54,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_carbamazepine_and_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_carbamazepine_and_HLA-B.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_carbamazepine_and_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_carbamazepine_and_HLA-B.json
index 9626d073e..054696fc7 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_carbamazepine_and_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_carbamazepine_and_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166265162",
     "name": "Annotation of DPWG Guideline for carbamazepine and HLA-B",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 7,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166265162",
@@ -111,5 +112,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_citalopram_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_citalopram_and_CYP2C19.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_citalopram_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_citalopram_and_CYP2C19.json
index 2a82af335..5b8d33751 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_citalopram_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_citalopram_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104977",
     "name": "Annotation of DPWG Guideline for citalopram and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 34,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104977",
@@ -188,5 +189,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_clomipramine_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_clomipramine_and_CYP2C19.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_clomipramine_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_clomipramine_and_CYP2C19.json
index a77f817b4..f8a6c56d2 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_clomipramine_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_clomipramine_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166184528",
     "name": "Annotation of DPWG Guideline for clomipramine and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 9,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166184528",
@@ -140,5 +141,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_clomipramine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_clomipramine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_clomipramine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_clomipramine_and_CYP2D6.json
index e2e396f34..666f36abe 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_clomipramine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_clomipramine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104964",
     "name": "Annotation of DPWG Guideline for clomipramine and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 33,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104964",
@@ -570,5 +571,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_clopidogrel_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_clopidogrel_and_CYP2C19.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_clopidogrel_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_clopidogrel_and_CYP2C19.json
index 30d2038e1..e27767606 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_clopidogrel_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_clopidogrel_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104956",
     "name": "Annotation of DPWG Guideline for clopidogrel and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104956",
@@ -164,5 +165,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_codeine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_codeine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_codeine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_codeine_and_CYP2D6.json
index 39fcb12d3..aefb0ca33 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_codeine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_codeine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104970",
     "name": "Annotation of DPWG Guideline for codeine and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 36,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104970",
@@ -593,5 +594,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_doxepin_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_doxepin_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_doxepin_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_doxepin_and_CYP2D6.json
index 9c8f8ef48..552b5766d 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_doxepin_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_doxepin_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104994",
     "name": "Annotation of DPWG Guideline for doxepin and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 30,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104994",
@@ -570,5 +571,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_efavirenz_and_CYP2B6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_efavirenz_and_CYP2B6.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_efavirenz_and_CYP2B6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_efavirenz_and_CYP2B6.json
index 33822675e..b5972a4a6 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_efavirenz_and_CYP2B6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_efavirenz_and_CYP2B6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182846",
     "name": "Annotation of DPWG Guideline for efavirenz and CYP2B6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 14,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182846",
@@ -111,5 +112,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_eliglustat_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_eliglustat_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_eliglustat_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_eliglustat_and_CYP2D6.json
index d31d234b8..91862b77a 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_eliglustat_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_eliglustat_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182823",
     "name": "Annotation of DPWG Guideline for eliglustat and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 12,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182823",
@@ -543,5 +544,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_escitalopram_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_escitalopram_and_CYP2C19.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_escitalopram_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_escitalopram_and_CYP2C19.json
index 2e444d983..977ace02c 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_escitalopram_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_escitalopram_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104975",
     "name": "Annotation of DPWG Guideline for escitalopram and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 33,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104975",
@@ -188,5 +189,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_flecainide_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_flecainide_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_flecainide_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_flecainide_and_CYP2D6.json
index 1ff47e67d..232abad9d 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_flecainide_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_flecainide_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104969",
     "name": "Annotation of DPWG Guideline for flecainide and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104969",
@@ -570,5 +571,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_flucloxacillin_and_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_flucloxacillin_and_HLA-B.json
similarity index 95%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_flucloxacillin_and_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_flucloxacillin_and_HLA-B.json
index aff93816b..a63c02021 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_flucloxacillin_and_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_flucloxacillin_and_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182810",
     "name": "Annotation of DPWG Guideline for flucloxacillin and HLA-B",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 12,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182810",
@@ -53,5 +54,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_flucytosine_and_DPYD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_flucytosine_and_DPYD.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_flucytosine_and_DPYD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_flucytosine_and_DPYD.json
index e343da600..a677251f7 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_flucytosine_and_DPYD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_flucytosine_and_DPYD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166222801",
     "name": "Annotation of DPWG Guideline for flucytosine and DPYD",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 10,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166222801",
@@ -195,5 +196,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_fluorouracil_and_DPYD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_fluorouracil_and_DPYD.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_fluorouracil_and_DPYD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_fluorouracil_and_DPYD.json
index 2669537e1..aaa9e8542 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_fluorouracil_and_DPYD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_fluorouracil_and_DPYD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104939",
     "name": "Annotation of DPWG Guideline for fluorouracil and DPYD",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 34,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104939",
@@ -243,5 +244,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_haloperidol_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_haloperidol_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_haloperidol_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_haloperidol_and_CYP2D6.json
index 603cb4fb7..650106abe 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_haloperidol_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_haloperidol_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104988",
     "name": "Annotation of DPWG Guideline for haloperidol and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 33,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104988",
@@ -594,5 +595,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_hormonal_contraceptives_for_systemic_use_and_F5.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_hormonal_contraceptives_for_systemic_use_and_F5.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_hormonal_contraceptives_for_systemic_use_and_F5.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_hormonal_contraceptives_for_systemic_use_and_F5.json
index d10472f5e..01e378b9e 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_hormonal_contraceptives_for_systemic_use_and_F5.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_hormonal_contraceptives_for_systemic_use_and_F5.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104955",
     "name": "Annotation of DPWG Guideline for hormonal contraceptives for systemic use and F5",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 28,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104955",
@@ -135,5 +136,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_imipramine_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_imipramine_and_CYP2C19.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_imipramine_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_imipramine_and_CYP2C19.json
index 71b148e4a..21df7e2e4 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_imipramine_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_imipramine_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104954",
     "name": "Annotation of DPWG Guideline for imipramine and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 31,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104954",
@@ -164,5 +165,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_imipramine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_imipramine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_imipramine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_imipramine_and_CYP2D6.json
index f4dcb5ffc..758500874 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_imipramine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_imipramine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104972",
     "name": "Annotation of DPWG Guideline for imipramine and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 33,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104972",
@@ -567,5 +568,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_irinotecan_and_UGT1A1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_irinotecan_and_UGT1A1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_irinotecan_and_UGT1A1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_irinotecan_and_UGT1A1.json
index 9ecd4c8da..22196e73f 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_irinotecan_and_UGT1A1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_irinotecan_and_UGT1A1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104951",
     "name": "Annotation of DPWG Guideline for irinotecan and UGT1A1",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 36,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104951",
@@ -280,5 +281,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_lamotrigine_and_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_lamotrigine_and_HLA-B.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_lamotrigine_and_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_lamotrigine_and_HLA-B.json
index 9965b9f48..ad906dc71 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_lamotrigine_and_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_lamotrigine_and_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166265341",
     "name": "Annotation of DPWG Guideline for lamotrigine and HLA-B",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 7,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166265341",
@@ -82,5 +83,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_lansoprazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_lansoprazole_and_CYP2C19.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_lansoprazole_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_lansoprazole_and_CYP2C19.json
index 2a16c35a4..7d47ea5b6 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_lansoprazole_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_lansoprazole_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104987",
     "name": "Annotation of DPWG Guideline for lansoprazole and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 29,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104987",
@@ -164,5 +165,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_mercaptopurine_and_NUDT15.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_mercaptopurine_and_NUDT15.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_mercaptopurine_and_NUDT15.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_mercaptopurine_and_NUDT15.json
index 5257e1467..ae0927bd7 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_mercaptopurine_and_NUDT15.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_mercaptopurine_and_NUDT15.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166184613",
     "name": "Annotation of DPWG Guideline for mercaptopurine and NUDT15",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 10,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166184613",
@@ -111,5 +112,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_mercaptopurine_and_TPMT.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_mercaptopurine_and_TPMT.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_mercaptopurine_and_TPMT.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_mercaptopurine_and_TPMT.json
index f4daed194..138b4a4a4 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_mercaptopurine_and_TPMT.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_mercaptopurine_and_TPMT.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104952",
     "name": "Annotation of DPWG Guideline for mercaptopurine and TPMT",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104952",
@@ -135,5 +136,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_metoprolol_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_metoprolol_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_metoprolol_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_metoprolol_and_CYP2D6.json
index 23cfa7db7..a8c809c88 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_metoprolol_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_metoprolol_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104995",
     "name": "Annotation of DPWG Guideline for metoprolol and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 34,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104995",
@@ -570,5 +571,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_nortriptyline_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_nortriptyline_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_nortriptyline_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_nortriptyline_and_CYP2D6.json
index 7f8c7aae3..16f152886 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_nortriptyline_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_nortriptyline_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104961",
     "name": "Annotation of DPWG Guideline for nortriptyline and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 34,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104961",
@@ -570,5 +571,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_omeprazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_omeprazole_and_CYP2C19.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_omeprazole_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_omeprazole_and_CYP2C19.json
index 08bfacc4f..e0a8d2d7e 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_omeprazole_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_omeprazole_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104957",
     "name": "Annotation of DPWG Guideline for omeprazole and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104957",
@@ -164,5 +165,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_oxcarbazepine_and_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_oxcarbazepine_and_HLA-B.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_oxcarbazepine_and_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_oxcarbazepine_and_HLA-B.json
index 0e74111bd..90dde6c10 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_oxcarbazepine_and_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_oxcarbazepine_and_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166265201",
     "name": "Annotation of DPWG Guideline for oxcarbazepine and HLA-B",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 6,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166265201",
@@ -53,5 +54,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_pantoprazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_pantoprazole_and_CYP2C19.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_pantoprazole_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_pantoprazole_and_CYP2C19.json
index 72451ebbe..9cffedecb 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_pantoprazole_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_pantoprazole_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104958",
     "name": "Annotation of DPWG Guideline for pantoprazole and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104958",
@@ -164,5 +165,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_paroxetine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_paroxetine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_paroxetine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_paroxetine_and_CYP2D6.json
index e2e769977..807663165 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_paroxetine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_paroxetine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104976",
     "name": "Annotation of DPWG Guideline for paroxetine and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 34,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104976",
@@ -594,5 +595,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_phenprocoumon_and_VKORC1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_phenprocoumon_and_VKORC1.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_phenprocoumon_and_VKORC1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_phenprocoumon_and_VKORC1.json
index 3bead6de4..76ca2b60e 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_phenprocoumon_and_VKORC1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_phenprocoumon_and_VKORC1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104940",
     "name": "Annotation of DPWG Guideline for phenprocoumon and VKORC1",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 37,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104940",
@@ -135,5 +136,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_phenytoin_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_phenytoin_and_CYP2C9.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_phenytoin_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_phenytoin_and_CYP2C9.json
index b3439359d..458e5cfed 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_phenytoin_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_phenytoin_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104984",
     "name": "Annotation of DPWG Guideline for phenytoin and CYP2C9",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104984",
@@ -293,5 +294,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_phenytoin_and_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_phenytoin_and_HLA-B.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_phenytoin_and_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_phenytoin_and_HLA-B.json
index f6a0ac0fc..4e0220bed 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_phenytoin_and_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_phenytoin_and_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166264881",
     "name": "Annotation of DPWG Guideline for phenytoin and HLA-B",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 7,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166264881",
@@ -53,5 +54,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_pimozide_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_pimozide_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_pimozide_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_pimozide_and_CYP2D6.json
index 9103025f5..78fe2a519 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_pimozide_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_pimozide_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182819",
     "name": "Annotation of DPWG Guideline for pimozide and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 17,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182819",
@@ -571,5 +572,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/37002327"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_propafenone_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_propafenone_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_propafenone_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_propafenone_and_CYP2D6.json
index bbfa21314..7e6de04c1 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_propafenone_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_propafenone_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104962",
     "name": "Annotation of DPWG Guideline for propafenone and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104962",
@@ -570,5 +571,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_quetiapine_and_CYP3A4.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_quetiapine_and_CYP3A4.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_quetiapine_and_CYP3A4.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_quetiapine_and_CYP3A4.json
index 05aea4dc8..f1f26af17 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_quetiapine_and_CYP3A4.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_quetiapine_and_CYP3A4.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166265421",
     "name": "Annotation of DPWG Guideline for quetiapine and CYP3A4",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 14,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166265421",
@@ -136,5 +137,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/37002327"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_risperidone_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_risperidone_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_risperidone_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_risperidone_and_CYP2D6.json
index 111ae670f..5585b5141 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_risperidone_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_risperidone_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104943",
     "name": "Annotation of DPWG Guideline for risperidone and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 38,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104943",
@@ -594,5 +595,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_sertraline_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_sertraline_and_CYP2C19.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_sertraline_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_sertraline_and_CYP2C19.json
index 6e1fb5f35..403c6ceeb 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_sertraline_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_sertraline_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104980",
     "name": "Annotation of DPWG Guideline for sertraline and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104980",
@@ -188,5 +189,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_simvastatin_and_SLCO1B1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_simvastatin_and_SLCO1B1.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_simvastatin_and_SLCO1B1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_simvastatin_and_SLCO1B1.json
index bf509e574..063e51e5b 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_simvastatin_and_SLCO1B1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_simvastatin_and_SLCO1B1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182844",
     "name": "Annotation of DPWG Guideline for simvastatin and SLCO1B1",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 13,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182844",
@@ -111,5 +112,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_siponimod_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_siponimod_and_CYP2C9.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_siponimod_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_siponimod_and_CYP2C9.json
index 8c76fb14e..ed5971b6d 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_siponimod_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_siponimod_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166211021",
     "name": "Annotation of DPWG Guideline for siponimod and CYP2C9",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 9,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166211021",
@@ -269,5 +270,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_tacrolimus_and_CYP3A5.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_tacrolimus_and_CYP3A5.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_tacrolimus_and_CYP3A5.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_tacrolimus_and_CYP3A5.json
index 8b749a1e4..d99bddb13 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_tacrolimus_and_CYP3A5.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_tacrolimus_and_CYP3A5.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104983",
     "name": "Annotation of DPWG Guideline for tacrolimus and CYP3A5",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104983",
@@ -135,5 +136,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_tamoxifen_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_tamoxifen_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_tamoxifen_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_tamoxifen_and_CYP2D6.json
index 38cb4df02..7797145d5 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_tamoxifen_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_tamoxifen_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104966",
     "name": "Annotation of DPWG Guideline for tamoxifen and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 30,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104966",
@@ -570,5 +571,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_tegafur_and_DPYD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_tegafur_and_DPYD.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_tegafur_and_DPYD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_tegafur_and_DPYD.json
index 1d74efd5a..d6e15a8e1 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_tegafur_and_DPYD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_tegafur_and_DPYD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104944",
     "name": "Annotation of DPWG Guideline for tegafur and DPYD",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104944",
@@ -243,5 +244,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_thioguanine_and_NUDT15.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_thioguanine_and_NUDT15.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_thioguanine_and_NUDT15.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_thioguanine_and_NUDT15.json
index 5c5850cb0..9f8c71cf8 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_thioguanine_and_NUDT15.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_thioguanine_and_NUDT15.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166184612",
     "name": "Annotation of DPWG Guideline for thioguanine and NUDT15",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 8,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166184612",
@@ -111,5 +112,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_thioguanine_and_TPMT.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_thioguanine_and_TPMT.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_thioguanine_and_TPMT.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_thioguanine_and_TPMT.json
index 5b3646acb..6dcbbe64c 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_thioguanine_and_TPMT.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_thioguanine_and_TPMT.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104960",
     "name": "Annotation of DPWG Guideline for thioguanine and TPMT",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104960",
@@ -135,5 +136,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_tramadol_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_tramadol_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_tramadol_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_tramadol_and_CYP2D6.json
index bf4aff7e5..66700f6f4 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_tramadol_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_tramadol_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104959",
     "name": "Annotation of DPWG Guideline for tramadol and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 35,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104959",
@@ -593,5 +594,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_venlafaxine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_venlafaxine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_venlafaxine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_venlafaxine_and_CYP2D6.json
index 0bca52369..2168d1c40 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_venlafaxine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_venlafaxine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104968",
     "name": "Annotation of DPWG Guideline for venlafaxine and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 32,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104968",
@@ -570,5 +571,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_voriconazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_voriconazole_and_CYP2C19.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_voriconazole_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_voriconazole_and_CYP2C19.json
index 45322d5ed..3d2508c1c 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_voriconazole_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_voriconazole_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104990",
     "name": "Annotation of DPWG Guideline for voriconazole and CYP2C19",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 27,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104990",
@@ -164,5 +165,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_warfarin_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_warfarin_and_CYP2C9.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_warfarin_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_warfarin_and_CYP2C9.json
index 4aa715324..25f5e176b 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_warfarin_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_warfarin_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182842",
     "name": "Annotation of DPWG Guideline for warfarin and CYP2C9",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 7,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182842",
@@ -269,5 +270,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_warfarin_and_VKORC1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_warfarin_and_VKORC1.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_warfarin_and_VKORC1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_warfarin_and_VKORC1.json
index 07ce684f8..33b4ba46d 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_warfarin_and_VKORC1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_warfarin_and_VKORC1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182841",
     "name": "Annotation of DPWG Guideline for warfarin and VKORC1",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 10,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182841",
@@ -111,5 +112,5 @@
     }
   ],
   "citations": [],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_zuclopenthixol_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_zuclopenthixol_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_zuclopenthixol_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_zuclopenthixol_and_CYP2D6.json
index 388d97d24..1e75e0b82 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_zuclopenthixol_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/DPWG_Guideline_Annotation_zuclopenthixol_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104992",
     "name": "Annotation of DPWG Guideline for zuclopenthixol and CYP2D6",
+    "objCls": "Guideline Annotation",
     "source": "DPWG",
     "version": 34,
     "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104992",
@@ -594,5 +595,5 @@
       "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Ascorbic_acid_vitamin_C_combinations_Ascorbic_acid_vitamin_C_plain_sodium_ascorbate_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_Ascorbic_acid_(vitamin_C),_plain_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Ascorbic_acid_vitamin_C_combinations_Ascorbic_acid_vitamin_C_plain_sodium_ascorbate_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_Ascorbic_acid_(vitamin_C),_plain_and_G6PD.json
index 417283be3..69a5b4399 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Ascorbic_acid_vitamin_C_combinations_Ascorbic_acid_vitamin_C_plain_sodium_ascorbate_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_Ascorbic_acid_(vitamin_C),_plain_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166293282",
     "name": "Annotation of FDA Label for Ascorbic acid (vitamin C), combinations, Ascorbic acid (vitamin C), plain, sodium ascorbate and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 8,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166293282",
@@ -115,5 +116,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209112"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_abacavir_and_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_abacavir_and_HLA-B.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_abacavir_and_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_abacavir_and_HLA-B.json
index aedf378e0..2d84d09ed 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_abacavir_and_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_abacavir_and_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104833",
     "name": "Annotation of FDA Label for abacavir and HLA-B",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 47,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104833",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020977"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_abrocitinib_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_abrocitinib_and_CYP2C19.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_abrocitinib_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_abrocitinib_and_CYP2C19.json
index eaf9f3e0b..5d292812b 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_abrocitinib_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_abrocitinib_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166272961",
     "name": "Annotation of FDA Label for abrocitinib and CYP2C19",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 5,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166272961",
@@ -81,5 +82,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213871"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_acetaminophen_caffeine_dihydrocodeine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_acetaminophen___caffeine___dihydrocodeine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_acetaminophen_caffeine_dihydrocodeine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_acetaminophen___caffeine___dihydrocodeine_and_CYP2D6.json
index 9bc037d4f..b97fdb80a 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_acetaminophen_caffeine_dihydrocodeine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_acetaminophen___caffeine___dihydrocodeine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166246301",
     "name": "Annotation of FDA Label for acetaminophen / caffeine / dihydrocodeine and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 5,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166246301",
@@ -561,5 +562,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204785"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_allopurinol_and_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_allopurinol_and_HLA-B.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_allopurinol_and_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_allopurinol_and_HLA-B.json
index 92c17eaec..9caede2a5 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_allopurinol_and_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_allopurinol_and_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166234701",
     "name": "Annotation of FDA Label for allopurinol and HLA-B",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 14,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166234701",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020298"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_aripiprazole_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_aripiprazole_and_CYP2D6.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_aripiprazole_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_aripiprazole_and_CYP2D6.json
index 07c54fe58..b92d841f1 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_aripiprazole_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_aripiprazole_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104839",
     "name": "Annotation of FDA Label for aripiprazole and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 32,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104839",
@@ -65,5 +66,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202971"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_aripiprazole_lauroxil_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_aripiprazole_lauroxil_and_CYP2D6.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_aripiprazole_lauroxil_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_aripiprazole_lauroxil_and_CYP2D6.json
index cbe09af3f..393e1ac72 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_aripiprazole_lauroxil_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_aripiprazole_lauroxil_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166161219",
     "name": "Annotation of FDA Label for aripiprazole lauroxil and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 27,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166161219",
@@ -89,5 +90,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209830"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_articaine_epinephrine_and_CYB5R3_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_articaine___epinephrine_and_CYB5R3_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_articaine_epinephrine_and_CYB5R3_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_articaine___epinephrine_and_CYB5R3_G6PD.json
index cfbabd931..77a8ced27 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_articaine_epinephrine_and_CYB5R3_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_articaine___epinephrine_and_CYB5R3_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182741",
     "name": "Annotation of FDA Label for articaine / epinephrine and CYB5R3, G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 10,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166182741",
@@ -110,5 +111,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022466"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_atomoxetine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_atomoxetine_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_atomoxetine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_atomoxetine_and_CYP2D6.json
index bdb5859da..271fd2c89 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_atomoxetine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_atomoxetine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104827",
     "name": "Annotation of FDA Label for atomoxetine and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 30,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104827",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021411"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_azathioprine_and_NUDT15_TPMT.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_azathioprine_and_NUDT15_TPMT.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_azathioprine_and_NUDT15_TPMT.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_azathioprine_and_NUDT15_TPMT.json
index c45c94947..e8ee69a24 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_azathioprine_and_NUDT15_TPMT.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_azathioprine_and_NUDT15_TPMT.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104782",
     "name": "Annotation of FDA Label for azathioprine and NUDT15, TPMT",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 33,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104782",
@@ -713,5 +714,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=016324"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_belinostat_and_UGT1A1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_belinostat_and_UGT1A1.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_belinostat_and_UGT1A1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_belinostat_and_UGT1A1.json
index 28c98abd0..f987236c8 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_belinostat_and_UGT1A1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_belinostat_and_UGT1A1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166129553",
     "name": "Annotation of FDA Label for belinostat and UGT1A1",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 38,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166129553",
@@ -59,5 +60,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206256"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_belzutifan_and_CYP2C19_UGT2B17.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_belzutifan_and_CYP2C19_UGT2B17.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_belzutifan_and_CYP2C19_UGT2B17.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_belzutifan_and_CYP2C19_UGT2B17.json
index 00318c357..c3dc10045 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_belzutifan_and_CYP2C19_UGT2B17.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_belzutifan_and_CYP2C19_UGT2B17.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166268882",
     "name": "Annotation of FDA Label for belzutifan and CYP2C19, UGT2B17",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 11,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166268882",
@@ -90,5 +91,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215383"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_brexpiprazole_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_brexpiprazole_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_brexpiprazole_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_brexpiprazole_and_CYP2D6.json
index 15210533e..fd9f57ce7 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_brexpiprazole_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_brexpiprazole_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166160054",
     "name": "Annotation of FDA Label for brexpiprazole and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 33,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166160054",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205422"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_brivaracetam_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_brivaracetam_and_CYP2C19.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_brivaracetam_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_brivaracetam_and_CYP2C19.json
index 209a54e23..05d1f1a9e 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_brivaracetam_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_brivaracetam_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166153492",
     "name": "Annotation of FDA Label for brivaracetam and CYP2C19",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 37,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166153492",
@@ -81,5 +82,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205836"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_capecitabine_and_DPYD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_capecitabine_and_DPYD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_capecitabine_and_DPYD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_capecitabine_and_DPYD.json
index 4e73b2eee..e2089c345 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_capecitabine_and_DPYD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_capecitabine_and_DPYD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104802",
     "name": "Annotation of FDA Label for capecitabine and DPYD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 33,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104802",
@@ -81,5 +82,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020896"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_carbamazepine_and_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_carbamazepine_and_HLA-B.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_carbamazepine_and_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_carbamazepine_and_HLA-B.json
index 6991421e8..fa5748c58 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_carbamazepine_and_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_carbamazepine_and_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104780",
     "name": "Annotation of FDA Label for carbamazepine and HLA-B",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 32,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104780",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=016608"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_carisoprodol_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_carisoprodol_and_CYP2C19.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_carisoprodol_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_carisoprodol_and_CYP2C19.json
index 73e5af570..bb4cffd54 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_carisoprodol_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_carisoprodol_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104832",
     "name": "Annotation of FDA Label for carisoprodol and CYP2C19",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 34,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104832",
@@ -81,5 +82,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=011792"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_ceftriaxone_and_CYB5R3_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_ceftriaxone_and_CYB5R3_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_ceftriaxone_and_CYB5R3_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_ceftriaxone_and_CYB5R3_G6PD.json
index d989170f6..210a5ae4b 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_ceftriaxone_and_CYB5R3_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_ceftriaxone_and_CYB5R3_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182746",
     "name": "Annotation of FDA Label for ceftriaxone and CYB5R3, G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 11,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166182746",
@@ -110,5 +111,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050585"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_celecoxib_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_celecoxib_and_CYP2C9.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_celecoxib_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_celecoxib_and_CYP2C9.json
index 7b3e44c0d..1307eb0bb 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_celecoxib_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_celecoxib_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104843",
     "name": "Annotation of FDA Label for celecoxib and CYP2C9",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 32,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104843",
@@ -81,5 +82,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020998"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_cevimeline_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_cevimeline_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_cevimeline_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_cevimeline_and_CYP2D6.json
index 044153fb9..e1da96c0d 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_cevimeline_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_cevimeline_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104787",
     "name": "Annotation of FDA Label for cevimeline and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 31,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104787",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020989"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_chloroquine_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_chloroquine_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_chloroquine_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_chloroquine_and_G6PD.json
index 6e8d51506..4e3845ab5 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_chloroquine_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_chloroquine_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104786",
     "name": "Annotation of FDA Label for chloroquine and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 32,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104786",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=006002"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_chlorpropamide_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_chlorpropamide_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_chlorpropamide_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_chlorpropamide_and_G6PD.json
index 69f88adfc..a91d8b38d 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_chlorpropamide_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_chlorpropamide_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166114910",
     "name": "Annotation of FDA Label for chlorpropamide and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 32,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166114910",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=011641"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_citalopram_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_citalopram_and_CYP2C19.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_citalopram_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_citalopram_and_CYP2C19.json
index 33d41765c..8631a120f 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_citalopram_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_citalopram_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104852",
     "name": "Annotation of FDA Label for citalopram and CYP2C19",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 40,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104852",
@@ -85,5 +86,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020822"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_clobazam_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_clobazam_and_CYP2C19.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_clobazam_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_clobazam_and_CYP2C19.json
index 0adb142b4..408ef9156 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_clobazam_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_clobazam_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104884",
     "name": "Annotation of FDA Label for clobazam and CYP2C19",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 30,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104884",
@@ -81,5 +82,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202067"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_clopidogrel_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_clopidogrel_and_CYP2C19.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_clopidogrel_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_clopidogrel_and_CYP2C19.json
index d6f216cdf..ab8a9774c 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_clopidogrel_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_clopidogrel_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104777",
     "name": "Annotation of FDA Label for clopidogrel and CYP2C19",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 35,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104777",
@@ -81,5 +82,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020839"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_clozapine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_clozapine_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_clozapine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_clozapine_and_CYP2D6.json
index d37edc96a..40bc4c588 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_clozapine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_clozapine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104815",
     "name": "Annotation of FDA Label for clozapine and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 30,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104815",
@@ -59,5 +60,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=019758"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_codeine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_codeine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_codeine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_codeine_and_CYP2D6.json
index 57df06653..071afdf8d 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_codeine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_codeine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104916",
     "name": "Annotation of FDA Label for codeine and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 36,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104916",
@@ -297,5 +298,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022402"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_desflurane_and_CACNA1S_RYR1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_desflurane_and_CACNA1S_RYR1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_desflurane_and_CACNA1S_RYR1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_desflurane_and_CACNA1S_RYR1.json
index 3f29b7fce..685891035 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_desflurane_and_CACNA1S_RYR1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_desflurane_and_CACNA1S_RYR1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166129515",
     "name": "Annotation of FDA Label for desflurane and CACNA1S, RYR1",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 33,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166129515",
@@ -238,5 +239,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020118"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_deutetrabenazine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_deutetrabenazine_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_deutetrabenazine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_deutetrabenazine_and_CYP2D6.json
index ce01f3b81..8826f7894 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_deutetrabenazine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_deutetrabenazine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166169882",
     "name": "Annotation of FDA Label for deutetrabenazine and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 21,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166169882",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208082"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_dextromethorphan_quinidine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_dextromethorphan___quinidine_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_dextromethorphan_quinidine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_dextromethorphan___quinidine_and_CYP2D6.json
index 3f060b0cd..20bf4b1ba 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_dextromethorphan_quinidine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_dextromethorphan___quinidine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104886",
     "name": "Annotation of FDA Label for dextromethorphan / quinidine and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 28,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104886",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021879"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_dextromethorphan_hydrobromide_bupropion_hydrochloride_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_dextromethorphan_hydrobromide___bupropion_hydrochloride_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_dextromethorphan_hydrobromide_bupropion_hydrochloride_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_dextromethorphan_hydrobromide___bupropion_hydrochloride_and_CYP2D6.json
index 51d832b75..5575ec79e 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_dextromethorphan_hydrobromide_bupropion_hydrochloride_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_dextromethorphan_hydrobromide___bupropion_hydrochloride_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166278361",
     "name": "Annotation of FDA Label for dextromethorphan hydrobromide / bupropion hydrochloride and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 5,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166278361",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215430"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_dronabinol_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_dronabinol_and_CYP2C9.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_dronabinol_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_dronabinol_and_CYP2C9.json
index d604a3bb5..bb067f237 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_dronabinol_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_dronabinol_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166163422",
     "name": "Annotation of FDA Label for dronabinol and CYP2C9",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 18,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166163422",
@@ -129,5 +130,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205525"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_eliglustat_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_eliglustat_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_eliglustat_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_eliglustat_and_CYP2D6.json
index 149766de5..e1df866ab 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_eliglustat_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_eliglustat_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166123487",
     "name": "Annotation of FDA Label for eliglustat and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 32,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166123487",
@@ -537,5 +538,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205494"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_erdafitinib_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_erdafitinib_and_CYP2C9.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_erdafitinib_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_erdafitinib_and_CYP2C9.json
index c5e69f048..6f529f88c 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_erdafitinib_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_erdafitinib_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182722",
     "name": "Annotation of FDA Label for erdafitinib and CYP2C9",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 14,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166182722",
@@ -59,5 +60,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212018"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_fluorouracil_and_DPYD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_fluorouracil_and_DPYD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_fluorouracil_and_DPYD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_fluorouracil_and_DPYD.json
index 83f9b6838..b903f9002 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_fluorouracil_and_DPYD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_fluorouracil_and_DPYD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104807",
     "name": "Annotation of FDA Label for fluorouracil and DPYD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 31,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104807",
@@ -97,5 +98,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=012209"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_flurbiprofen_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_flurbiprofen_and_CYP2C9.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_flurbiprofen_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_flurbiprofen_and_CYP2C9.json
index 728dca6f4..e66e1a112 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_flurbiprofen_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_flurbiprofen_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104922",
     "name": "Annotation of FDA Label for flurbiprofen and CYP2C9",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 31,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104922",
@@ -89,5 +90,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018766"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_fosphenytoin_and_CYP2C19_CYP2C9_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_fosphenytoin_and_CYP2C19_CYP2C9_HLA-B.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_fosphenytoin_and_CYP2C19_CYP2C9_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_fosphenytoin_and_CYP2C19_CYP2C9_HLA-B.json
index f923cd108..dc0d01523 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_fosphenytoin_and_CYP2C19_CYP2C9_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_fosphenytoin_and_CYP2C19_CYP2C9_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182766",
     "name": "Annotation of FDA Label for fosphenytoin and CYP2C19, CYP2C9, HLA-B",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 11,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166182766",
@@ -393,5 +394,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020450"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_gefitinib_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_gefitinib_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_gefitinib_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_gefitinib_and_CYP2D6.json
index e8bc5e225..345fb4c55 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_gefitinib_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_gefitinib_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166170929",
     "name": "Annotation of FDA Label for gefitinib and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 20,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166170929",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206995"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_glimepiride_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_glimepiride_and_G6PD.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_glimepiride_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_glimepiride_and_G6PD.json
index 3ae096132..0c65a956b 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_glimepiride_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_glimepiride_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166105147",
     "name": "Annotation of FDA Label for glimepiride and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 32,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166105147",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020496"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_glipizide_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_glipizide_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_glipizide_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_glipizide_and_G6PD.json
index 9665dadd7..0677b8928 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_glipizide_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_glipizide_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166105148",
     "name": "Annotation of FDA Label for glipizide and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 27,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166105148",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017783"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_glyburide_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_glyburide_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_glyburide_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_glyburide_and_G6PD.json
index 5f95aee3a..eb742d725 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_glyburide_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_glyburide_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104881",
     "name": "Annotation of FDA Label for glyburide and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 31,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104881",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020051"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_hydroxychloroquine_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_hydroxychloroquine_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_hydroxychloroquine_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_hydroxychloroquine_and_G6PD.json
index ee3608e68..789409783 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_hydroxychloroquine_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_hydroxychloroquine_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182769",
     "name": "Annotation of FDA Label for hydroxychloroquine and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 15,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166182769",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009768"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_iloperidone_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_iloperidone_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_iloperidone_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_iloperidone_and_CYP2D6.json
index f7b5a6c72..c0ae2a7a2 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_iloperidone_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_iloperidone_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104887",
     "name": "Annotation of FDA Label for iloperidone and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 27,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104887",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022192"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_irinotecan_and_UGT1A1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_irinotecan_and_UGT1A1.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_irinotecan_and_UGT1A1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_irinotecan_and_UGT1A1.json
index c5dc1c147..b2f0127d6 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_irinotecan_and_UGT1A1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_irinotecan_and_UGT1A1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104831",
     "name": "Annotation of FDA Label for irinotecan and UGT1A1",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 30,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104831",
@@ -59,5 +60,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020571"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_isoflurane_and_CACNA1S_RYR1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_isoflurane_and_CACNA1S_RYR1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_isoflurane_and_CACNA1S_RYR1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_isoflurane_and_CACNA1S_RYR1.json
index a67d176ef..711b457ed 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_isoflurane_and_CACNA1S_RYR1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_isoflurane_and_CACNA1S_RYR1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166129517",
     "name": "Annotation of FDA Label for isoflurane and CACNA1S, RYR1",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 30,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166129517",
@@ -238,5 +239,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017624"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_ivacaftor_and_CFTR.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_ivacaftor_and_CFTR.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_ivacaftor_and_CFTR.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_ivacaftor_and_CFTR.json
index 4f3b9bcad..67ec85f20 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_ivacaftor_and_CFTR.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_ivacaftor_and_CFTR.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104890",
     "name": "Annotation of FDA Label for ivacaftor and CFTR",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 41,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104890",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203188"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_lesinurad_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_lesinurad_and_CYP2C9.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_lesinurad_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_lesinurad_and_CYP2C9.json
index 7cab87a67..1256d7878 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_lesinurad_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_lesinurad_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166160007",
     "name": "Annotation of FDA Label for lesinurad and CYP2C9",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 26,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166160007",
@@ -81,5 +82,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207988"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_lidocaine_and_tetracaine_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_lidocaine_and_tetracaine_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_lidocaine_and_tetracaine_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_lidocaine_and_tetracaine_and_G6PD.json
index 82e5a9dfc..58cab1a4e 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_lidocaine_and_tetracaine_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_lidocaine_and_tetracaine_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182737",
     "name": "Annotation of FDA Label for lidocaine and tetracaine and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 10,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166182737",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021623"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_lofexidine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_lofexidine_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_lofexidine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_lofexidine_and_CYP2D6.json
index 486e6fe16..592ca2db6 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_lofexidine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_lofexidine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166179848",
     "name": "Annotation of FDA Label for lofexidine and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 13,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166179848",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209229"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_meclizine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_meclizine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_meclizine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_meclizine_and_CYP2D6.json
index a61aef89d..3e3c5c4c5 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_meclizine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_meclizine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166180000",
     "name": "Annotation of FDA Label for meclizine and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 12,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166180000",
@@ -579,5 +580,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=010721"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_meloxicam_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_meloxicam_and_CYP2C9.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_meloxicam_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_meloxicam_and_CYP2C9.json
index bf2023093..7a4463816 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_meloxicam_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_meloxicam_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182753",
     "name": "Annotation of FDA Label for meloxicam and CYP2C9",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 14,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166182753",
@@ -97,5 +98,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207233"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_mepivacaine_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_mepivacaine_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_mepivacaine_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_mepivacaine_and_G6PD.json
index f1a759192..4cda10b0c 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_mepivacaine_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_mepivacaine_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182751",
     "name": "Annotation of FDA Label for mepivacaine and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 12,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166182751",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=012250"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_mercaptopurine_and_NUDT15_TPMT.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_mercaptopurine_and_NUDT15_TPMT.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_mercaptopurine_and_NUDT15_TPMT.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_mercaptopurine_and_NUDT15_TPMT.json
index f853c3483..98660d6f3 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_mercaptopurine_and_NUDT15_TPMT.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_mercaptopurine_and_NUDT15_TPMT.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104810",
     "name": "Annotation of FDA Label for mercaptopurine and NUDT15, TPMT",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 34,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104810",
@@ -713,5 +714,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205919"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_methylene_blue_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_methylene_blue_and_G6PD.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_methylene_blue_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_methylene_blue_and_G6PD.json
index b241da06c..a155b0540 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_methylene_blue_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_methylene_blue_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104878",
     "name": "Annotation of FDA Label for methylene blue and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 29,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104878",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204630"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_metoclopramide_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_metoclopramide_and_CYP2D6.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_metoclopramide_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_metoclopramide_and_CYP2D6.json
index 7a4e744e1..ebd529489 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_metoclopramide_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_metoclopramide_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166178750",
     "name": "Annotation of FDA Label for metoclopramide and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 15,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166178750",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017854"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_moviprep_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_moviprep_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_moviprep_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_moviprep_and_G6PD.json
index c42cb03ec..4bf5c9eb2 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_moviprep_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_moviprep_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104897",
     "name": "Annotation of FDA Label for moviprep and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 34,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104897",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021881"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_nalidixic_acid_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_nalidixic_acid_and_G6PD.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_nalidixic_acid_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_nalidixic_acid_and_G6PD.json
index 3cd40df75..e4bdb2610 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_nalidixic_acid_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_nalidixic_acid_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104891",
     "name": "Annotation of FDA Label for nalidixic acid and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 31,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104891",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=014214"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_oliceridine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_oliceridine_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_oliceridine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_oliceridine_and_CYP2D6.json
index 47a3aa124..1b5b84052 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_oliceridine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_oliceridine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166225161",
     "name": "Annotation of FDA Label for oliceridine and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 7,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166225161",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210730"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_oxcarbazepine_and_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_oxcarbazepine_and_HLA-B.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_oxcarbazepine_and_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_oxcarbazepine_and_HLA-B.json
index 876f8ee79..b2d9959ea 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_oxcarbazepine_and_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_oxcarbazepine_and_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166105213",
     "name": "Annotation of FDA Label for oxcarbazepine and HLA-B",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 31,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166105213",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202810"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_oxymetazoline_and_tetracaine_and_BCHE_CYB5R3_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_oxymetazoline_and_tetracaine_and_BCHE_CYB5R3_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_oxymetazoline_and_tetracaine_and_BCHE_CYB5R3_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_oxymetazoline_and_tetracaine_and_BCHE_CYB5R3_G6PD.json
index 0c9d99be4..be5db022e 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_oxymetazoline_and_tetracaine_and_BCHE_CYB5R3_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_oxymetazoline_and_tetracaine_and_BCHE_CYB5R3_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166184637",
     "name": "Annotation of FDA Label for oxymetazoline and tetracaine and BCHE, CYB5R3, G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 6,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166184637",
@@ -115,5 +116,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208032"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_pantoprazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_pantoprazole_and_CYP2C19.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_pantoprazole_and_CYP2C19.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_pantoprazole_and_CYP2C19.json
index 1a1e53c83..1986dc621 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_pantoprazole_and_CYP2C19.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_pantoprazole_and_CYP2C19.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104901",
     "name": "Annotation of FDA Label for pantoprazole and CYP2C19",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 33,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104901",
@@ -81,5 +82,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020987"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_pegloticase_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_pegloticase_and_G6PD.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_pegloticase_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_pegloticase_and_G6PD.json
index 3fe6caadc..0a35c46e8 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_pegloticase_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_pegloticase_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104900",
     "name": "Annotation of FDA Label for pegloticase and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 32,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104900",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125293"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_phenytoin_and_CYP2C19_CYP2C9_HLA_B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_phenytoin_and_CYP2C19_CYP2C9_HLA-B.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_phenytoin_and_CYP2C19_CYP2C9_HLA_B.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_phenytoin_and_CYP2C19_CYP2C9_HLA-B.json
index 7ba23b348..ab0146f7a 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_phenytoin_and_CYP2C19_CYP2C9_HLA_B.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_phenytoin_and_CYP2C19_CYP2C9_HLA-B.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104860",
     "name": "Annotation of FDA Label for phenytoin and CYP2C19, CYP2C9, HLA-B",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 34,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104860",
@@ -393,5 +394,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=008762"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_pimozide_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_pimozide_and_CYP2D6.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_pimozide_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_pimozide_and_CYP2D6.json
index 8b5f28224..f918ece91 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_pimozide_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_pimozide_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104870",
     "name": "Annotation of FDA Label for pimozide and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 29,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104870",
@@ -81,5 +82,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=017473"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_piroxicam_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_piroxicam_and_CYP2C9.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_piroxicam_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_piroxicam_and_CYP2C9.json
index ababd3974..1b1217561 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_piroxicam_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_piroxicam_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166105222",
     "name": "Annotation of FDA Label for piroxicam and CYP2C9",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 24,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166105222",
@@ -81,5 +82,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=018147"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_pitolisant_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_pitolisant_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_pitolisant_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_pitolisant_and_CYP2D6.json
index 184bbf9d2..1ac811f39 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_pitolisant_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_pitolisant_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166185168",
     "name": "Annotation of FDA Label for pitolisant and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 9,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166185168",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211150"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_primaquine_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_primaquine_and_G6PD.json
similarity index 97%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_primaquine_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_primaquine_and_G6PD.json
index 2523b1172..c846559da 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_primaquine_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_primaquine_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104876",
     "name": "Annotation of FDA Label for primaquine and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 30,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104876",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=008316"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_rasburicase_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_rasburicase_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_rasburicase_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_rasburicase_and_G6PD.json
index 6fea05cf2..5c65bf43e 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_rasburicase_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_rasburicase_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166151881",
     "name": "Annotation of FDA Label for rasburicase and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 24,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166151881",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=103946"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_sacituzumab_govitecan_and_UGT1A1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_sacituzumab_govitecan_and_UGT1A1.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_sacituzumab_govitecan_and_UGT1A1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_sacituzumab_govitecan_and_UGT1A1.json
index fc7278ffb..aa1cd3a7d 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_sacituzumab_govitecan_and_UGT1A1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_sacituzumab_govitecan_and_UGT1A1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166225101",
     "name": "Annotation of FDA Label for sacituzumab govitecan and UGT1A1",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 9,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166225101",
@@ -59,5 +60,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761115"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_sevoflurane_and_CACNA1S_RYR1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_sevoflurane_and_CACNA1S_RYR1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_sevoflurane_and_CACNA1S_RYR1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_sevoflurane_and_CACNA1S_RYR1.json
index b495fef27..5fbd06822 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_sevoflurane_and_CACNA1S_RYR1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_sevoflurane_and_CACNA1S_RYR1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166129519",
     "name": "Annotation of FDA Label for sevoflurane and CACNA1S, RYR1",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 33,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166129519",
@@ -238,5 +239,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020478"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_siponimod_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_siponimod_and_CYP2C9.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_siponimod_and_CYP2C9.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_siponimod_and_CYP2C9.json
index 034a44d3a..0a296f5f7 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_siponimod_and_CYP2C9.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_siponimod_and_CYP2C9.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182738",
     "name": "Annotation of FDA Label for siponimod and CYP2C9",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 13,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166182738",
@@ -192,5 +193,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209884"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_sodium_nitrite_and_CYB5R3_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_sodium_nitrite_and_CYB5R3_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_sodium_nitrite_and_CYB5R3_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_sodium_nitrite_and_CYB5R3_G6PD.json
index a3170b447..651e7e462 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_sodium_nitrite_and_CYB5R3_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_sodium_nitrite_and_CYB5R3_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166115362",
     "name": "Annotation of FDA Label for sodium nitrite and CYB5R3, G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 32,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166115362",
@@ -110,5 +111,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203922"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_succinylcholine_and_BCHE_CACNA1S_RYR1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_succinylcholine_and_BCHE_CACNA1S_RYR1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_succinylcholine_and_BCHE_CACNA1S_RYR1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_succinylcholine_and_BCHE_CACNA1S_RYR1.json
index 9f67207ff..e74b1d25b 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_succinylcholine_and_BCHE_CACNA1S_RYR1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_succinylcholine_and_BCHE_CACNA1S_RYR1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166122970",
     "name": "Annotation of FDA Label for succinylcholine and BCHE, CACNA1S, RYR1",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 40,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166122970",
@@ -243,5 +244,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=008453"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_sulfasalazine_and_G6PD_NAT2.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_sulfasalazine_and_G6PD_NAT2.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_sulfasalazine_and_G6PD_NAT2.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_sulfasalazine_and_G6PD_NAT2.json
index d55df0dc8..5444ebc15 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_sulfasalazine_and_G6PD_NAT2.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_sulfasalazine_and_G6PD_NAT2.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104892",
     "name": "Annotation of FDA Label for sulfasalazine and G6PD, NAT2",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 33,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104892",
@@ -110,5 +111,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=007073"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tafenoquine_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tafenoquine_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tafenoquine_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tafenoquine_and_G6PD.json
index be7b3f907..9374e9528 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tafenoquine_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tafenoquine_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182739",
     "name": "Annotation of FDA Label for tafenoquine and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 11,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166182739",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210607"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tamsulosin_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tamsulosin_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tamsulosin_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tamsulosin_and_CYP2D6.json
index f53e79f2b..64f0a1d7c 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tamsulosin_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tamsulosin_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166160672",
     "name": "Annotation of FDA Label for tamsulosin and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 25,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166160672",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020579"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tetrabenazine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tetrabenazine_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tetrabenazine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tetrabenazine_and_CYP2D6.json
index 52f4685ee..50836bd47 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tetrabenazine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tetrabenazine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104829",
     "name": "Annotation of FDA Label for tetrabenazine and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 28,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104829",
@@ -273,5 +274,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021894"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_thioguanine_and_NUDT15_TPMT.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_thioguanine_and_NUDT15_TPMT.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_thioguanine_and_NUDT15_TPMT.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_thioguanine_and_NUDT15_TPMT.json
index feedde72b..cacc6ded9 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_thioguanine_and_NUDT15_TPMT.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_thioguanine_and_NUDT15_TPMT.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104838",
     "name": "Annotation of FDA Label for thioguanine and NUDT15, TPMT",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 30,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104838",
@@ -713,5 +714,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=012429"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_thioridazine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_thioridazine_and_CYP2D6.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_thioridazine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_thioridazine_and_CYP2D6.json
index faf5402ac..1829316cb 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_thioridazine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_thioridazine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104805",
     "name": "Annotation of FDA Label for thioridazine and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 30,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104805",
@@ -153,5 +154,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=088004"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tolazamide_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tolazamide_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tolazamide_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tolazamide_and_G6PD.json
index d0826918d..0f36510c9 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tolazamide_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tolazamide_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182786",
     "name": "Annotation of FDA Label for tolazamide and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 9,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166182786",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=070259"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tolbutamide_and_G6PD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tolbutamide_and_G6PD.json
similarity index 98%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tolbutamide_and_G6PD.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tolbutamide_and_G6PD.json
index bf4a17b39..5560e8ed8 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tolbutamide_and_G6PD.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tolbutamide_and_G6PD.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166182787",
     "name": "Annotation of FDA Label for tolbutamide and G6PD",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 9,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166182787",
@@ -105,5 +106,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=086445"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tramadol_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tramadol_and_CYP2D6.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tramadol_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tramadol_and_CYP2D6.json
index 8ca4794ac..1fe92ac15 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_tramadol_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_tramadol_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104799",
     "name": "Annotation of FDA Label for tramadol and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 35,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104799",
@@ -297,5 +298,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020281"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_valbenazine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_valbenazine_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_valbenazine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_valbenazine_and_CYP2D6.json
index 2894f0a6b..5358e36d1 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_valbenazine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_valbenazine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166170052",
     "name": "Annotation of FDA Label for valbenazine and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 18,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166170052",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209241"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_vortioxetine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_vortioxetine_and_CYP2D6.json
similarity index 96%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_vortioxetine_and_CYP2D6.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_vortioxetine_and_CYP2D6.json
index 95a3f1c8e..886b5d0c6 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_vortioxetine_and_CYP2D6.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_vortioxetine_and_CYP2D6.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166122607",
     "name": "Annotation of FDA Label for vortioxetine and CYP2D6",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 35,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166122607",
@@ -57,5 +58,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204447"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_warfarin_and_CYP2C9_PROC_PROS1_VKORC1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_warfarin_and_CYP2C9_PROC_PROS1_VKORC1.json
similarity index 99%
rename from src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_warfarin_and_CYP2C9_PROC_PROS1_VKORC1.json
rename to src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_warfarin_and_CYP2C9_PROC_PROS1_VKORC1.json
index 0235e11c1..a689aaf73 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_warfarin_and_CYP2C9_PROC_PROS1_VKORC1.json
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_Label_Annotation_warfarin_and_CYP2C9_PROC_PROS1_VKORC1.json
@@ -2,6 +2,7 @@
   "guideline": {
     "id": "PA166104776",
     "name": "Annotation of FDA Label for warfarin and CYP2C9, PROC, PROS1, VKORC1",
+    "objCls": "Label Annotation",
     "source": "FDA",
     "version": 35,
     "url": "https://www.pharmgkb.org/labelAnnotation/PA166104776",
@@ -585,5 +586,5 @@
       "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=009218"
     }
   ],
-  "version": "2024-02-29-20-19"
+  "version": "2024-03-08-14-34"
 }
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_abacavir_and_HLA-B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_abacavir_and_HLA-B.json
new file mode 100644
index 000000000..077272ad8
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_abacavir_and_HLA-B.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328661",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Abacavir - HLA-B",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328661",
+    "relatedChemicals": [
+      {
+        "id": "PA448004",
+        "name": "abacavir",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA35056",
+        "name": "major histocompatibility complex, class I, B",
+        "symbol": "HLA-B"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166310781",
+      "name": "Recommendation Annotation PA166310781",
+      "population": "Affected subgroup: HLA-B*57:01 allele positive",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448004",
+          "name": "abacavir",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213220,
+        "html": "<p>&quot;Results in higher adverse reaction risk (hypersensitivity reactions). Do not use abacavir in patients positive for HLA-B*57:01.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "HLA-B": "*57:01 positive"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_abrocitinib_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_abrocitinib_and_CYP2C19.json
new file mode 100644
index 000000000..2772b21dd
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_abrocitinib_and_CYP2C19.json
@@ -0,0 +1,77 @@
+{
+  "guideline": {
+    "id": "PA166328662",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Abrocitinib - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328662",
+    "relatedChemicals": [
+      {
+        "id": "PA166272921",
+        "name": "abrocitinib",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166309883",
+      "name": "Recommendation Annotation PA166309883",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166272921",
+          "name": "abrocitinib",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452208382,
+        "html": "<p>&quot;Results in higher systemic concentrations and may result in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166309884",
+      "name": "Recommendation Annotation PA166309884",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166272921",
+          "name": "abrocitinib",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452208383,
+        "html": "<p>&quot;Results in higher systemic concentrations and may result in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_allopurinol_and_HLA-B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_allopurinol_and_HLA-B.json
new file mode 100644
index 000000000..477e198d6
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_allopurinol_and_HLA-B.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328723",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Allopurinol - HLA-B",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328723",
+    "relatedChemicals": [
+      {
+        "id": "PA448320",
+        "name": "allopurinol",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA35056",
+        "name": "major histocompatibility complex, class I, B",
+        "symbol": "HLA-B"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166310842",
+      "name": "Recommendation Annotation PA166310842",
+      "population": "Affected subgroup: HLA-B*58:01 allele positive",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448320",
+          "name": "allopurinol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213281,
+        "html": "<p>&quot;Results in higher adverse reaction risk (severe skin reactions).&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "HLA-B": "*58:01 positive"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_amitriptyline_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_amitriptyline_and_CYP2D6.json
new file mode 100644
index 000000000..93877ff28
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_amitriptyline_and_CYP2D6.json
@@ -0,0 +1,413 @@
+{
+  "guideline": {
+    "id": "PA166328747",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Amitriptyline - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328747",
+    "relatedChemicals": [
+      {
+        "id": "PA448385",
+        "name": "amitriptyline",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315508",
+      "name": "Recommendation Annotation PA166315508",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246427,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315506",
+      "name": "Recommendation Annotation PA166315506",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246425,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315504",
+      "name": "Recommendation Annotation PA166315504",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246423,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315462",
+      "name": "Recommendation Annotation PA166315462",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246381,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥6.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315501",
+      "name": "Recommendation Annotation PA166315501",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246420,
+        "html": "<p>&quot;May alter systemic concentrations&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315523",
+      "name": "Recommendation Annotation PA166315523",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246442,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315510",
+      "name": "Recommendation Annotation PA166315510",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246429,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315481",
+      "name": "Recommendation Annotation PA166315481",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246400,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥5.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315521",
+      "name": "Recommendation Annotation PA166315521",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246440,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315509",
+      "name": "Recommendation Annotation PA166315509",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246428,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315507",
+      "name": "Recommendation Annotation PA166315507",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246426,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315505",
+      "name": "Recommendation Annotation PA166315505",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246424,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315503",
+      "name": "Recommendation Annotation PA166315503",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246422,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315461",
+      "name": "Recommendation Annotation PA166315461",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246380,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315502",
+      "name": "Recommendation Annotation PA166315502",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246421,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315522",
+      "name": "Recommendation Annotation PA166315522",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448385",
+          "name": "amitriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246441,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_amoxapine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_amoxapine_and_CYP2D6.json
new file mode 100644
index 000000000..dbe7aea6d
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_amoxapine_and_CYP2D6.json
@@ -0,0 +1,413 @@
+{
+  "guideline": {
+    "id": "PA166328748",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Amoxapine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328748",
+    "relatedChemicals": [
+      {
+        "id": "PA448405",
+        "name": "amoxapine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315541",
+      "name": "Recommendation Annotation PA166315541",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246460,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315528",
+      "name": "Recommendation Annotation PA166315528",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246447,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315525",
+      "name": "Recommendation Annotation PA166315525",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246444,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315536",
+      "name": "Recommendation Annotation PA166315536",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246455,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315534",
+      "name": "Recommendation Annotation PA166315534",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246453,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315532",
+      "name": "Recommendation Annotation PA166315532",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246451,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315530",
+      "name": "Recommendation Annotation PA166315530",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246449,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥5.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315529",
+      "name": "Recommendation Annotation PA166315529",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246448,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥6.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315527",
+      "name": "Recommendation Annotation PA166315527",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246446,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315526",
+      "name": "Recommendation Annotation PA166315526",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246445,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315537",
+      "name": "Recommendation Annotation PA166315537",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246456,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315524",
+      "name": "Recommendation Annotation PA166315524",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246443,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315535",
+      "name": "Recommendation Annotation PA166315535",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246454,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315533",
+      "name": "Recommendation Annotation PA166315533",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246452,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315531",
+      "name": "Recommendation Annotation PA166315531",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246450,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315542",
+      "name": "Recommendation Annotation PA166315542",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448405",
+          "name": "amoxapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246461,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_amphetamine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_amphetamine_and_CYP2D6.json
new file mode 100644
index 000000000..b62df6661
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_amphetamine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328665",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Amphetamine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328665",
+    "relatedChemicals": [
+      {
+        "id": "PA448408",
+        "name": "amphetamine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315182",
+      "name": "Recommendation Annotation PA166315182",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448408",
+          "name": "amphetamine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452245821,
+        "html": "<p>&quot;May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_aripiprazole_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_aripiprazole_and_CYP2D6.json
new file mode 100644
index 000000000..df63ad962
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_aripiprazole_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328666",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Aripiprazole - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328666",
+    "relatedChemicals": [
+      {
+        "id": "PA10026",
+        "name": "aripiprazole",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312184",
+      "name": "Recommendation Annotation PA166312184",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10026",
+          "name": "aripiprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216423,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_aripiprazole_lauroxil_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_aripiprazole_lauroxil_and_CYP2D6.json
new file mode 100644
index 000000000..e91b624c3
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_aripiprazole_lauroxil_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328667",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Aripiprazole Lauroxil - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328667",
+    "relatedChemicals": [
+      {
+        "id": "PA166161216",
+        "name": "aripiprazole lauroxil",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312324",
+      "name": "Recommendation Annotation PA166312324",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166161216",
+          "name": "aripiprazole lauroxil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216583,
+        "html": "<p>&quot;Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_atomoxetine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_atomoxetine_and_CYP2D6.json
new file mode 100644
index 000000000..2c4ec8129
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_atomoxetine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328668",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Atomoxetine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328668",
+    "relatedChemicals": [
+      {
+        "id": "PA134688071",
+        "name": "atomoxetine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312161",
+      "name": "Recommendation Annotation PA166312161",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA134688071",
+          "name": "atomoxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216400,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_atorvastatin_and_SLCO1B1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_atorvastatin_and_SLCO1B1.json
new file mode 100644
index 000000000..3a36d3eaf
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_atorvastatin_and_SLCO1B1.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328749",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Atorvastatin - SLCO1B1",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328749",
+    "relatedChemicals": [
+      {
+        "id": "PA448500",
+        "name": "atorvastatin",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA134865839",
+        "name": "solute carrier organic anion transporter family member 1B1",
+        "symbol": "SLCO1B1"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315761",
+      "name": "Recommendation Annotation PA166315761",
+      "population": "Affected subgroup: SLCO1B1 521 CC (poor function transporters)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448500",
+          "name": "atorvastatin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246720,
+        "html": "<p>&quot;May result in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "SLCO1B1": "Poor Function"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_avatrombopag_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_avatrombopag_and_CYP2C9.json
new file mode 100644
index 000000000..52e0448cc
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_avatrombopag_and_CYP2C9.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328750",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Avatrombopag - CYP2C9",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328750",
+    "relatedChemicals": [
+      {
+        "id": "PA166179849",
+        "name": "avatrombopag",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA126",
+        "name": "cytochrome P450 family 2 subfamily C member 9",
+        "symbol": "CYP2C9"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315783",
+      "name": "Recommendation Annotation PA166315783",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166179849",
+          "name": "avatrombopag",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246742,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315801",
+      "name": "Recommendation Annotation PA166315801",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166179849",
+          "name": "avatrombopag",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246760,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "1.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315781",
+      "name": "Recommendation Annotation PA166315781",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166179849",
+          "name": "avatrombopag",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246740,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315782",
+      "name": "Recommendation Annotation PA166315782",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166179849",
+          "name": "avatrombopag",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246741,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_azathioprine_and_NUDT15_TPMT.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_azathioprine_and_NUDT15_TPMT.json
new file mode 100644
index 000000000..23b0ec7b8
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_azathioprine_and_NUDT15_TPMT.json
@@ -0,0 +1,709 @@
+{
+  "guideline": {
+    "id": "PA166328669",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Azathioprine - TPMT and/or NUDT15",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328669",
+    "relatedChemicals": [
+      {
+        "id": "PA448515",
+        "name": "azathioprine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA134963132",
+        "name": "nudix hydrolase 15",
+        "symbol": "NUDT15"
+      },
+      {
+        "id": "PA356",
+        "name": "thiopurine S-methyltransferase",
+        "symbol": "TPMT"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166310891",
+      "name": "Recommendation Annotation PA166310891",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213330,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Indeterminate"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310922",
+      "name": "Recommendation Annotation PA166310922",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213361,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Indeterminate"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310895",
+      "name": "Recommendation Annotation PA166310895",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213334,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310900",
+      "name": "Recommendation Annotation PA166310900",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213339,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Normal Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310882",
+      "name": "Recommendation Annotation PA166310882",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213321,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "No Result"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310897",
+      "name": "Recommendation Annotation PA166310897",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213336,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "No Result",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310884",
+      "name": "Recommendation Annotation PA166310884",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213323,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Indeterminate"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310887",
+      "name": "Recommendation Annotation PA166310887",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213326,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "No Result",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310863",
+      "name": "Recommendation Annotation PA166310863",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213302,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310898",
+      "name": "Recommendation Annotation PA166310898",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213337,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310889",
+      "name": "Recommendation Annotation PA166310889",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213328,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Normal Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310865",
+      "name": "Recommendation Annotation PA166310865",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213304,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Normal Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310890",
+      "name": "Recommendation Annotation PA166310890",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213329,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "No Result"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310892",
+      "name": "Recommendation Annotation PA166310892",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213331,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310921",
+      "name": "Recommendation Annotation PA166310921",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213360,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310883",
+      "name": "Recommendation Annotation PA166310883",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213322,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310881",
+      "name": "Recommendation Annotation PA166310881",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213320,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "No Result",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310894",
+      "name": "Recommendation Annotation PA166310894",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213333,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310901",
+      "name": "Recommendation Annotation PA166310901",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213340,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "No Result"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310885",
+      "name": "Recommendation Annotation PA166310885",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213324,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310861",
+      "name": "Recommendation Annotation PA166310861",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213300,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310896",
+      "name": "Recommendation Annotation PA166310896",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213335,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Normal Metabolizer",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310899",
+      "name": "Recommendation Annotation PA166310899",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213338,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Indeterminate",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310886",
+      "name": "Recommendation Annotation PA166310886",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213325,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Normal Metabolizer",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310862",
+      "name": "Recommendation Annotation PA166310862",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213301,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Normal Metabolizer",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310888",
+      "name": "Recommendation Annotation PA166310888",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213327,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Indeterminate",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310864",
+      "name": "Recommendation Annotation PA166310864",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448515",
+          "name": "azathioprine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213303,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Indeterminate",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_belinostat_and_UGT1A1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_belinostat_and_UGT1A1.json
new file mode 100644
index 000000000..5df48b03d
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_belinostat_and_UGT1A1.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328670",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Belinostat - UGT1A1",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328670",
+    "relatedChemicals": [
+      {
+        "id": "PA165971474",
+        "name": "belinostat",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA420",
+        "name": "UDP glucuronosyltransferase 1 family, polypeptide A1",
+        "symbol": "UGT1A1"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166310461",
+      "name": "Recommendation Annotation PA166310461",
+      "population": "Affected subgroup: UGT1A1*28/*28 (poor metabolizers)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA165971474",
+          "name": "belinostat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452211680,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk. Reduce starting dose to 750 mg/m<sup>2</sup> in poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "UGT1A1": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_belzutifan_and_CYP2C19_UGT2B17.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_belzutifan_and_CYP2C19_UGT2B17.json
new file mode 100644
index 000000000..4ec134a7d
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_belzutifan_and_CYP2C19_UGT2B17.json
@@ -0,0 +1,82 @@
+{
+  "guideline": {
+    "id": "PA166328671",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Belzutifan - CYP2C19 and/or UGT2B17",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328671",
+    "relatedChemicals": [
+      {
+        "id": "PA166268761",
+        "name": "belzutifan",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      },
+      {
+        "id": "PA37189",
+        "name": "UDP glucuronosyltransferase family 2 member B17",
+        "symbol": "UGT2B17"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166309881",
+      "name": "Recommendation Annotation PA166309881",
+      "population": "Affected subgroup: CYP2C19 and/or UGT2B17 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166268761",
+          "name": "belzutifan",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452208380,
+        "html": "<p>&quot;Results in higher systemic concentrations and may result in higher adverse reaction risk (anemia, hypoxia). Monitor patients who are poor metabolizers for both genes for adverse reactions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166308261",
+      "name": "Recommendation Annotation PA166308261",
+      "population": "Affected subgroup: CYP2C19 and/or UGT2B17 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166268761",
+          "name": "belzutifan",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452193140,
+        "html": "<p>&quot;Results in higher systemic concentrations and may result in higher adverse reaction risk (anemia, hypoxia). Monitor patients who are poor metabolizers for both genes for adverse reactions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_brexpiprazole_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_brexpiprazole_and_CYP2D6.json
new file mode 100644
index 000000000..020af8069
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_brexpiprazole_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328672",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Brexpiprazole - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328672",
+    "relatedChemicals": [
+      {
+        "id": "PA166160053",
+        "name": "brexpiprazole",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312225",
+      "name": "Recommendation Annotation PA166312225",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166160053",
+          "name": "brexpiprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216484,
+        "html": "<p>&quot;Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_brivaracetam_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_brivaracetam_and_CYP2C19.json
new file mode 100644
index 000000000..1a71e1217
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_brivaracetam_and_CYP2C19.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328673",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Brivaracetam - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328673",
+    "relatedChemicals": [
+      {
+        "id": "PA166153491",
+        "name": "brivaracetam",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166310382",
+      "name": "Recommendation Annotation PA166310382",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166153491",
+          "name": "brivaracetam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452211561,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310361",
+      "name": "Recommendation Annotation PA166310361",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166153491",
+          "name": "brivaracetam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452211540,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310341",
+      "name": "Recommendation Annotation PA166310341",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166153491",
+          "name": "brivaracetam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452211521,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310381",
+      "name": "Recommendation Annotation PA166310381",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166153491",
+          "name": "brivaracetam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452211560,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_capecitabine_and_DPYD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_capecitabine_and_DPYD.json
new file mode 100644
index 000000000..01e14fc50
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_capecitabine_and_DPYD.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328674",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Capecitabine - DPYD",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328674",
+    "relatedChemicals": [
+      {
+        "id": "PA448771",
+        "name": "capecitabine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA145",
+        "name": "dihydropyrimidine dehydrogenase",
+        "symbol": "DPYD"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166310722",
+      "name": "Recommendation Annotation PA166310722",
+      "population": "Affected subgroup: DPYD intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448771",
+          "name": "capecitabine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213161,
+        "html": "<p>&quot;Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers, and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "DPYD": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166310701",
+      "name": "Recommendation Annotation PA166310701",
+      "population": "Affected subgroup: DPYD intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448771",
+          "name": "capecitabine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213140,
+        "html": "<p>&quot;Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers, and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "DPYD": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310721",
+      "name": "Recommendation Annotation PA166310721",
+      "population": "Affected subgroup: DPYD intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448771",
+          "name": "capecitabine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213160,
+        "html": "<p>&quot;Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers, and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "DPYD": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310723",
+      "name": "Recommendation Annotation PA166310723",
+      "population": "Affected subgroup: DPYD intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448771",
+          "name": "capecitabine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213162,
+        "html": "<p>&quot;Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers, and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "DPYD": "1.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carbamazepine_and_HLA-A.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carbamazepine_and_HLA-A.json
new file mode 100644
index 000000000..9c8de44c7
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carbamazepine_and_HLA-A.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328724",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Carbamazepine - HLA-A",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328724",
+    "relatedChemicals": [
+      {
+        "id": "PA448785",
+        "name": "carbamazepine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA35055",
+        "name": "major histocompatibility complex, class I, A",
+        "symbol": "HLA-A"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315301",
+      "name": "Recommendation Annotation PA166315301",
+      "population": "Affected subgroup: HLA-A*31:01 allele positive",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448785",
+          "name": "carbamazepine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246160,
+        "html": "<p>&quot;Results in higher adverse reaction risk (severe skin reactions). Consider risk and benefit of carbamazepine use in patients positive for HLA-A*31:01. Genotyping is not a substitute for clinical vigilance.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "HLA-A": "*31:01 positive"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carbamazepine_and_HLA-B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carbamazepine_and_HLA-B.json
new file mode 100644
index 000000000..61a7fcdc9
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carbamazepine_and_HLA-B.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328675",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Carbamazepine - HLA-B",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328675",
+    "relatedChemicals": [
+      {
+        "id": "PA448785",
+        "name": "carbamazepine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA35056",
+        "name": "major histocompatibility complex, class I, B",
+        "symbol": "HLA-B"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166310801",
+      "name": "Recommendation Annotation PA166310801",
+      "population": "Affected subgroup: HLA-B*15:02 allele positive",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448785",
+          "name": "carbamazepine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213240,
+        "html": "<p>&quot;Results in higher adverse reaction risk (severe skin reactions). Avoid use unless potential benefits outweigh risks and consider risks of alternative therapies. Patients positive for HLA-B*15:02 may be at increased risk of severe skin reactions with other drugs that are associated with a risk of Stevens Johnson Syndrome/Toxic Epidermal necrolysis (SJS/TEN). Genotyping is not a substitute for clinical vigilance.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "HLA-B": "*15:02 positive"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carisoprodol_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carisoprodol_and_CYP2C19.json
new file mode 100644
index 000000000..741f5f12c
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carisoprodol_and_CYP2C19.json
@@ -0,0 +1,77 @@
+{
+  "guideline": {
+    "id": "PA166328751",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Carisoprodol - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328751",
+    "relatedChemicals": [
+      {
+        "id": "PA448809",
+        "name": "carisoprodol",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166310281",
+      "name": "Recommendation Annotation PA166310281",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448809",
+          "name": "carisoprodol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452211460,
+        "html": "<p>&quot;Results in higher systemic concentrations. Use with caution.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166307662",
+      "name": "Recommendation Annotation PA166307662",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448809",
+          "name": "carisoprodol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452157581,
+        "html": "<p>&quot;Results in higher systemic concentrations. Use with caution.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carvedilol_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carvedilol_and_CYP2D6.json
new file mode 100644
index 000000000..b23ec95db
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_carvedilol_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328725",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Carvedilol - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328725",
+    "relatedChemicals": [
+      {
+        "id": "PA448817",
+        "name": "carvedilol",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315302",
+      "name": "Recommendation Annotation PA166315302",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448817",
+          "name": "carvedilol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246161,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk (dizziness).&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_celecoxib_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_celecoxib_and_CYP2C9.json
new file mode 100644
index 000000000..2a8df4ae1
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_celecoxib_and_CYP2C9.json
@@ -0,0 +1,104 @@
+{
+  "guideline": {
+    "id": "PA166328676",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Celecoxib - CYP2C9",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328676",
+    "relatedChemicals": [
+      {
+        "id": "PA448871",
+        "name": "celecoxib",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA126",
+        "name": "cytochrome P450 family 2 subfamily C member 9",
+        "symbol": "CYP2C9"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166311941",
+      "name": "Recommendation Annotation PA166311941",
+      "population": "Affected subgroup: CYP2C9 poor metabolizers or *3 carriers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448871",
+          "name": "celecoxib",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216140,
+        "html": "<p>&quot;Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in poor metabolizers with juvenile rheumatoid arthritis.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.5"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312641",
+      "name": "Recommendation Annotation PA166312641",
+      "population": "Affected subgroup: CYP2C9 poor metabolizers or *3 carriers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448871",
+          "name": "celecoxib",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452218940,
+        "html": "<p>&quot;Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in poor metabolizers with juvenile rheumatoid arthritis.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": {
+          "*1": 1.0,
+          "*3": 1.0
+        }
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311927",
+      "name": "Recommendation Annotation PA166311927",
+      "population": "Affected subgroup: CYP2C9 poor metabolizers or *3 carriers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA448871",
+          "name": "celecoxib",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216126,
+        "html": "<p>&quot;Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in poor metabolizers with juvenile rheumatoid arthritis.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_cevimeline_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_cevimeline_and_CYP2D6.json
new file mode 100644
index 000000000..8791c8c5a
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_cevimeline_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328726",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Cevimeline - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328726",
+    "relatedChemicals": [
+      {
+        "id": "PA164754754",
+        "name": "cevimeline",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312151",
+      "name": "Recommendation Annotation PA166312151",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA164754754",
+          "name": "cevimeline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216390,
+        "html": "<p>&quot;May result in higher adverse reaction risk. Use with caution.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_citalopram_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_citalopram_and_CYP2C19.json
new file mode 100644
index 000000000..8f2d95d90
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_citalopram_and_CYP2C19.json
@@ -0,0 +1,77 @@
+{
+  "guideline": {
+    "id": "PA166328677",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Citalopram - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328677",
+    "relatedChemicals": [
+      {
+        "id": "PA449015",
+        "name": "citalopram",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166309901",
+      "name": "Recommendation Annotation PA166309901",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449015",
+          "name": "citalopram",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452208400,
+        "html": "<p>&quot;Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166309921",
+      "name": "Recommendation Annotation PA166309921",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449015",
+          "name": "citalopram",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452208420,
+        "html": "<p>&quot;Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clobazam_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clobazam_and_CYP2C19.json
new file mode 100644
index 000000000..c1f536ff2
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clobazam_and_CYP2C19.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328678",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Clobazam - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328678",
+    "relatedChemicals": [
+      {
+        "id": "PA10888",
+        "name": "clobazam",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166309942",
+      "name": "Recommendation Annotation PA166309942",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10888",
+          "name": "clobazam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452208481,
+        "html": "<p>&quot;Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166307882",
+      "name": "Recommendation Annotation PA166307882",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10888",
+          "name": "clobazam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452189301,
+        "html": "<p>&quot;Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166309941",
+      "name": "Recommendation Annotation PA166309941",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10888",
+          "name": "clobazam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452208480,
+        "html": "<p>&quot;Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166308981",
+      "name": "Recommendation Annotation PA166308981",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10888",
+          "name": "clobazam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452198000,
+        "html": "<p>&quot;Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clomipramine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clomipramine_and_CYP2D6.json
new file mode 100644
index 000000000..8cd4dfbe7
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clomipramine_and_CYP2D6.json
@@ -0,0 +1,437 @@
+{
+  "guideline": {
+    "id": "PA166328752",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Clomipramine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328752",
+    "relatedChemicals": [
+      {
+        "id": "PA449048",
+        "name": "clomipramine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315589",
+      "name": "Recommendation Annotation PA166315589",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246508,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315587",
+      "name": "Recommendation Annotation PA166315587",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246506,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315563",
+      "name": "Recommendation Annotation PA166315563",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246482,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315585",
+      "name": "Recommendation Annotation PA166315585",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246504,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315561",
+      "name": "Recommendation Annotation PA166315561",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246480,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315603",
+      "name": "Recommendation Annotation PA166315603",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246522,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥5.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315601",
+      "name": "Recommendation Annotation PA166315601",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246520,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315583",
+      "name": "Recommendation Annotation PA166315583",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246502,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315588",
+      "name": "Recommendation Annotation PA166315588",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246507,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315586",
+      "name": "Recommendation Annotation PA166315586",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246505,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315562",
+      "name": "Recommendation Annotation PA166315562",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246481,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315604",
+      "name": "Recommendation Annotation PA166315604",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246523,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥6.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315584",
+      "name": "Recommendation Annotation PA166315584",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246503,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315602",
+      "name": "Recommendation Annotation PA166315602",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246521,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315582",
+      "name": "Recommendation Annotation PA166315582",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246501,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315581",
+      "name": "Recommendation Annotation PA166315581",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246500,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315590",
+      "name": "Recommendation Annotation PA166315590",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449048",
+          "name": "clomipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246509,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clopidogrel_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clopidogrel_and_CYP2C19.json
new file mode 100644
index 000000000..b6cdb20c9
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clopidogrel_and_CYP2C19.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328679",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Clopidogrel - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328679",
+    "relatedChemicals": [
+      {
+        "id": "PA449053",
+        "name": "clopidogrel",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166310303",
+      "name": "Recommendation Annotation PA166310303",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449053",
+          "name": "clopidogrel",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452211483,
+        "html": "<p>&quot;Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166307922",
+      "name": "Recommendation Annotation PA166307922",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449053",
+          "name": "clopidogrel",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452189341,
+        "html": "<p>&quot;Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166307921",
+      "name": "Recommendation Annotation PA166307921",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449053",
+          "name": "clopidogrel",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452189340,
+        "html": "<p>&quot;Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310302",
+      "name": "Recommendation Annotation PA166310302",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449053",
+          "name": "clopidogrel",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452211482,
+        "html": "<p>&quot;Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clozapine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clozapine_and_CYP2D6.json
new file mode 100644
index 000000000..f47e02996
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_clozapine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328680",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Clozapine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328680",
+    "relatedChemicals": [
+      {
+        "id": "PA449061",
+        "name": "clozapine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166311202",
+      "name": "Recommendation Annotation PA166311202",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449061",
+          "name": "clozapine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452214441,
+        "html": "<p>&quot;Results in higher systemic concentrations. Dosage reductions may be necessary.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_codeine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_codeine_and_CYP2D6.json
new file mode 100644
index 000000000..bc3b0eb80
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_codeine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328727",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Codeine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328727",
+    "relatedChemicals": [
+      {
+        "id": "PA449088",
+        "name": "codeine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166313001",
+      "name": "Recommendation Annotation PA166313001",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449088",
+          "name": "codeine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452221500,
+        "html": "<p>&quot;Results in lower systemic active metabolite concentrations and may result in reduced efficacy.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_darifenacin_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_darifenacin_and_CYP2D6.json
new file mode 100644
index 000000000..1d54e7267
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_darifenacin_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328753",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Darifenacin - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328753",
+    "relatedChemicals": [
+      {
+        "id": "PA164774901",
+        "name": "darifenacin",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315821",
+      "name": "Recommendation Annotation PA166315821",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA164774901",
+          "name": "darifenacin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246800,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_desipramine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_desipramine_and_CYP2D6.json
new file mode 100644
index 000000000..73f7d66f6
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_desipramine_and_CYP2D6.json
@@ -0,0 +1,413 @@
+{
+  "guideline": {
+    "id": "PA166328754",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Desipramine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328754",
+    "relatedChemicals": [
+      {
+        "id": "PA449233",
+        "name": "desipramine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315629",
+      "name": "Recommendation Annotation PA166315629",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246548,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315627",
+      "name": "Recommendation Annotation PA166315627",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246546,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315625",
+      "name": "Recommendation Annotation PA166315625",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246544,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315636",
+      "name": "Recommendation Annotation PA166315636",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246555,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥6.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315622",
+      "name": "Recommendation Annotation PA166315622",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246541,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315635",
+      "name": "Recommendation Annotation PA166315635",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246554,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥5.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315633",
+      "name": "Recommendation Annotation PA166315633",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246552,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315631",
+      "name": "Recommendation Annotation PA166315631",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246550,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315628",
+      "name": "Recommendation Annotation PA166315628",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246547,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315626",
+      "name": "Recommendation Annotation PA166315626",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246545,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315624",
+      "name": "Recommendation Annotation PA166315624",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246543,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315623",
+      "name": "Recommendation Annotation PA166315623",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246542,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315621",
+      "name": "Recommendation Annotation PA166315621",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246540,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315634",
+      "name": "Recommendation Annotation PA166315634",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246553,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315632",
+      "name": "Recommendation Annotation PA166315632",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246551,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315630",
+      "name": "Recommendation Annotation PA166315630",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449233",
+          "name": "desipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246549,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_deutetrabenazine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_deutetrabenazine_and_CYP2D6.json
new file mode 100644
index 000000000..c5a1b41dd
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_deutetrabenazine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328682",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Deutetrabenazine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328682",
+    "relatedChemicals": [
+      {
+        "id": "PA166169881",
+        "name": "deutetrabenazine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312306",
+      "name": "Recommendation Annotation PA166312306",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166169881",
+          "name": "deutetrabenazine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216567,
+        "html": "<p>&quot;Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.25"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_dexlansoprazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_dexlansoprazole_and_CYP2C19.json
new file mode 100644
index 000000000..bc0fc87bf
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_dexlansoprazole_and_CYP2C19.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328755",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Dexlansoprazole - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328755",
+    "relatedChemicals": [
+      {
+        "id": "PA166110257",
+        "name": "dexlansoprazole",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315841",
+      "name": "Recommendation Annotation PA166315841",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166110257",
+          "name": "dexlansoprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246820,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315843",
+      "name": "Recommendation Annotation PA166315843",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizer",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166110257",
+          "name": "dexlansoprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246822,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315844",
+      "name": "Recommendation Annotation PA166315844",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizer",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166110257",
+          "name": "dexlansoprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246823,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315842",
+      "name": "Recommendation Annotation PA166315842",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166110257",
+          "name": "dexlansoprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246821,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_diazepam_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_diazepam_and_CYP2C19.json
new file mode 100644
index 000000000..2fe97f591
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_diazepam_and_CYP2C19.json
@@ -0,0 +1,77 @@
+{
+  "guideline": {
+    "id": "PA166328756",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Diazepam - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328756",
+    "relatedChemicals": [
+      {
+        "id": "PA449283",
+        "name": "diazepam",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315845",
+      "name": "Recommendation Annotation PA166315845",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449283",
+          "name": "diazepam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246824,
+        "html": "<p>&quot;May affect systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315846",
+      "name": "Recommendation Annotation PA166315846",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449283",
+          "name": "diazepam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246825,
+        "html": "<p>&quot;May affect systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_dolutegravir_and_UGT1A1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_dolutegravir_and_UGT1A1.json
new file mode 100644
index 000000000..3a5b48f59
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_dolutegravir_and_UGT1A1.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328757",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Dolutegravir - UGT1A1",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328757",
+    "relatedChemicals": [
+      {
+        "id": "PA166114961",
+        "name": "dolutegravir",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA420",
+        "name": "UDP glucuronosyltransferase 1 family, polypeptide A1",
+        "symbol": "UGT1A1"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315847",
+      "name": "Recommendation Annotation PA166315847",
+      "population": "Affected subgroup: UGT1A1 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166114961",
+          "name": "dolutegravir",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246826,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "UGT1A1": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_donepezil_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_donepezil_and_CYP2D6.json
new file mode 100644
index 000000000..cd7ba19af
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_donepezil_and_CYP2D6.json
@@ -0,0 +1,317 @@
+{
+  "guideline": {
+    "id": "PA166328758",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Donepezil - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328758",
+    "relatedChemicals": [
+      {
+        "id": "PA449394",
+        "name": "donepezil",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315849",
+      "name": "Recommendation Annotation PA166315849",
+      "population": "Affected subgroup: CYP2D6 ultrarapid or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449394",
+          "name": "donepezil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246828,
+        "html": "<p>&quot;Alters systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥6.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315858",
+      "name": "Recommendation Annotation PA166315858",
+      "population": "Affected subgroup: CYP2D6 ultrarapid or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449394",
+          "name": "donepezil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246837,
+        "html": "<p>&quot;Alters systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315856",
+      "name": "Recommendation Annotation PA166315856",
+      "population": "Affected subgroup: CYP2D6 ultrarapid or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449394",
+          "name": "donepezil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246835,
+        "html": "<p>&quot;Alters systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315854",
+      "name": "Recommendation Annotation PA166315854",
+      "population": "Affected subgroup: CYP2D6 ultrarapid or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449394",
+          "name": "donepezil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246833,
+        "html": "<p>&quot;Alters systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315851",
+      "name": "Recommendation Annotation PA166315851",
+      "population": "Affected subgroup: CYP2D6 ultrarapid or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449394",
+          "name": "donepezil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246830,
+        "html": "<p>&quot;Alters systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315848",
+      "name": "Recommendation Annotation PA166315848",
+      "population": "Affected subgroup: CYP2D6 ultrarapid or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449394",
+          "name": "donepezil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246827,
+        "html": "<p>&quot;Alters systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315859",
+      "name": "Recommendation Annotation PA166315859",
+      "population": "Affected subgroup: CYP2D6 ultrarapid or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449394",
+          "name": "donepezil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246838,
+        "html": "<p>&quot;Alters systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315857",
+      "name": "Recommendation Annotation PA166315857",
+      "population": "Affected subgroup: CYP2D6 ultrarapid or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449394",
+          "name": "donepezil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246836,
+        "html": "<p>&quot;Alters systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315853",
+      "name": "Recommendation Annotation PA166315853",
+      "population": "Affected subgroup: CYP2D6 ultrarapid or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449394",
+          "name": "donepezil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246832,
+        "html": "<p>&quot;Alters systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315855",
+      "name": "Recommendation Annotation PA166315855",
+      "population": "Affected subgroup: CYP2D6 ultrarapid or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449394",
+          "name": "donepezil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246834,
+        "html": "<p>&quot;Alters systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315852",
+      "name": "Recommendation Annotation PA166315852",
+      "population": "Affected subgroup: CYP2D6 ultrarapid or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449394",
+          "name": "donepezil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246831,
+        "html": "<p>&quot;Alters systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315850",
+      "name": "Recommendation Annotation PA166315850",
+      "population": "Affected subgroup: CYP2D6 ultrarapid or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449394",
+          "name": "donepezil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246829,
+        "html": "<p>&quot;Alters systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥5.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_doxepin_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_doxepin_and_CYP2C19.json
new file mode 100644
index 000000000..324f4257b
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_doxepin_and_CYP2C19.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328759",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Doxepin - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328759",
+    "relatedChemicals": [
+      {
+        "id": "PA449409",
+        "name": "doxepin",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315862",
+      "name": "Recommendation Annotation PA166315862",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246841,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315860",
+      "name": "Recommendation Annotation PA166315860",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246839,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315863",
+      "name": "Recommendation Annotation PA166315863",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246842,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315861",
+      "name": "Recommendation Annotation PA166315861",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246840,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_doxepin_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_doxepin_and_CYP2D6.json
new file mode 100644
index 000000000..c2146bf54
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_doxepin_and_CYP2D6.json
@@ -0,0 +1,413 @@
+{
+  "guideline": {
+    "id": "PA166328760",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Doxepin - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328760",
+    "relatedChemicals": [
+      {
+        "id": "PA449409",
+        "name": "doxepin",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315638",
+      "name": "Recommendation Annotation PA166315638",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246557,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315649",
+      "name": "Recommendation Annotation PA166315649",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246588,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315646",
+      "name": "Recommendation Annotation PA166315646",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246585,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315644",
+      "name": "Recommendation Annotation PA166315644",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246583,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315642",
+      "name": "Recommendation Annotation PA166315642",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246581,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315640",
+      "name": "Recommendation Annotation PA166315640",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246559,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315651",
+      "name": "Recommendation Annotation PA166315651",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246590,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥5.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315650",
+      "name": "Recommendation Annotation PA166315650",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246589,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315639",
+      "name": "Recommendation Annotation PA166315639",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246558,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315637",
+      "name": "Recommendation Annotation PA166315637",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246556,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315648",
+      "name": "Recommendation Annotation PA166315648",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246587,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315647",
+      "name": "Recommendation Annotation PA166315647",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246586,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315645",
+      "name": "Recommendation Annotation PA166315645",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246584,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315643",
+      "name": "Recommendation Annotation PA166315643",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246582,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315641",
+      "name": "Recommendation Annotation PA166315641",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246580,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315652",
+      "name": "Recommendation Annotation PA166315652",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449409",
+          "name": "doxepin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246591,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥6.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_dronabinol_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_dronabinol_and_CYP2C9.json
new file mode 100644
index 000000000..84bd9fa19
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_dronabinol_and_CYP2C9.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328683",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Dronabinol - CYP2C9",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328683",
+    "relatedChemicals": [
+      {
+        "id": "PA449421",
+        "name": "dronabinol",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA126",
+        "name": "cytochrome P450 family 2 subfamily C member 9",
+        "symbol": "CYP2C9"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312022",
+      "name": "Recommendation Annotation PA166312022",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449421",
+          "name": "dronabinol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216221,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312001",
+      "name": "Recommendation Annotation PA166312001",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449421",
+          "name": "dronabinol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216200,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312021",
+      "name": "Recommendation Annotation PA166312021",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449421",
+          "name": "dronabinol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216220,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312023",
+      "name": "Recommendation Annotation PA166312023",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449421",
+          "name": "dronabinol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216222,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "1.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_efavirenz_and_CYP2B6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_efavirenz_and_CYP2B6.json
new file mode 100644
index 000000000..38339e82c
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_efavirenz_and_CYP2B6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328728",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Efavirenz - CYP2B6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328728",
+    "relatedChemicals": [
+      {
+        "id": "PA449441",
+        "name": "efavirenz",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA123",
+        "name": "cytochrome P450 family 2 subfamily B member 6",
+        "symbol": "CYP2B6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166313981",
+      "name": "Recommendation Annotation PA166313981",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449441",
+          "name": "efavirenz",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452236980,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2B6": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_elagolix_and_SLCO1B1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_elagolix_and_SLCO1B1.json
new file mode 100644
index 000000000..e002ea9b6
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_elagolix_and_SLCO1B1.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328761",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Elagolix - SLCO1B1",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328761",
+    "relatedChemicals": [
+      {
+        "id": "PA166182348",
+        "name": "elagolix",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA134865839",
+        "name": "solute carrier organic anion transporter family member 1B1",
+        "symbol": "SLCO1B1"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315864",
+      "name": "Recommendation Annotation PA166315864",
+      "population": "Affected subgroup: SLCO1B1 521 CC (poor function transporters)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166182348",
+          "name": "elagolix",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246843,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "SLCO1B1": "Poor Function"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_eliglustat_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_eliglustat_and_CYP2D6.json
new file mode 100644
index 000000000..4be54e0a5
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_eliglustat_and_CYP2D6.json
@@ -0,0 +1,533 @@
+{
+  "guideline": {
+    "id": "PA166328684",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Eliglustat - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328684",
+    "relatedChemicals": [
+      {
+        "id": "PA166123486",
+        "name": "eliglustat",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312389",
+      "name": "Recommendation Annotation PA166312389",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216669,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312407",
+      "name": "Recommendation Annotation PA166312407",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216706,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312409",
+      "name": "Recommendation Annotation PA166312409",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216708,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312396",
+      "name": "Recommendation Annotation PA166312396",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216676,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥5.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312403",
+      "name": "Recommendation Annotation PA166312403",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216702,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312387",
+      "name": "Recommendation Annotation PA166312387",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216667,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312405",
+      "name": "Recommendation Annotation PA166312405",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216704,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312392",
+      "name": "Recommendation Annotation PA166312392",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216672,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312410",
+      "name": "Recommendation Annotation PA166312410",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216709,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312423",
+      "name": "Recommendation Annotation PA166312423",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216722,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312412",
+      "name": "Recommendation Annotation PA166312412",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216711,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312390",
+      "name": "Recommendation Annotation PA166312390",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216670,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312388",
+      "name": "Recommendation Annotation PA166312388",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216668,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312406",
+      "name": "Recommendation Annotation PA166312406",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216705,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312408",
+      "name": "Recommendation Annotation PA166312408",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216707,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312404",
+      "name": "Recommendation Annotation PA166312404",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216703,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312422",
+      "name": "Recommendation Annotation PA166312422",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216721,
+        "html": "<p>Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312393",
+      "name": "Recommendation Annotation PA166312393",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216673,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312411",
+      "name": "Recommendation Annotation PA166312411",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216710,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312413",
+      "name": "Recommendation Annotation PA166312413",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216712,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥6.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312391",
+      "name": "Recommendation Annotation PA166312391",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166123486",
+          "name": "eliglustat",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216671,
+        "html": "<p>&quot;Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_erdafitinib_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_erdafitinib_and_CYP2C9.json
new file mode 100644
index 000000000..08b6eb015
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_erdafitinib_and_CYP2C9.json
@@ -0,0 +1,77 @@
+{
+  "guideline": {
+    "id": "PA166328685",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Erdafitinib - CYP2C9",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328685",
+    "relatedChemicals": [
+      {
+        "id": "PA166182720",
+        "name": "erdafitinib",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA126",
+        "name": "cytochrome P450 family 2 subfamily C member 9",
+        "symbol": "CYP2C9"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312701",
+      "name": "Recommendation Annotation PA166312701",
+      "population": "Affected subgroup: CYP2C9*3/*3 (poor metabolizers)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166182720",
+          "name": "erdafitinib",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452219000,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312681",
+      "name": "Recommendation Annotation PA166312681",
+      "population": "Affected subgroup: CYP2C9*3/*3 (poor metabolizers)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166182720",
+          "name": "erdafitinib",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452218980,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_escitalopram_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_escitalopram_and_CYP2C19.json
new file mode 100644
index 000000000..8c75e3aca
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_escitalopram_and_CYP2C19.json
@@ -0,0 +1,149 @@
+{
+  "guideline": {
+    "id": "PA166328762",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Escitalopram - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328762",
+    "relatedChemicals": [
+      {
+        "id": "PA10074",
+        "name": "escitalopram",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315869",
+      "name": "Recommendation Annotation PA166315869",
+      "population": "Affected subgroup: CYP2C19 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10074",
+          "name": "escitalopram",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246848,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Ultrarapid Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315867",
+      "name": "Recommendation Annotation PA166315867",
+      "population": "Affected subgroup: CYP2C19 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10074",
+          "name": "escitalopram",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246846,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315868",
+      "name": "Recommendation Annotation PA166315868",
+      "population": "Affected subgroup: CYP2C19 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10074",
+          "name": "escitalopram",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246847,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315866",
+      "name": "Recommendation Annotation PA166315866",
+      "population": "Affected subgroup: CYP2C19 ultrarapid, intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10074",
+          "name": "escitalopram",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246845,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315865",
+      "name": "Recommendation Annotation PA166315865",
+      "population": "Affected subgroup: CYP2C19 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10074",
+          "name": "escitalopram",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246844,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_esomeprazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_esomeprazole_and_CYP2C19.json
new file mode 100644
index 000000000..e5413fa2b
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_esomeprazole_and_CYP2C19.json
@@ -0,0 +1,77 @@
+{
+  "guideline": {
+    "id": "PA166328763",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Esomeprazole - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328763",
+    "relatedChemicals": [
+      {
+        "id": "PA10075",
+        "name": "esomeprazole",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315871",
+      "name": "Recommendation Annotation PA166315871",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10075",
+          "name": "esomeprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246850,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315870",
+      "name": "Recommendation Annotation PA166315870",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10075",
+          "name": "esomeprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246849,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fesoterodine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fesoterodine_and_CYP2D6.json
new file mode 100644
index 000000000..1df4f6bfd
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fesoterodine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328764",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Fesoterodine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328764",
+    "relatedChemicals": [
+      {
+        "id": "PA165958376",
+        "name": "fesoterodine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315872",
+      "name": "Recommendation Annotation PA166315872",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA165958376",
+          "name": "fesoterodine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246851,
+        "html": "<p>&quot;Results in higher systemic active metabolite concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_flibanserin_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_flibanserin_and_CYP2C19.json
new file mode 100644
index 000000000..adb9bf87f
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_flibanserin_and_CYP2C19.json
@@ -0,0 +1,77 @@
+{
+  "guideline": {
+    "id": "PA166328686",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Flibanserin - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328686",
+    "relatedChemicals": [
+      {
+        "id": "PA166153431",
+        "name": "flibanserin",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315202",
+      "name": "Recommendation Annotation PA166315202",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166153431",
+          "name": "flibanserin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452245881,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315201",
+      "name": "Recommendation Annotation PA166315201",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166153431",
+          "name": "flibanserin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452245880,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fluorouracil_and_DPYD.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fluorouracil_and_DPYD.json
new file mode 100644
index 000000000..49b4d9e6f
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fluorouracil_and_DPYD.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328688",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Fluorouracil - DPYD",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328688",
+    "relatedChemicals": [
+      {
+        "id": "PA128406956",
+        "name": "fluorouracil",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA145",
+        "name": "dihydropyrimidine dehydrogenase",
+        "symbol": "DPYD"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166310702",
+      "name": "Recommendation Annotation PA166310702",
+      "population": "Affected subgroup: DPYD intermediate or poor metabolizer",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA128406956",
+          "name": "fluorouracil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213141,
+        "html": "<p>&quot;Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "DPYD": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310704",
+      "name": "Recommendation Annotation PA166310704",
+      "population": "Affected subgroup: DPYD intermediate or poor metabolizer",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA128406956",
+          "name": "fluorouracil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213143,
+        "html": "<p>&quot;Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "DPYD": "1.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166310703",
+      "name": "Recommendation Annotation PA166310703",
+      "population": "Affected subgroup: DPYD intermediate or poor metabolizer",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA128406956",
+          "name": "fluorouracil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213142,
+        "html": "<p>&quot;Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "DPYD": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310741",
+      "name": "Recommendation Annotation PA166310741",
+      "population": "Affected subgroup: DPYD intermediate or poor metabolizer",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA128406956",
+          "name": "fluorouracil",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213180,
+        "html": "<p>&quot;Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "DPYD": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_flurbiprofen_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_flurbiprofen_and_CYP2C9.json
new file mode 100644
index 000000000..517c82c4c
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_flurbiprofen_and_CYP2C9.json
@@ -0,0 +1,104 @@
+{
+  "guideline": {
+    "id": "PA166328687",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Flurbiprofen - CYP2C9",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328687",
+    "relatedChemicals": [
+      {
+        "id": "PA449683",
+        "name": "flurbiprofen",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA126",
+        "name": "cytochrome P450 family 2 subfamily C member 9",
+        "symbol": "CYP2C9"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166311942",
+      "name": "Recommendation Annotation PA166311942",
+      "population": "Affected subgroup: CYP2C9 poor metabolizers or *3 carriers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449683",
+          "name": "flurbiprofen",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216141,
+        "html": "<p>&quot;Results in higher systemic concentrations. Use a reduced dosage in poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312662",
+      "name": "Recommendation Annotation PA166312662",
+      "population": "Affected subgroup: CYP2C9 poor metabolizers or *3 carriers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449683",
+          "name": "flurbiprofen",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452218961,
+        "html": "<p>&quot;Results in higher systemic concentrations. Use a reduced dosage in poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": {
+          "*1": 1.0,
+          "*3": 1.0
+        }
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311928",
+      "name": "Recommendation Annotation PA166311928",
+      "population": "Affected subgroup: CYP2C9 poor metabolizers or *3 carriers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449683",
+          "name": "flurbiprofen",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216127,
+        "html": "<p>&quot;Results in higher systemic concentrations. Use a reduced dosage in poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.5"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fluvoxamine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fluvoxamine_and_CYP2D6.json
new file mode 100644
index 000000000..b85828bfa
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fluvoxamine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328765",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Fluvoxamine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328765",
+    "relatedChemicals": [
+      {
+        "id": "PA449690",
+        "name": "fluvoxamine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315873",
+      "name": "Recommendation Annotation PA166315873",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449690",
+          "name": "fluvoxamine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246852,
+        "html": "<p>&quot;Results in higher systemic concentrations. Use with caution.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fosphenytoin_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fosphenytoin_and_CYP2C9.json
new file mode 100644
index 000000000..7728f9c38
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fosphenytoin_and_CYP2C9.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328689",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Fosphenytoin - CYP2C9",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328689",
+    "relatedChemicals": [
+      {
+        "id": "PA164746820",
+        "name": "fosphenytoin",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA126",
+        "name": "cytochrome P450 family 2 subfamily C member 9",
+        "symbol": "CYP2C9"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166324225",
+      "name": "Recommendation Annotation PA166324225",
+      "population": "CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA164746820",
+          "name": "fosphenytoin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452337684,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk (central nervous system toxicity). Consider starting at the lower end of the dosage range and monitor serum concentrations. Refer to FDA labeling for specific dosing recommendations. Carriers of CYP2C9*3 alleles may be at increased risk of severe cutaneous adverse reactions. Consider avoiding fosphenytoin as an alternative to carbamazepine in patients who are CYP2C9*3 carriers. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "1.5"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166324223",
+      "name": "Recommendation Annotation PA166324223",
+      "population": "CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA164746820",
+          "name": "fosphenytoin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452337682,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk (central nervous system toxicity). Consider starting at the lower end of the dosage range and monitor serum concentrations. Refer to FDA labeling for specific dosing recommendations. Carriers of CYP2C9*3 alleles may be at increased risk of severe cutaneous adverse reactions. Consider avoiding fosphenytoin as an alternative to carbamazepine in patients who are CYP2C9*3 carriers. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.5"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166324224",
+      "name": "Recommendation Annotation PA166324224",
+      "population": "CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA164746820",
+          "name": "fosphenytoin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452337683,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk (central nervous system toxicity). Consider starting at the lower end of the dosage range and monitor serum concentrations. Refer to FDA labeling for specific dosing recommendations. Carriers of CYP2C9*3 alleles may be at increased risk of severe cutaneous adverse reactions. Consider avoiding fosphenytoin as an alternative to carbamazepine in patients who are CYP2C9*3 carriers. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "1.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166324222",
+      "name": "Recommendation Annotation PA166324222",
+      "population": "CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA164746820",
+          "name": "fosphenytoin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452337681,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk (central nervous system toxicity). Consider starting at the lower end of the dosage range and monitor serum concentrations. Refer to FDA labeling for specific dosing recommendations. Carriers of CYP2C9*3 alleles may be at increased risk of severe cutaneous adverse reactions. Consider avoiding fosphenytoin as an alternative to carbamazepine in patients who are CYP2C9*3 carriers. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fosphenytoin_and_HLA-B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fosphenytoin_and_HLA-B.json
new file mode 100644
index 000000000..b601657aa
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_fosphenytoin_and_HLA-B.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328690",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Fosphenytoin - HLA-B",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328690",
+    "relatedChemicals": [
+      {
+        "id": "PA164746820",
+        "name": "fosphenytoin",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA35056",
+        "name": "major histocompatibility complex, class I, B",
+        "symbol": "HLA-B"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166324221",
+      "name": "Recommendation Annotation PA166324221",
+      "population": "HLA-B*15:02 allele positive",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA164746820",
+          "name": "fosphenytoin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452337680,
+        "html": "<p>&quot;May result in higher adverse reaction risk (severe cutaneous reactions). Patients positive for HLA-B*15:02 may be at increased risk of Stevens Johnson Syndrome/Toxic Epidermal necrolysis (SJS/TEN). Consider avoiding fosphenytoin as an alternative to carbamazepine in patients who are positive for HLA-B*15:02. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "HLA-B": "*15:02 positive"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_galantamine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_galantamine_and_CYP2D6.json
new file mode 100644
index 000000000..1e1c3cb94
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_galantamine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328766",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Galantamine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328766",
+    "relatedChemicals": [
+      {
+        "id": "PA449726",
+        "name": "galantamine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315874",
+      "name": "Recommendation Annotation PA166315874",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449726",
+          "name": "galantamine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246853,
+        "html": "<p>&quot;Results in higher systemic concentrations. Titrate dosage based on tolerability.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_gefitinib_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_gefitinib_and_CYP2D6.json
new file mode 100644
index 000000000..e4a776e57
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_gefitinib_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328691",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Gefitinib - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328691",
+    "relatedChemicals": [
+      {
+        "id": "PA131301952",
+        "name": "gefitinib",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166311201",
+      "name": "Recommendation Annotation PA166311201",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA131301952",
+          "name": "gefitinib",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452214440,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_ibuprofen_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_ibuprofen_and_CYP2C9.json
new file mode 100644
index 000000000..5fea98aee
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_ibuprofen_and_CYP2C9.json
@@ -0,0 +1,77 @@
+{
+  "guideline": {
+    "id": "PA166328768",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Ibuprofen - CYP2C9",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328768",
+    "relatedChemicals": [
+      {
+        "id": "PA449957",
+        "name": "ibuprofen",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA126",
+        "name": "cytochrome P450 family 2 subfamily C member 9",
+        "symbol": "CYP2C9"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315875",
+      "name": "Recommendation Annotation PA166315875",
+      "population": "Affected subgroup: CYP2C9 poor metabolizers or *3 carriers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449957",
+          "name": "ibuprofen",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246854,
+        "html": "<p>&quot;May result in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315876",
+      "name": "Recommendation Annotation PA166315876",
+      "population": "Affected subgroup: CYP2C9 poor metabolizers or *3 carriers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449957",
+          "name": "ibuprofen",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246855,
+        "html": "<p>&quot;May result in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_iloperidone_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_iloperidone_and_CYP2D6.json
new file mode 100644
index 000000000..3543cc540
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_iloperidone_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328692",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Iloperidone - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328692",
+    "relatedChemicals": [
+      {
+        "id": "PA161199368",
+        "name": "iloperidone",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312221",
+      "name": "Recommendation Annotation PA166312221",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA161199368",
+          "name": "iloperidone",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216480,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_imipramine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_imipramine_and_CYP2D6.json
new file mode 100644
index 000000000..ccdd07981
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_imipramine_and_CYP2D6.json
@@ -0,0 +1,413 @@
+{
+  "guideline": {
+    "id": "PA166328769",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Imipramine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328769",
+    "relatedChemicals": [
+      {
+        "id": "PA449969",
+        "name": "imipramine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315662",
+      "name": "Recommendation Annotation PA166315662",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246601,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315660",
+      "name": "Recommendation Annotation PA166315660",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246599,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315659",
+      "name": "Recommendation Annotation PA166315659",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246598,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315657",
+      "name": "Recommendation Annotation PA166315657",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246596,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315655",
+      "name": "Recommendation Annotation PA166315655",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246594,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315668",
+      "name": "Recommendation Annotation PA166315668",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246607,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥6.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315666",
+      "name": "Recommendation Annotation PA166315666",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246605,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315653",
+      "name": "Recommendation Annotation PA166315653",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246592,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315664",
+      "name": "Recommendation Annotation PA166315664",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246603,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315661",
+      "name": "Recommendation Annotation PA166315661",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246600,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315658",
+      "name": "Recommendation Annotation PA166315658",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246597,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315656",
+      "name": "Recommendation Annotation PA166315656",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246595,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315654",
+      "name": "Recommendation Annotation PA166315654",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246593,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315667",
+      "name": "Recommendation Annotation PA166315667",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246606,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥5.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315665",
+      "name": "Recommendation Annotation PA166315665",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246604,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315663",
+      "name": "Recommendation Annotation PA166315663",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA449969",
+          "name": "imipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246602,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_irinotecan_and_UGT1A1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_irinotecan_and_UGT1A1.json
new file mode 100644
index 000000000..49fd01922
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_irinotecan_and_UGT1A1.json
@@ -0,0 +1,77 @@
+{
+  "guideline": {
+    "id": "PA166328693",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Irinotecan - UGT1A1",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328693",
+    "relatedChemicals": [
+      {
+        "id": "PA450085",
+        "name": "irinotecan",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA420",
+        "name": "UDP glucuronosyltransferase 1 family, polypeptide A1",
+        "symbol": "UGT1A1"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166310422",
+      "name": "Recommendation Annotation PA166310422",
+      "population": "Affected subgroup: UGAT1A1*1/*6, *1/*28 (intermediate metabolizers) or  *6/*6, *6/*28, *28/*28 (poor metabolizers)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450085",
+          "name": "irinotecan",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452211641,
+        "html": "<p>&quot;Results in higher systemic active metabolite concentrations and higher adverse reaction risk (severe or life-threatening neutropenia, severe diarrhea). Closely monitor for neutropenia during and after treatment. Consider reducing the starting dosage by at least one level in poor metabolizers and modify the dosage based on individual patient tolerance. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "UGT1A1": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166310421",
+      "name": "Recommendation Annotation PA166310421",
+      "population": "Affected subgroup: UGT1A1*1/*6, *1/*28 (intermediate metabolizers) or  *6/*6, *6/*28, *28/*28 (poor metabolizers)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450085",
+          "name": "irinotecan",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452211640,
+        "html": "<p>&quot;Results in higher systemic active metabolite concentrations and higher adverse reaction risk (severe or life-threatening neutropenia, severe diarrhea). Closely monitor for neutropenia during and after treatment. Consider reducing the starting dosage by at least one level in poor metabolizers and modify the dosage based on individual patient tolerance. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "UGT1A1": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_lansoprazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_lansoprazole_and_CYP2C19.json
new file mode 100644
index 000000000..53546f173
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_lansoprazole_and_CYP2C19.json
@@ -0,0 +1,77 @@
+{
+  "guideline": {
+    "id": "PA166328770",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Lansoprazole - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328770",
+    "relatedChemicals": [
+      {
+        "id": "PA450180",
+        "name": "lansoprazole",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315882",
+      "name": "Recommendation Annotation PA166315882",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450180",
+          "name": "lansoprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246861,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315881",
+      "name": "Recommendation Annotation PA166315881",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450180",
+          "name": "lansoprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246860,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_lofexidine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_lofexidine_and_CYP2D6.json
new file mode 100644
index 000000000..cf0b829f8
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_lofexidine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328694",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Lofexidine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328694",
+    "relatedChemicals": [
+      {
+        "id": "PA164744510",
+        "name": "lofexidine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166311324",
+      "name": "Recommendation Annotation PA166311324",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA164744510",
+          "name": "lofexidine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215503,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_mavacamten_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_mavacamten_and_CYP2C19.json
new file mode 100644
index 000000000..e5e48a762
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_mavacamten_and_CYP2C19.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328732",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Mavacamten - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328732",
+    "relatedChemicals": [
+      {
+        "id": "PA166272922",
+        "name": "mavacamten",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315343",
+      "name": "Recommendation Annotation PA166315343",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166272922",
+          "name": "mavacamten",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246222,
+        "html": "<p>&quot;Results in higher systemic concentrations and may have higher adverse reaction risk (heart failure). Dosage is based on individual response. The dose titration and monitoring schedule accounts for differences due to CYP2C19 genetic variation, so adjustments based on CYP2C19 genotype are not necessary. Refer to FDA labeling for specific dosing recommendations and monitoring.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315341",
+      "name": "Recommendation Annotation PA166315341",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166272922",
+          "name": "mavacamten",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246220,
+        "html": "<p>&quot;Results in higher systemic concentrations and may have higher adverse reaction risk (heart failure). Dosage is based on individual response. The dose titration and monitoring schedule accounts for differences due to CYP2C19 genetic variation, so adjustments based on CYP2C19 genotype are not necessary. Refer to FDA labeling for specific dosing recommendations and monitoring.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315344",
+      "name": "Recommendation Annotation PA166315344",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166272922",
+          "name": "mavacamten",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246223,
+        "html": "<p>&quot;Results in higher systemic concentrations and may have higher adverse reaction risk (heart failure). Dosage is based on individual response. The dose titration and monitoring schedule accounts for differences due to CYP2C19 genetic variation, so adjustments based on CYP2C19 genotype are not necessary. Refer to FDA labeling for specific dosing recommendations and monitoring.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315342",
+      "name": "Recommendation Annotation PA166315342",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166272922",
+          "name": "mavacamten",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246221,
+        "html": "<p>&quot;Results in higher systemic concentrations and may have higher adverse reaction risk (heart failure). Dosage is based on individual response. The dose titration and monitoring schedule accounts for differences due to CYP2C19 genetic variation, so adjustments based on CYP2C19 genotype are not necessary. Refer to FDA labeling for specific dosing recommendations and monitoring.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_meclizine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_meclizine_and_CYP2D6.json
new file mode 100644
index 000000000..ae4e90939
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_meclizine_and_CYP2D6.json
@@ -0,0 +1,413 @@
+{
+  "guideline": {
+    "id": "PA166328695",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Meclizine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328695",
+    "relatedChemicals": [
+      {
+        "id": "PA450338",
+        "name": "meclizine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166311344",
+      "name": "Recommendation Annotation PA166311344",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215523,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311342",
+      "name": "Recommendation Annotation PA166311342",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215521,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311364",
+      "name": "Recommendation Annotation PA166311364",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215543,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥6.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311348",
+      "name": "Recommendation Annotation PA166311348",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215527,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311346",
+      "name": "Recommendation Annotation PA166311346",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215525,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311363",
+      "name": "Recommendation Annotation PA166311363",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215542,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥5.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311350",
+      "name": "Recommendation Annotation PA166311350",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215529,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311361",
+      "name": "Recommendation Annotation PA166311361",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215540,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311343",
+      "name": "Recommendation Annotation PA166311343",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215522,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311341",
+      "name": "Recommendation Annotation PA166311341",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215520,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311352",
+      "name": "Recommendation Annotation PA166311352",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215531,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311347",
+      "name": "Recommendation Annotation PA166311347",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215526,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311345",
+      "name": "Recommendation Annotation PA166311345",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215524,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311349",
+      "name": "Recommendation Annotation PA166311349",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215528,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311351",
+      "name": "Recommendation Annotation PA166311351",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215530,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166311362",
+      "name": "Recommendation Annotation PA166311362",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450338",
+          "name": "meclizine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215541,
+        "html": "<p>&quot;May affect systemic concentrations. Monitor for adverse reactions and clinical effect.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_meloxicam_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_meloxicam_and_CYP2C9.json
new file mode 100644
index 000000000..8cd36e6cc
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_meloxicam_and_CYP2C9.json
@@ -0,0 +1,104 @@
+{
+  "guideline": {
+    "id": "PA166328696",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Meloxicam - CYP2C9",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328696",
+    "relatedChemicals": [
+      {
+        "id": "PA450353",
+        "name": "meloxicam",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA126",
+        "name": "cytochrome P450 family 2 subfamily C member 9",
+        "symbol": "CYP2C9"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312028",
+      "name": "Recommendation Annotation PA166312028",
+      "population": "Affected subgroup: CYP2C9 poor metabolizers or *3 carriers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450353",
+          "name": "meloxicam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216227,
+        "html": "<p>&quot;Results in higher systemic concentrations. Consider dose reductions in poor metabolizers. Monitor patients for adverse reactions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.5"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312722",
+      "name": "Recommendation Annotation PA166312722",
+      "population": "Affected subgroup: CYP2C9 poor metabolizers or *3 carriers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450353",
+          "name": "meloxicam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452219021,
+        "html": "<p>&quot;Results in higher systemic concentrations. Consider dose reductions in poor metabolizers. Monitor patients for adverse reactions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": {
+          "*1": 1.0,
+          "*3": 1.0
+        }
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312041",
+      "name": "Recommendation Annotation PA166312041",
+      "population": "Affected subgroup: CYP2C9 poor metabolizers or *3 carriers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450353",
+          "name": "meloxicam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216280,
+        "html": "<p>&quot;Results in higher systemic concentrations. Consider dose reductions in poor metabolizers. Monitor patients for adverse reactions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_mercaptopurine_and_NUDT15_TPMT.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_mercaptopurine_and_NUDT15_TPMT.json
new file mode 100644
index 000000000..8133a37b8
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_mercaptopurine_and_NUDT15_TPMT.json
@@ -0,0 +1,709 @@
+{
+  "guideline": {
+    "id": "PA166328698",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Mercaptopurine - TPMT and/or NUDT15",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328698",
+    "relatedChemicals": [
+      {
+        "id": "PA450379",
+        "name": "mercaptopurine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA134963132",
+        "name": "nudix hydrolase 15",
+        "symbol": "NUDT15"
+      },
+      {
+        "id": "PA356",
+        "name": "thiopurine S-methyltransferase",
+        "symbol": "TPMT"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166311029",
+      "name": "Recommendation Annotation PA166311029",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213628,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311126",
+      "name": "Recommendation Annotation PA166311126",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213725,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Indeterminate"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311084",
+      "name": "Recommendation Annotation PA166311084",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213683,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "No Result"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311027",
+      "name": "Recommendation Annotation PA166311027",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213626,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Normal Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311124",
+      "name": "Recommendation Annotation PA166311124",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213723,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Normal Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311082",
+      "name": "Recommendation Annotation PA166311082",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213681,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311122",
+      "name": "Recommendation Annotation PA166311122",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213721,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "No Result",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311001",
+      "name": "Recommendation Annotation PA166311001",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213601,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311062",
+      "name": "Recommendation Annotation PA166311062",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213661,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "No Result",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311121",
+      "name": "Recommendation Annotation PA166311121",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213720,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Normal Metabolizer",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311024",
+      "name": "Recommendation Annotation PA166311024",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213623,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311022",
+      "name": "Recommendation Annotation PA166311022",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213621,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Normal Metabolizer",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311101",
+      "name": "Recommendation Annotation PA166311101",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213700,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311028",
+      "name": "Recommendation Annotation PA166311028",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213627,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "No Result"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311125",
+      "name": "Recommendation Annotation PA166311125",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213724,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "No Result"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311083",
+      "name": "Recommendation Annotation PA166311083",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213682,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Normal Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311123",
+      "name": "Recommendation Annotation PA166311123",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213722,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Indeterminate",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311026",
+      "name": "Recommendation Annotation PA166311026",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213625,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311081",
+      "name": "Recommendation Annotation PA166311081",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213680,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Indeterminate",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311063",
+      "name": "Recommendation Annotation PA166311063",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213662,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311061",
+      "name": "Recommendation Annotation PA166311061",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213660,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Normal Metabolizer",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311085",
+      "name": "Recommendation Annotation PA166311085",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213684,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Indeterminate"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311030",
+      "name": "Recommendation Annotation PA166311030",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213629,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Indeterminate"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311041",
+      "name": "Recommendation Annotation PA166311041",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213640,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311025",
+      "name": "Recommendation Annotation PA166311025",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213624,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Indeterminate",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311023",
+      "name": "Recommendation Annotation PA166311023",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213622,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "No Result",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311021",
+      "name": "Recommendation Annotation PA166311021",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450379",
+          "name": "mercaptopurine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213620,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_metoclopramide_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_metoclopramide_and_CYP2D6.json
new file mode 100644
index 000000000..a01fe29ac
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_metoclopramide_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328697",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Metoclopramide - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328697",
+    "relatedChemicals": [
+      {
+        "id": "PA450475",
+        "name": "metoclopramide",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312383",
+      "name": "Recommendation Annotation PA166312383",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450475",
+          "name": "metoclopramide",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216663,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_metoprolol_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_metoprolol_and_CYP2D6.json
new file mode 100644
index 000000000..7609d8caf
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_metoprolol_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328771",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Metoprolol - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328771",
+    "relatedChemicals": [
+      {
+        "id": "PA450480",
+        "name": "metoprolol",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315883",
+      "name": "Recommendation Annotation PA166315883",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450480",
+          "name": "metoprolol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246862,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_mirabegron_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_mirabegron_and_CYP2D6.json
new file mode 100644
index 000000000..c37612d16
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_mirabegron_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328772",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Mirabegron - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328772",
+    "relatedChemicals": [
+      {
+        "id": "PA166177513",
+        "name": "mirabegron",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315884",
+      "name": "Recommendation Annotation PA166315884",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166177513",
+          "name": "mirabegron",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246863,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nateglinide_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nateglinide_and_CYP2C9.json
new file mode 100644
index 000000000..f585a90a2
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nateglinide_and_CYP2C9.json
@@ -0,0 +1,77 @@
+{
+  "guideline": {
+    "id": "PA166328700",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Nateglinide - CYP2C9",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328700",
+    "relatedChemicals": [
+      {
+        "id": "PA450600",
+        "name": "nateglinide",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA126",
+        "name": "cytochrome P450 family 2 subfamily C member 9",
+        "symbol": "CYP2C9"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315222",
+      "name": "Recommendation Annotation PA166315222",
+      "population": "Affected subgroups: CYP2C9 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450600",
+          "name": "nateglinide",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452245922,
+        "html": "<p>&quot;Results in higher systemic concentrations and may result in higher adverse reaction risk (hypoglycemia). Dosage reduction is recommended. Increase monitoring frequency for adverse reactions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.5"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315221",
+      "name": "Recommendation Annotation PA166315221",
+      "population": "Affected subgroup: CYP2C9 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450600",
+          "name": "nateglinide",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452245921,
+        "html": "<p>&quot;Results in higher systemic concentrations and may result in higher adverse reaction risk (hypoglycemia). Dosage reduction is recommended. Increase monitoring frequency for adverse reactions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nebivolol_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nebivolol_and_CYP2D6.json
new file mode 100644
index 000000000..e70e07c8a
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nebivolol_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328773",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Nebivolol - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328773",
+    "relatedChemicals": [
+      {
+        "id": "PA151958426",
+        "name": "nebivolol",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315901",
+      "name": "Recommendation Annotation PA166315901",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA151958426",
+          "name": "nebivolol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246880,
+        "html": "<p>&quot;May result in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nilotinib_and_UGT1A1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nilotinib_and_UGT1A1.json
new file mode 100644
index 000000000..00a234b2d
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nilotinib_and_UGT1A1.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328733",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Nilotinib - UGT1A1",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328733",
+    "relatedChemicals": [
+      {
+        "id": "PA165958345",
+        "name": "nilotinib",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA420",
+        "name": "UDP glucuronosyltransferase 1 family, polypeptide A1",
+        "symbol": "UGT1A1"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166317862",
+      "name": "Recommendation Annotation PA166317862",
+      "population": "Affected subgroup: UGT1A1*28/*28 (poor metabolizers)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA165958345",
+          "name": "nilotinib",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452269121,
+        "html": "<p>&quot;Results in higher adverse reaction risk (hyperbilirubinemia).&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "UGT1A1": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nortriptyline_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nortriptyline_and_CYP2D6.json
new file mode 100644
index 000000000..ac15aaf3f
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_nortriptyline_and_CYP2D6.json
@@ -0,0 +1,413 @@
+{
+  "guideline": {
+    "id": "PA166328774",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Nortriptyline - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328774",
+    "relatedChemicals": [
+      {
+        "id": "PA450657",
+        "name": "nortriptyline",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315673",
+      "name": "Recommendation Annotation PA166315673",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246612,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315702",
+      "name": "Recommendation Annotation PA166315702",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246641,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥6.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315671",
+      "name": "Recommendation Annotation PA166315671",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246610,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315682",
+      "name": "Recommendation Annotation PA166315682",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246621,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315680",
+      "name": "Recommendation Annotation PA166315680",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246619,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315679",
+      "name": "Recommendation Annotation PA166315679",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246618,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315677",
+      "name": "Recommendation Annotation PA166315677",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246616,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315675",
+      "name": "Recommendation Annotation PA166315675",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246614,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315674",
+      "name": "Recommendation Annotation PA166315674",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246613,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315672",
+      "name": "Recommendation Annotation PA166315672",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246611,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315701",
+      "name": "Recommendation Annotation PA166315701",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246640,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥5.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315670",
+      "name": "Recommendation Annotation PA166315670",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246609,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315681",
+      "name": "Recommendation Annotation PA166315681",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246620,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315669",
+      "name": "Recommendation Annotation PA166315669",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246608,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315678",
+      "name": "Recommendation Annotation PA166315678",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246617,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315676",
+      "name": "Recommendation Annotation PA166315676",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450657",
+          "name": "nortriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246615,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_oliceridine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_oliceridine_and_CYP2D6.json
new file mode 100644
index 000000000..6fa6363c6
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_oliceridine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328701",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Oliceridine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328701",
+    "relatedChemicals": [
+      {
+        "id": "PA166223601",
+        "name": "oliceridine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312415",
+      "name": "Recommendation Annotation PA166312415",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166223601",
+          "name": "oliceridine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216714,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk (respiratory depression and sedation). May require less frequent dosing.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_omeprazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_omeprazole_and_CYP2C19.json
new file mode 100644
index 000000000..73e95ffb3
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_omeprazole_and_CYP2C19.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328775",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Omeprazole - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328775",
+    "relatedChemicals": [
+      {
+        "id": "PA450704",
+        "name": "omeprazole",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315922",
+      "name": "Recommendation Annotation PA166315922",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450704",
+          "name": "omeprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246901,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315921",
+      "name": "Recommendation Annotation PA166315921",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450704",
+          "name": "omeprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246900,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315941",
+      "name": "Recommendation Annotation PA166315941",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450704",
+          "name": "omeprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246920,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315923",
+      "name": "Recommendation Annotation PA166315923",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450704",
+          "name": "omeprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246902,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_oxcarbazepine_and_HLA-B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_oxcarbazepine_and_HLA-B.json
new file mode 100644
index 000000000..79b42c45c
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_oxcarbazepine_and_HLA-B.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328736",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Oxcarbazepine - HLA-B",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328736",
+    "relatedChemicals": [
+      {
+        "id": "PA450732",
+        "name": "oxcarbazepine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA35056",
+        "name": "major histocompatibility complex, class I, B",
+        "symbol": "HLA-B"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166310802",
+      "name": "Recommendation Annotation PA166310802",
+      "population": "Affected subgroup: HLA-B*15:02 allele positive",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450732",
+          "name": "oxcarbazepine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452213241,
+        "html": "<p>&quot;Results in higher adverse reaction risk (severe skin reactions). Patients positive for HLA-B*15:02 may be at increased risk of severe skin reactions with other drugs that are associated with a risk of Stevens Johnson Syndrome/Toxic Epidermal necrolysis (SJS/TEN). Genotyping is not a substitute for clinical vigilance.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "HLA-B": "*15:02 positive"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pantoprazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pantoprazole_and_CYP2C19.json
new file mode 100644
index 000000000..ae9a213ad
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pantoprazole_and_CYP2C19.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328702",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Pantoprazole - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328702",
+    "relatedChemicals": [
+      {
+        "id": "PA450774",
+        "name": "pantoprazole",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166310323",
+      "name": "Recommendation Annotation PA166310323",
+      "population": "Pediatrics; Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450774",
+          "name": "pantoprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452211502,
+        "html": "<p>&quot;Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are intermediate or poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310321",
+      "name": "Recommendation Annotation PA166310321",
+      "population": "Pediatrics; Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450774",
+          "name": "pantoprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452211500,
+        "html": "<p>&quot;Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are intermediate or poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310324",
+      "name": "Recommendation Annotation PA166310324",
+      "population": "Pediatrics; Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450774",
+          "name": "pantoprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452211503,
+        "html": "<p>&quot;Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are intermediate or poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166310322",
+      "name": "Recommendation Annotation PA166310322",
+      "population": "Pediatrics; Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450774",
+          "name": "pantoprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452211501,
+        "html": "<p>&quot;Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are intermediate or poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_paroxetine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_paroxetine_and_CYP2D6.json
new file mode 100644
index 000000000..01a2385e1
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_paroxetine_and_CYP2D6.json
@@ -0,0 +1,413 @@
+{
+  "guideline": {
+    "id": "PA166328776",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Paroxetine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328776",
+    "relatedChemicals": [
+      {
+        "id": "PA450801",
+        "name": "paroxetine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315686",
+      "name": "Recommendation Annotation PA166315686",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246625,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315704",
+      "name": "Recommendation Annotation PA166315704",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246643,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315684",
+      "name": "Recommendation Annotation PA166315684",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246623,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315711",
+      "name": "Recommendation Annotation PA166315711",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246650,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315708",
+      "name": "Recommendation Annotation PA166315708",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246647,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315688",
+      "name": "Recommendation Annotation PA166315688",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246627,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥6.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315706",
+      "name": "Recommendation Annotation PA166315706",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246645,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315685",
+      "name": "Recommendation Annotation PA166315685",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246624,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315703",
+      "name": "Recommendation Annotation PA166315703",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246642,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315683",
+      "name": "Recommendation Annotation PA166315683",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246622,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315712",
+      "name": "Recommendation Annotation PA166315712",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246651,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315710",
+      "name": "Recommendation Annotation PA166315710",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246649,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315709",
+      "name": "Recommendation Annotation PA166315709",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246648,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315707",
+      "name": "Recommendation Annotation PA166315707",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246646,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315687",
+      "name": "Recommendation Annotation PA166315687",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246626,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥5.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315705",
+      "name": "Recommendation Annotation PA166315705",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450801",
+          "name": "paroxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246644,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pazopanib_and_HLA-B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pazopanib_and_HLA-B.json
new file mode 100644
index 000000000..11f35f615
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pazopanib_and_HLA-B.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328737",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Pazopanib - HLA-B",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328737",
+    "relatedChemicals": [
+      {
+        "id": "PA165291492",
+        "name": "pazopanib",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA35056",
+        "name": "major histocompatibility complex, class I, B",
+        "symbol": "HLA-B"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315381",
+      "name": "Recommendation Annotation PA166315381",
+      "population": "Affected subgroup: HLA-B*57:01 allele positive",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA165291492",
+          "name": "pazopanib",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246280,
+        "html": "<p>&quot;May result in higher adverse reaction risk (liver enzyme elevations). Monitor liver function tests regardless of genotype.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "HLA-B": "*57:01 positive"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pazopanib_and_UGT1A1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pazopanib_and_UGT1A1.json
new file mode 100644
index 000000000..93ec3514d
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pazopanib_and_UGT1A1.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328738",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Pazopanib - UGT1A1",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328738",
+    "relatedChemicals": [
+      {
+        "id": "PA165291492",
+        "name": "pazopanib",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA420",
+        "name": "UDP glucuronosyltransferase 1 family, polypeptide A1",
+        "symbol": "UGT1A1"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166317863",
+      "name": "Recommendation Annotation PA166317863",
+      "population": "Affected subgroup: UGT1A1*28/*28 (poor metabolizers)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA165291492",
+          "name": "pazopanib",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452269122,
+        "html": "<p>&quot;Results in higher adverse reaction risk (hyperbilirubinemia).&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "UGT1A1": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_perphenazine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_perphenazine_and_CYP2D6.json
new file mode 100644
index 000000000..ba4b2395a
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_perphenazine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328739",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Perphenazine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328739",
+    "relatedChemicals": [
+      {
+        "id": "PA450882",
+        "name": "perphenazine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315401",
+      "name": "Recommendation Annotation PA166315401",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450882",
+          "name": "perphenazine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246300,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_phenytoin_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_phenytoin_and_CYP2C9.json
new file mode 100644
index 000000000..2c2bd8d85
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_phenytoin_and_CYP2C9.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328703",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Phenytoin - CYP2C9",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328703",
+    "relatedChemicals": [
+      {
+        "id": "PA450947",
+        "name": "phenytoin",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA126",
+        "name": "cytochrome P450 family 2 subfamily C member 9",
+        "symbol": "CYP2C9"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166324201",
+      "name": "Recommendation Annotation PA166324201",
+      "population": "CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450947",
+          "name": "phenytoin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452337660,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk (central nervous system toxicity). Refer to FDA labeling for specific dosing recommendations. Carriers of CYP2C9*3 alleles may be at increased risk of severe cutaneous adverse reactions. Consider avoiding phenytoin as an alternative to carbamazepine in patients who are CYP2C9*3 carriers. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166324204",
+      "name": "Recommendation Annotation PA166324204",
+      "population": "CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450947",
+          "name": "phenytoin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452337663,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk (central nervous system toxicity). Refer to FDA labeling for specific dosing recommendations. Carriers of CYP2C9*3 alleles may be at increased risk of severe cutaneous adverse reactions. Consider avoiding phenytoin as an alternative to carbamazepine in patients who are CYP2C9*3 carriers. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "1.5"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166324202",
+      "name": "Recommendation Annotation PA166324202",
+      "population": "CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450947",
+          "name": "phenytoin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452337661,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk (central nervous system toxicity). Refer to FDA labeling for specific dosing recommendations. Carriers of CYP2C9*3 alleles may be at increased risk of severe cutaneous adverse reactions. Consider avoiding phenytoin as an alternative to carbamazepine in patients who are CYP2C9*3 carriers. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.5"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166324203",
+      "name": "Recommendation Annotation PA166324203",
+      "population": "CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450947",
+          "name": "phenytoin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452337662,
+        "html": "<p>&quot;May result in higher systemic concentrations and higher adverse reaction risk (central nervous system toxicity). Refer to FDA labeling for specific dosing recommendations. Carriers of CYP2C9*3 alleles may be at increased risk of severe cutaneous adverse reactions. Consider avoiding phenytoin as an alternative to carbamazepine in patients who are CYP2C9*3 carriers. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "1.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_phenytoin_and_HLA-B.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_phenytoin_and_HLA-B.json
new file mode 100644
index 000000000..e0f02773a
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_phenytoin_and_HLA-B.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328704",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Phenytoin - HLA-B",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328704",
+    "relatedChemicals": [
+      {
+        "id": "PA450947",
+        "name": "phenytoin",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA35056",
+        "name": "major histocompatibility complex, class I, B",
+        "symbol": "HLA-B"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166324181",
+      "name": "Recommendation Annotation PA166324181",
+      "population": "HLA-B*15:02 allele positive",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450947",
+          "name": "phenytoin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452337620,
+        "html": "<p>&quot;May result in higher adverse reaction risk (severe cutaneous reactions). Patients positive for HLA-B*15:02 may be at increased risk of Stevens Johnson Syndrome/Toxic Epidermal necrolysis (SJS/TEN). Consider avoiding phenytoin as an alternative to carbamazepine in patients who are positive for HLA-B*15:02. Genotyping is not a substitute for clinical vigilance and patient management.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "HLA-B": "*15:02 positive"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pimozide_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pimozide_and_CYP2D6.json
new file mode 100644
index 000000000..3a69e20a4
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pimozide_and_CYP2D6.json
@@ -0,0 +1,77 @@
+{
+  "guideline": {
+    "id": "PA166328705",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Pimozide - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328705",
+    "relatedChemicals": [
+      {
+        "id": "PA450965",
+        "name": "pimozide",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312149",
+      "name": "Recommendation Annotation PA166312149",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450965",
+          "name": "pimozide",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216388,
+        "html": "<p>&quot;Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312150",
+      "name": "Recommendation Annotation PA166312150",
+      "population": "Pediatrics; Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450965",
+          "name": "pimozide",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216389,
+        "html": "<p>&quot;Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_piroxicam_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_piroxicam_and_CYP2C9.json
new file mode 100644
index 000000000..878049c6d
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_piroxicam_and_CYP2C9.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328706",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Piroxicam - CYP2C9",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328706",
+    "relatedChemicals": [
+      {
+        "id": "PA450985",
+        "name": "piroxicam",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA126",
+        "name": "cytochrome P450 family 2 subfamily C member 9",
+        "symbol": "CYP2C9"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166311930",
+      "name": "Recommendation Annotation PA166311930",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450985",
+          "name": "piroxicam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216129,
+        "html": "<p>&quot;Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311932",
+      "name": "Recommendation Annotation PA166311932",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450985",
+          "name": "piroxicam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216131,
+        "html": "<p>&quot;Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "1.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311944",
+      "name": "Recommendation Annotation PA166311944",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450985",
+          "name": "piroxicam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216143,
+        "html": "<p>&quot;Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "1.5"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311931",
+      "name": "Recommendation Annotation PA166311931",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA450985",
+          "name": "piroxicam",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216130,
+        "html": "<p>&quot;Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.5"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pitolisant_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pitolisant_and_CYP2D6.json
new file mode 100644
index 000000000..dfe644d40
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_pitolisant_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328707",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Pitolisant - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328707",
+    "relatedChemicals": [
+      {
+        "id": "PA166185163",
+        "name": "pitolisant",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312424",
+      "name": "Recommendation Annotation PA166312424",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166185163",
+          "name": "pitolisant",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216723,
+        "html": "<p>&quot;Results in higher systemic concentrations. Use lowest recommended starting dosage. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_propafenone_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_propafenone_and_CYP2D6.json
new file mode 100644
index 000000000..a40d61597
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_propafenone_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328708",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Propafenone - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328708",
+    "relatedChemicals": [
+      {
+        "id": "PA451131",
+        "name": "propafenone",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312181",
+      "name": "Recommendation Annotation PA166312181",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451131",
+          "name": "propafenone",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216420,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_propranolol_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_propranolol_and_CYP2D6.json
new file mode 100644
index 000000000..0d1c28f87
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_propranolol_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328734",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Propranolol - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328734",
+    "relatedChemicals": [
+      {
+        "id": "PA451145",
+        "name": "propranolol",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315942",
+      "name": "Recommendation Annotation PA166315942",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451145",
+          "name": "propranolol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246921,
+        "html": "<p>&quot;May affect systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_protriptyline_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_protriptyline_and_CYP2D6.json
new file mode 100644
index 000000000..927954b95
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_protriptyline_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328735",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Protriptyline - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328735",
+    "relatedChemicals": [
+      {
+        "id": "PA451168",
+        "name": "protriptyline",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315961",
+      "name": "Recommendation Annotation PA166315961",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451168",
+          "name": "protriptyline",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246940,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_rabeprazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_rabeprazole_and_CYP2C19.json
new file mode 100644
index 000000000..382aaa1ad
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_rabeprazole_and_CYP2C19.json
@@ -0,0 +1,77 @@
+{
+  "guideline": {
+    "id": "PA166328777",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Rabeprazole - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328777",
+    "relatedChemicals": [
+      {
+        "id": "PA451216",
+        "name": "rabeprazole",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315962",
+      "name": "Recommendation Annotation PA166315962",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451216",
+          "name": "rabeprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246941,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315981",
+      "name": "Recommendation Annotation PA166315981",
+      "population": "Affected subgroup: CYP2C19 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451216",
+          "name": "rabeprazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246960,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_raltegravir_and_UGT1A1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_raltegravir_and_UGT1A1.json
new file mode 100644
index 000000000..302e79b8a
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_raltegravir_and_UGT1A1.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328778",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Raltegravir - UGT1A1",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328778",
+    "relatedChemicals": [
+      {
+        "id": "PA164888966",
+        "name": "raltegravir",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA420",
+        "name": "UDP glucuronosyltransferase 1 family, polypeptide A1",
+        "symbol": "UGT1A1"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166317864",
+      "name": "Recommendation Annotation PA166317864",
+      "population": "Affected subgroup: UGT1A1*28/*28 (poor metabolizers)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA164888966",
+          "name": "raltegravir",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452269123,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "UGT1A1": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_risperidone_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_risperidone_and_CYP2D6.json
new file mode 100644
index 000000000..45c8e2681
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_risperidone_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328779",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Risperidone - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328779",
+    "relatedChemicals": [
+      {
+        "id": "PA451257",
+        "name": "risperidone",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166316001",
+      "name": "Recommendation Annotation PA166316001",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451257",
+          "name": "risperidone",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246980,
+        "html": "<p>&quot;Alters systemic parent drug and metabolite concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_rosuvastatin_and_SLCO1B1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_rosuvastatin_and_SLCO1B1.json
new file mode 100644
index 000000000..2fec6274c
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_rosuvastatin_and_SLCO1B1.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328780",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Rosuvastatin - SLCO1B1",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328780",
+    "relatedChemicals": [
+      {
+        "id": "PA134308647",
+        "name": "rosuvastatin",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA134865839",
+        "name": "solute carrier organic anion transporter family member 1B1",
+        "symbol": "SLCO1B1"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166316021",
+      "name": "Recommendation Annotation PA166316021",
+      "population": "Affected subgroup: SLCO1B1 521 CC (poor function transporters)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA134308647",
+          "name": "rosuvastatin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452247000,
+        "html": "<p>&quot;Results in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "SLCO1B1": "Poor Function"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_sacituzumab_govitecan_and_UGT1A1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_sacituzumab_govitecan_and_UGT1A1.json
new file mode 100644
index 000000000..1e2f692fa
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_sacituzumab_govitecan_and_UGT1A1.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328709",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Sacituzumab Govitecan-hziy - UGT1A1",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328709",
+    "relatedChemicals": [
+      {
+        "id": "PA166225061",
+        "name": "sacituzumab govitecan",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA420",
+        "name": "UDP glucuronosyltransferase 1 family, polypeptide A1",
+        "symbol": "UGT1A1"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166317861",
+      "name": "Recommendation Annotation PA166317861",
+      "population": "Affected subgroup: UGT1A1*28/*28 (poor metabolizers)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166225061",
+          "name": "sacituzumab govitecan",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452269120,
+        "html": "<p>&quot;May result in higher systemic concentrations and adverse reaction risk (neutropenia). Monitor for adverse reactions and tolerance to treatment.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "UGT1A1": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_simvastatin_and_SLCO1B1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_simvastatin_and_SLCO1B1.json
new file mode 100644
index 000000000..8e95b1325
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_simvastatin_and_SLCO1B1.json
@@ -0,0 +1,101 @@
+{
+  "guideline": {
+    "id": "PA166328741",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Simvastatin - SLCO1B1",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328741",
+    "relatedChemicals": [
+      {
+        "id": "PA451363",
+        "name": "simvastatin",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA134865839",
+        "name": "solute carrier organic anion transporter family member 1B1",
+        "symbol": "SLCO1B1"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315422",
+      "name": "Recommendation Annotation PA166315422",
+      "population": "Affected subgroup: SLCO1B1 521 TC or 521 CC (intermediate or poor function transporters)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451363",
+          "name": "simvastatin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246341,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "SLCO1B1": "Decreased Function"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315423",
+      "name": "Recommendation Annotation PA166315423",
+      "population": "Affected subgroup: SLCO1B1 521 TC or 521 CC (intermediate or poor function transporters)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451363",
+          "name": "simvastatin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246342,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "SLCO1B1": "Possible Decreased Function"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315421",
+      "name": "Recommendation Annotation PA166315421",
+      "population": "Affected subgroup: SLCO1B1 521 TC or 521 CC (intermediate or poor function transporters)",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451363",
+          "name": "simvastatin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246340,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "SLCO1B1": "Poor Function"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_siponimod_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_siponimod_and_CYP2C9.json
new file mode 100644
index 000000000..7aa7ff801
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_siponimod_and_CYP2C9.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328710",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Siponimod - CYP2C9",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328710",
+    "relatedChemicals": [
+      {
+        "id": "PA166182736",
+        "name": "siponimod",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA126",
+        "name": "cytochrome P450 family 2 subfamily C member 9",
+        "symbol": "CYP2C9"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312703",
+      "name": "Recommendation Annotation PA166312703",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166182736",
+          "name": "siponimod",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452219002,
+        "html": "<p>&quot;Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.5"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312705",
+      "name": "Recommendation Annotation PA166312705",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166182736",
+          "name": "siponimod",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452219004,
+        "html": "<p>&quot;Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "1.5"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312721",
+      "name": "Recommendation Annotation PA166312721",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166182736",
+          "name": "siponimod",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452219020,
+        "html": "<p>&quot;Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312704",
+      "name": "Recommendation Annotation PA166312704",
+      "population": "Affected subgroup: CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166182736",
+          "name": "siponimod",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452219003,
+        "html": "<p>&quot;Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "1.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tacrolimus_and_CYP3A5.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tacrolimus_and_CYP3A5.json
new file mode 100644
index 000000000..b85ec1fef
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tacrolimus_and_CYP3A5.json
@@ -0,0 +1,101 @@
+{
+  "guideline": {
+    "id": "PA166328712",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Tacrolimus - CYP3A5",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328712",
+    "relatedChemicals": [
+      {
+        "id": "PA451578",
+        "name": "tacrolimus",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA131",
+        "name": "cytochrome P450 family 3 subfamily A member 5",
+        "symbol": "CYP3A5"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315261",
+      "name": "Recommendation Annotation PA166315261",
+      "population": "Affected subgroup: CYP3A5 intermediate or normal metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451578",
+          "name": "tacrolimus",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246020,
+        "html": "<p>&quot;Results in lower systemic concentrations, lower probability of achieving target concentrations and may result in higher rejection risk. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP3A5": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166315263",
+      "name": "Recommendation Annotation PA166315263",
+      "population": "Affected subgroup: CYP3A5 intermediate or normal metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451578",
+          "name": "tacrolimus",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246022,
+        "html": "<p>&quot;Results in lower systemic concentrations, lower probability of achieving target concentrations and may result in higher rejection risk. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP3A5": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166315262",
+      "name": "Recommendation Annotation PA166315262",
+      "population": "Affected subgroup: CYP3A5 intermediate or normal metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451578",
+          "name": "tacrolimus",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246021,
+        "html": "<p>&quot;Results in lower systemic concentrations, lower probability of achieving target concentrations and may result in higher rejection risk. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP3A5": "Normal Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tamoxifen_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tamoxifen_and_CYP2D6.json
new file mode 100644
index 000000000..931a611fb
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tamoxifen_and_CYP2D6.json
@@ -0,0 +1,149 @@
+{
+  "guideline": {
+    "id": "PA166328781",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Tamoxifen - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328781",
+    "relatedChemicals": [
+      {
+        "id": "PA451581",
+        "name": "tamoxifen",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166316022",
+      "name": "Recommendation Annotation PA166316022",
+      "population": "Affected subgroup: CYP2D6 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451581",
+          "name": "tamoxifen",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452247001,
+        "html": "<p>&quot;Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166316024",
+      "name": "Recommendation Annotation PA166316024",
+      "population": "Affected subgroups: CYP2D6 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451581",
+          "name": "tamoxifen",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452247003,
+        "html": "<p>&quot;Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166316026",
+      "name": "Recommendation Annotation PA166316026",
+      "population": "Affected subgroup: CYP2D6 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451581",
+          "name": "tamoxifen",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452247005,
+        "html": "<p>&quot;Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166316023",
+      "name": "Recommendation Annotation PA166316023",
+      "population": "Affected subgroup: CYP2D6 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451581",
+          "name": "tamoxifen",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452247002,
+        "html": "<p>&quot;Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166316025",
+      "name": "Recommendation Annotation PA166316025",
+      "population": "Affected subgroup: CYP2D6 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451581",
+          "name": "tamoxifen",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452247004,
+        "html": "<p>&quot;Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tamsulosin_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tamsulosin_and_CYP2D6.json
new file mode 100644
index 000000000..a294815fe
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tamsulosin_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328782",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Tamsulosin - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328782",
+    "relatedChemicals": [
+      {
+        "id": "PA451583",
+        "name": "tamsulosin",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312281",
+      "name": "Recommendation Annotation PA166312281",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451583",
+          "name": "tamsulosin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216540,
+        "html": "<p>&quot;Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tetrabenazine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tetrabenazine_and_CYP2D6.json
new file mode 100644
index 000000000..cd123808a
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tetrabenazine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328713",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Tetrabenazine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328713",
+    "relatedChemicals": [
+      {
+        "id": "PA140222719",
+        "name": "tetrabenazine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166311407",
+      "name": "Recommendation Annotation PA166311407",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA140222719",
+          "name": "tetrabenazine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215586,
+        "html": "<p>&quot;Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_thioguanine_and_NUDT15_TPMT.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_thioguanine_and_NUDT15_TPMT.json
new file mode 100644
index 000000000..85bc6a67c
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_thioguanine_and_NUDT15_TPMT.json
@@ -0,0 +1,709 @@
+{
+  "guideline": {
+    "id": "PA166328714",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Thioguanine - TPMT and/or NUDT15",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328714",
+    "relatedChemicals": [
+      {
+        "id": "PA451663",
+        "name": "thioguanine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA134963132",
+        "name": "nudix hydrolase 15",
+        "symbol": "NUDT15"
+      },
+      {
+        "id": "PA356",
+        "name": "thiopurine S-methyltransferase",
+        "symbol": "TPMT"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312070",
+      "name": "Recommendation Annotation PA166312070",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216309,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "No Result"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312081",
+      "name": "Recommendation Annotation PA166312081",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216320,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Normal Metabolizer",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312072",
+      "name": "Recommendation Annotation PA166312072",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216311,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "No Result"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312083",
+      "name": "Recommendation Annotation PA166312083",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216322,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312101",
+      "name": "Recommendation Annotation PA166312101",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216340,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Indeterminate"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312033",
+      "name": "Recommendation Annotation PA166312033",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216232,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312042",
+      "name": "Recommendation Annotation PA166312042",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216282,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312066",
+      "name": "Recommendation Annotation PA166312066",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216305,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "No Result",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312068",
+      "name": "Recommendation Annotation PA166312068",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216307,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Normal Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312044",
+      "name": "Recommendation Annotation PA166312044",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216284,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Normal Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312031",
+      "name": "Recommendation Annotation PA166312031",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216230,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312062",
+      "name": "Recommendation Annotation PA166312062",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216301,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312102",
+      "name": "Recommendation Annotation PA166312102",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216341,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Indeterminate",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312104",
+      "name": "Recommendation Annotation PA166312104",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216343,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Indeterminate"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312073",
+      "name": "Recommendation Annotation PA166312073",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216312,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312064",
+      "name": "Recommendation Annotation PA166312064",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216303,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312082",
+      "name": "Recommendation Annotation PA166312082",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216321,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "No Result",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312071",
+      "name": "Recommendation Annotation PA166312071",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216310,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "No Result"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312069",
+      "name": "Recommendation Annotation PA166312069",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216308,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Intermediate Metabolizer",
+        "NUDT15": "Normal Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312065",
+      "name": "Recommendation Annotation PA166312065",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216304,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Normal Metabolizer",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312032",
+      "name": "Recommendation Annotation PA166312032",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216231,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Normal Metabolizer",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312043",
+      "name": "Recommendation Annotation PA166312043",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216283,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Possible Intermediate Metabolizer",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312067",
+      "name": "Recommendation Annotation PA166312067",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216306,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Indeterminate",
+        "NUDT15": "Poor Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312103",
+      "name": "Recommendation Annotation PA166312103",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216342,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Indeterminate"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312074",
+      "name": "Recommendation Annotation PA166312074",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216313,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Poor Metabolizer",
+        "NUDT15": "Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312061",
+      "name": "Recommendation Annotation PA166312061",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216300,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "No Result",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166312063",
+      "name": "Recommendation Annotation PA166312063",
+      "population": "Affected subgroup: TPMT and/or NUDT15 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451663",
+          "name": "thioguanine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216302,
+        "html": "<p>&quot;Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "TPMT": "Indeterminate",
+        "NUDT15": "Possible Intermediate Metabolizer"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_thioridazine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_thioridazine_and_CYP2D6.json
new file mode 100644
index 000000000..79eb384d7
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_thioridazine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328715",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Thioridazine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328715",
+    "relatedChemicals": [
+      {
+        "id": "PA451666",
+        "name": "thioridazine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312402",
+      "name": "Recommendation Annotation PA166312402",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451666",
+          "name": "thioridazine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216701,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tolterodine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tolterodine_and_CYP2D6.json
new file mode 100644
index 000000000..9a737face
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tolterodine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328744",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Tolterodine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328744",
+    "relatedChemicals": [
+      {
+        "id": "PA164746757",
+        "name": "tolterodine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166316028",
+      "name": "Recommendation Annotation PA166316028",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA164746757",
+          "name": "tolterodine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452247007,
+        "html": "<p>&quot;Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tramadol_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tramadol_and_CYP2D6.json
new file mode 100644
index 000000000..fed59976b
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_tramadol_and_CYP2D6.json
@@ -0,0 +1,293 @@
+{
+  "guideline": {
+    "id": "PA166328716",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Tramadol - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328716",
+    "relatedChemicals": [
+      {
+        "id": "PA451735",
+        "name": "tramadol",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166311223",
+      "name": "Recommendation Annotation PA166311223",
+      "population": "Affected subgroup: CYP2D6 ultrarapid metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451735",
+          "name": "tramadol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452214462,
+        "html": "<p>&quot;Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311243",
+      "name": "Recommendation Annotation PA166311243",
+      "population": "Affected subgroup: CYP2D6 ultrarapid metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451735",
+          "name": "tramadol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452214482,
+        "html": "<p>&quot;Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311227",
+      "name": "Recommendation Annotation PA166311227",
+      "population": "Affected subgroup: CYP2D6 ultrarapid metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451735",
+          "name": "tramadol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452214467,
+        "html": "<p>&quot;Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311225",
+      "name": "Recommendation Annotation PA166311225",
+      "population": "Affected subgroup: CYP2D6 ultrarapid metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451735",
+          "name": "tramadol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452214464,
+        "html": "<p>&quot;Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311242",
+      "name": "Recommendation Annotation PA166311242",
+      "population": "Affected subgroup: CYP2D6 ultrarapid metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451735",
+          "name": "tramadol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452214481,
+        "html": "<p>&quot;Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311222",
+      "name": "Recommendation Annotation PA166311222",
+      "population": "Affected subgroup: CYP2D6 ultrarapid metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451735",
+          "name": "tramadol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452214461,
+        "html": "<p>&quot;Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311226",
+      "name": "Recommendation Annotation PA166311226",
+      "population": "Affected subgroup: CYP2D6 ultrarapid metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451735",
+          "name": "tramadol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452214465,
+        "html": "<p>&quot;Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311224",
+      "name": "Recommendation Annotation PA166311224",
+      "population": "Affected subgroup: CYP2D6 ultrarapid metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451735",
+          "name": "tramadol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452214463,
+        "html": "<p>&quot;Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311261",
+      "name": "Recommendation Annotation PA166311261",
+      "population": "Affected subgroup: CYP2D6 ultrarapid metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451735",
+          "name": "tramadol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452214500,
+        "html": "<p>&quot;Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥6.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311228",
+      "name": "Recommendation Annotation PA166311228",
+      "population": "Affected subgroup: CYP2D6 ultrarapid metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451735",
+          "name": "tramadol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452214468,
+        "html": "<p>&quot;Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥5.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    },
+    {
+      "id": "PA166311241",
+      "name": "Recommendation Annotation PA166311241",
+      "population": "Affected subgroup: CYP2D6 ultrarapid metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451735",
+          "name": "tramadol",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452214480,
+        "html": "<p>&quot;Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": true,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_trimipramine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_trimipramine_and_CYP2D6.json
new file mode 100644
index 000000000..9372fd7d2
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_trimipramine_and_CYP2D6.json
@@ -0,0 +1,413 @@
+{
+  "guideline": {
+    "id": "PA166328783",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Trimipramine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328783",
+    "relatedChemicals": [
+      {
+        "id": "PA451791",
+        "name": "trimipramine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315697",
+      "name": "Recommendation Annotation PA166315697",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246636,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315695",
+      "name": "Recommendation Annotation PA166315695",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246634,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315693",
+      "name": "Recommendation Annotation PA166315693",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246632,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "1.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315722",
+      "name": "Recommendation Annotation PA166315722",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246681,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315691",
+      "name": "Recommendation Annotation PA166315691",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246630,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315690",
+      "name": "Recommendation Annotation PA166315690",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246629,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315743",
+      "name": "Recommendation Annotation PA166315743",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246702,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥5.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315741",
+      "name": "Recommendation Annotation PA166315741",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246700,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315698",
+      "name": "Recommendation Annotation PA166315698",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246637,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315696",
+      "name": "Recommendation Annotation PA166315696",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246635,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "3.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315694",
+      "name": "Recommendation Annotation PA166315694",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246633,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "2.5"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315721",
+      "name": "Recommendation Annotation PA166315721",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246680,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥3.25"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315692",
+      "name": "Recommendation Annotation PA166315692",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246631,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.75"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315744",
+      "name": "Recommendation Annotation PA166315744",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246703,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥6.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315742",
+      "name": "Recommendation Annotation PA166315742",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246701,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "≥4.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315689",
+      "name": "Recommendation Annotation PA166315689",
+      "population": "Affected subgroup: CYP2D6 ultrarapid, intermediate, or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451791",
+          "name": "trimipramine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246628,
+        "html": "<p>&quot;May alter systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_valbenazine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_valbenazine_and_CYP2D6.json
new file mode 100644
index 000000000..5dd42f8b2
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_valbenazine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328717",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Valbenazine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328717",
+    "relatedChemicals": [
+      {
+        "id": "PA166170051",
+        "name": "valbenazine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312307",
+      "name": "Recommendation Annotation PA166312307",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166170051",
+          "name": "valbenazine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452216568,
+        "html": "<p>&quot;Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_venlafaxine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_venlafaxine_and_CYP2D6.json
new file mode 100644
index 000000000..19cb60289
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_venlafaxine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328718",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Venlafaxine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328718",
+    "relatedChemicals": [
+      {
+        "id": "PA451866",
+        "name": "venlafaxine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315281",
+      "name": "Recommendation Annotation PA166315281",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451866",
+          "name": "venlafaxine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246120,
+        "html": "<p>&quot;Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_viloxazine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_viloxazine_and_CYP2D6.json
new file mode 100644
index 000000000..6a7208989
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_viloxazine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328784",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Demonstrate a Potential Impact on Pharmacokinetic Properties Only]: Viloxazine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328784",
+    "relatedChemicals": [
+      {
+        "id": "PA166251581",
+        "name": "viloxazine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166316027",
+      "name": "Recommendation Annotation PA166316027",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166251581",
+          "name": "viloxazine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452247006,
+        "html": "<p>&quot;May result in higher systemic concentrations.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_voriconazole_and_CYP2C19.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_voriconazole_and_CYP2C19.json
new file mode 100644
index 000000000..e5985a3cf
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_voriconazole_and_CYP2C19.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328746",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Indicate a Potential Impact on Safety or Response]: Voriconazole - CYP2C19",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328746",
+    "relatedChemicals": [
+      {
+        "id": "PA10233",
+        "name": "voriconazole",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA124",
+        "name": "cytochrome P450 family 2 subfamily C member 19",
+        "symbol": "CYP2C19"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166315444",
+      "name": "Recommendation Annotation PA166315444",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10233",
+          "name": "voriconazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246363,
+        "html": "<p>&quot;Results in higher systemic concentrations and may result in higher adverse reaction risk.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315442",
+      "name": "Recommendation Annotation PA166315442",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10233",
+          "name": "voriconazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246361,
+        "html": "<p>&quot;Results in higher systemic concentrations and may result in higher adverse reaction risk.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Intermediate Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315443",
+      "name": "Recommendation Annotation PA166315443",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10233",
+          "name": "voriconazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246362,
+        "html": "<p>&quot;Results in higher systemic concentrations and may result in higher adverse reaction risk.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Likely Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166315441",
+      "name": "Recommendation Annotation PA166315441",
+      "population": "Affected subgroup: CYP2C19 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA10233",
+          "name": "voriconazole",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452246360,
+        "html": "<p>&quot;Results in higher systemic concentrations and may result in higher adverse reaction risk.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C19": "Poor Metabolizer"
+      },
+      "dosingInformation": false,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_vortioxetine_and_CYP2D6.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_vortioxetine_and_CYP2D6.json
new file mode 100644
index 000000000..89a150294
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_vortioxetine_and_CYP2D6.json
@@ -0,0 +1,53 @@
+{
+  "guideline": {
+    "id": "PA166328719",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Vortioxetine - CYP2D6",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328719",
+    "relatedChemicals": [
+      {
+        "id": "PA166122595",
+        "name": "vortioxetine",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA128",
+        "name": "cytochrome P450 family 2 subfamily D member 6",
+        "symbol": "CYP2D6"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166311321",
+      "name": "Recommendation Annotation PA166311321",
+      "population": "Affected subgroup: CYP2D6 poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA166122595",
+          "name": "vortioxetine",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452215500,
+        "html": "<p>&quot;Results in higher systemic concentrations. The maximum recommended dose is 10 mg.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2D6": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": false
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_warfarin_and_CYP2C9.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_warfarin_and_CYP2C9.json
new file mode 100644
index 000000000..d09571623
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_warfarin_and_CYP2C9.json
@@ -0,0 +1,125 @@
+{
+  "guideline": {
+    "id": "PA166328720",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Warfarin - CYP2C9",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328720",
+    "relatedChemicals": [
+      {
+        "id": "PA451906",
+        "name": "warfarin",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA126",
+        "name": "cytochrome P450 family 2 subfamily C member 9",
+        "symbol": "CYP2C9"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166312744",
+      "name": "Recommendation Annotation PA166312744",
+      "population": "CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451906",
+          "name": "warfarin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452219043,
+        "html": "<p>&quot;Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "1.5"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312742",
+      "name": "Recommendation Annotation PA166312742",
+      "population": "CYP2C9 intermediate and poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451906",
+          "name": "warfarin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452219041,
+        "html": "<p>&quot;Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.5"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312743",
+      "name": "Recommendation Annotation PA166312743",
+      "population": "CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451906",
+          "name": "warfarin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452219042,
+        "html": "<p>&quot;Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "1.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166312741",
+      "name": "Recommendation Annotation PA166312741",
+      "population": "CYP2C9 intermediate or poor metabolizers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451906",
+          "name": "warfarin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452219040,
+        "html": "<p>&quot;Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "CYP2C9": "0.0"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_warfarin_and_VKORC1.json b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_warfarin_and_VKORC1.json
new file mode 100644
index 000000000..d4091726e
--- /dev/null
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/guidelines/FDA_PGx_Association_warfarin_and_VKORC1.json
@@ -0,0 +1,77 @@
+{
+  "guideline": {
+    "id": "PA166328722",
+    "name": "FDA PGx Association [Pharmacogenetic Associations for which the Data Support Therapeutic Management Recommendations]: Warfarin - VKORC1",
+    "objCls": "PGx Association",
+    "source": "FDA",
+    "version": 0,
+    "url": "https://www.pharmgkb.org/fdaPgxAssociations#PA166328722",
+    "relatedChemicals": [
+      {
+        "id": "PA451906",
+        "name": "warfarin",
+        "symbol": null
+      }
+    ],
+    "relatedGenes": [
+      {
+        "id": "PA133787052",
+        "name": "vitamin K epoxide reductase complex subunit 1",
+        "symbol": "VKORC1"
+      }
+    ],
+    "recommendation": false
+  },
+  "recommendations": [
+    {
+      "id": "PA166324226",
+      "name": "Recommendation Annotation PA166324226",
+      "population": "-1639G>A variant carriers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451906",
+          "name": "warfarin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452337685,
+        "html": "<p>&quot;Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "VKORC1": "-1639 AA"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    },
+    {
+      "id": "PA166324227",
+      "name": "Recommendation Annotation PA166324227",
+      "population": "-1639G>A variant carriers",
+      "classification": null,
+      "relatedChemicals": [
+        {
+          "id": "PA451906",
+          "name": "warfarin",
+          "symbol": null
+        }
+      ],
+      "text": {
+        "id": 1452337686,
+        "html": "<p>&quot;Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.&quot;</p>\n"
+      },
+      "implications": [],
+      "lookupKey": {
+        "VKORC1": "-1639 AG"
+      },
+      "dosingInformation": true,
+      "alternateDrugAvailable": false,
+      "otherPrescribingGuidance": true
+    }
+  ],
+  "citations": [],
+  "version": "2024-03-08-14-34"
+}
\ No newline at end of file
diff --git a/src/main/resources/org/pharmgkb/pharmcat/reporter/report.hbs b/src/main/resources/org/pharmgkb/pharmcat/reporter/report.hbs
index c51275ecc..5dbdc6706 100644
--- a/src/main/resources/org/pharmgkb/pharmcat/reporter/report.hbs
+++ b/src/main/resources/org/pharmgkb/pharmcat/reporter/report.hbs
@@ -233,7 +233,7 @@
                     <tr class="top-aligned {{{rxAnnotationClass source drug}}}">
                       <td>
                         <p>
-                          <b>{{source.displayName}}</b>
+                          <b>{{source}}</b>
                           {{#unless notCalled}}
                             <sup class="sources">
                               {{{listSources urls}}}
diff --git a/src/test/java/org/pharmgkb/pharmcat/Cacna1sTest.java b/src/test/java/org/pharmgkb/pharmcat/Cacna1sTest.java
index 5aac59289..5f3d90965 100644
--- a/src/test/java/org/pharmgkb/pharmcat/Cacna1sTest.java
+++ b/src/test/java/org/pharmgkb/pharmcat/Cacna1sTest.java
@@ -14,6 +14,7 @@
 import org.pharmgkb.pharmcat.reporter.TextConstants;
 import org.pharmgkb.pharmcat.reporter.handlebars.ReportHelpers;
 import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.ObjectType;
 
 import static org.pharmgkb.pharmcat.PipelineTest.*;
 
@@ -91,8 +92,8 @@ void cacna1sHet_ryr1Missing(TestInfo testInfo) throws Exception {
 
     testWrapper.testSourceDiplotypes(DataSource.CPIC, "CACNA1S", cacna1sCpicStyleCalls);
     testWrapper.testRecommendedDiplotypes(DataSource.CPIC, "CACNA1S", expectedCallsToRecommendedDiplotypes(cacna1sExpectedCalls));
-    testWrapper.testMatchedAnnotations("enflurane", DataSource.CPIC, 1);
-    testWrapper.testNoMatchFromSource("desflurane", DataSource.DPWG);
+    testWrapper.testMatchedAnnotations("enflurane", DataSource.CPIC, ObjectType.GUIDELINE, 1);
+    testWrapper.testNoMatchFromSource("desflurane", DataSource.DPWG, ObjectType.GUIDELINE);
 
     Document document = readHtmlReport(vcfFile);
     htmlChecks(document,
@@ -126,8 +127,8 @@ void cacna1sHet2_ryr1Missing(TestInfo testInfo) throws Exception {
     testWrapper.testRecommendedDiplotypes(DataSource.CPIC, "CACNA1S", expectedCallsToRecommendedDiplotypes(expectedCalls));
     testWrapper.testPrintCalls(DataSource.CPIC, "CACNA1S", expectedCalls);
 
-    testWrapper.testMatchedAnnotations("desflurane", DataSource.CPIC, 1);
-    testWrapper.testNoMatchFromSource("desflurane", DataSource.DPWG);
+    testWrapper.testMatchedAnnotations("desflurane", DataSource.CPIC, ObjectType.GUIDELINE, 1);
+    testWrapper.testNoMatchFromSource("desflurane", DataSource.DPWG, ObjectType.GUIDELINE);
 
     Document document = readHtmlReport(vcfFile);
     htmlChecks(document,
diff --git a/src/test/java/org/pharmgkb/pharmcat/DpydTest.java b/src/test/java/org/pharmgkb/pharmcat/DpydTest.java
index cc0419d6a..9c62610fb 100644
--- a/src/test/java/org/pharmgkb/pharmcat/DpydTest.java
+++ b/src/test/java/org/pharmgkb/pharmcat/DpydTest.java
@@ -25,6 +25,7 @@
 import org.pharmgkb.pharmcat.reporter.TextConstants;
 import org.pharmgkb.pharmcat.reporter.handlebars.ReportHelpers;
 import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.ObjectType;
 import org.pharmgkb.pharmcat.reporter.model.VariantReport;
 import org.pharmgkb.pharmcat.reporter.model.result.AnnotationReport;
 import org.pharmgkb.pharmcat.reporter.model.result.DrugReport;
@@ -94,23 +95,23 @@ public static void dpydHasReports(PipelineWrapper testWrapper, RecPresence hasCp
     int numAnnotations = 0;
 
     if (hasCpicReport == RecPresence.YES) {
-      testWrapper.testAnyMatchFromSource("fluorouracil", DataSource.CPIC);
-      testWrapper.testAnyMatchFromSource("capecitabine", DataSource.CPIC);
+      testWrapper.testAnyMatchFromSource("fluorouracil", DataSource.CPIC, ObjectType.GUIDELINE);
+      testWrapper.testAnyMatchFromSource("capecitabine", DataSource.CPIC, ObjectType.GUIDELINE);
       numAnnotations += 1;
 
     } else {
-      testWrapper.testNoMatchFromSource("fluorouracil", DataSource.CPIC);
-      testWrapper.testNoMatchFromSource("capecitabine", DataSource.CPIC);
+      testWrapper.testNoMatchFromSource("fluorouracil", DataSource.CPIC, ObjectType.GUIDELINE);
+      testWrapper.testNoMatchFromSource("capecitabine", DataSource.CPIC, ObjectType.GUIDELINE);
     }
 
     if (hasDpwgReport == RecPresence.YES) {
-      testWrapper.testAnyMatchFromSource("fluorouracil", DataSource.DPWG);
-      testWrapper.testAnyMatchFromSource("capecitabine", DataSource.DPWG);
+      testWrapper.testAnyMatchFromSource("fluorouracil", DataSource.DPWG, ObjectType.GUIDELINE);
+      testWrapper.testAnyMatchFromSource("capecitabine", DataSource.DPWG, ObjectType.GUIDELINE);
       numAnnotations += 1;
 
     } else {
-      testWrapper.testNoMatchFromSource("fluorouracil", DataSource.DPWG);
-      testWrapper.testNoMatchFromSource("capecitabine", DataSource.DPWG);
+      testWrapper.testNoMatchFromSource("fluorouracil", DataSource.DPWG, ObjectType.GUIDELINE);
+      testWrapper.testNoMatchFromSource("capecitabine", DataSource.DPWG, ObjectType.GUIDELINE);
     }
 
     if (numAnnotations > 0) {
@@ -409,8 +410,8 @@ void testDpydDifferenceOnScore(TestInfo testInfo) throws Exception {
     assertNotNull(highScoreDpydReport);
     assertTrue(highScoreDpydReport.getRecommendationDiplotypes().stream().allMatch((d) -> d.getActivityScore().equals("1.5")));
 
-    highScoreWrapper.testAnyMatchFromSource("capecitabine", DataSource.CPIC);
-    DrugReport highScoreDrug = highScoreWrapper.getContext().getDrugReport(DataSource.CPIC, "capecitabine");
+    highScoreWrapper.testAnyMatchFromSource("capecitabine", DataSource.CPIC, ObjectType.GUIDELINE);
+    DrugReport highScoreDrug = highScoreWrapper.getContext().getDrugReport(DataSource.CPIC, ObjectType.GUIDELINE, "capecitabine");
     assertNotNull(highScoreDrug);
     List<String> highRecs = highScoreDrug.getGuidelines().stream()
         .flatMap(g -> g.getAnnotations().stream())
@@ -430,8 +431,8 @@ void testDpydDifferenceOnScore(TestInfo testInfo) throws Exception {
     assertNotNull(lowScoreDpydReport);
     assertTrue(lowScoreDpydReport.getRecommendationDiplotypes().stream().allMatch((d) -> d.getActivityScore().equals("1.0")));
 
-    lowScoreWrapper.testAnyMatchFromSource("capecitabine", DataSource.CPIC);
-    DrugReport lowScoreDrug = lowScoreWrapper.getContext().getDrugReport(DataSource.CPIC, "capecitabine");
+    lowScoreWrapper.testAnyMatchFromSource("capecitabine", DataSource.CPIC, ObjectType.GUIDELINE);
+    DrugReport lowScoreDrug = lowScoreWrapper.getContext().getDrugReport(DataSource.CPIC, ObjectType.GUIDELINE, "capecitabine");
     assertNotNull(lowScoreDrug);
     List<String> lowRecs = lowScoreDrug.getGuidelines().stream()
         .flatMap(g -> g.getAnnotations().stream())
diff --git a/src/test/java/org/pharmgkb/pharmcat/PipelineTest.java b/src/test/java/org/pharmgkb/pharmcat/PipelineTest.java
index 3b22958b1..f258af6ff 100644
--- a/src/test/java/org/pharmgkb/pharmcat/PipelineTest.java
+++ b/src/test/java/org/pharmgkb/pharmcat/PipelineTest.java
@@ -33,6 +33,7 @@
 import org.pharmgkb.pharmcat.reporter.handlebars.ReportHelpers;
 import org.pharmgkb.pharmcat.reporter.model.DataSource;
 import org.pharmgkb.pharmcat.reporter.model.MessageAnnotation;
+import org.pharmgkb.pharmcat.reporter.model.ObjectType;
 import org.pharmgkb.pharmcat.reporter.model.VariantReport;
 import org.pharmgkb.pharmcat.reporter.model.result.AnnotationReport;
 import org.pharmgkb.pharmcat.reporter.model.result.Diplotype;
@@ -674,10 +675,10 @@ void testCyp2c19(TestInfo testInfo) throws Exception {
     testWrapper.testCalledByMatcher("CYP2C19");
     testWrapper.testPrintCpicCalls( "CYP2C19", "*1/*1");
 
-    testWrapper.testMatchedAnnotations("amitriptyline", DataSource.CPIC, 1);
-    testWrapper.testMatchedAnnotations("amitriptyline", DataSource.DPWG, 1);
-    testWrapper.testMatchedAnnotations("citalopram", DataSource.CPIC, 1);
-    testWrapper.testMatchedAnnotations("citalopram", DataSource.DPWG, 1);
+    testWrapper.testMatchedAnnotations("amitriptyline", DataSource.CPIC, ObjectType.GUIDELINE, 1);
+    testWrapper.testMatchedAnnotations("amitriptyline", DataSource.DPWG, ObjectType.GUIDELINE, 1);
+    testWrapper.testMatchedAnnotations("citalopram", DataSource.CPIC, ObjectType.GUIDELINE, 1);
+    testWrapper.testMatchedAnnotations("citalopram", DataSource.DPWG, ObjectType.GUIDELINE, 1);
     testWrapper.testMatchedAnnotations("ivacaftor", 0);
   }
 
@@ -701,14 +702,14 @@ void testCyp2c19_s1s2rs58973490het(TestInfo testInfo) throws Exception {
     testWrapper.testPrintCpicCalls( "CYP2D6", "*3/*4");
 
     testWrapper.testMatchedAnnotations("amitriptyline", 2);
-    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.DPWG, ObjectType.GUIDELINE);
     testWrapper.testMatchedAnnotations("citalopram", 2);
-    testWrapper.testAnyMatchFromSource("citalopram", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("citalopram", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("citalopram", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("citalopram", DataSource.DPWG, ObjectType.GUIDELINE);
     testWrapper.testMatchedAnnotations("clomipramine", 3);
-    testWrapper.testAnyMatchFromSource("clomipramine", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("clomipramine", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("clomipramine", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("clomipramine", DataSource.DPWG, ObjectType.GUIDELINE);
     testWrapper.testMatchedAnnotations("ivacaftor", 0);
 
     GeneReport cyp2c19report = testWrapper.getContext().getGeneReport(DataSource.CPIC, "CYP2C19");
@@ -724,7 +725,7 @@ void testCyp2c19_s1s2rs58973490het(TestInfo testInfo) throws Exception {
             Objects.requireNonNull(m.getMatches().getVariant()).equals("rs58973490"))
         .count());
 
-    testWrapper.testMessageCountForDrug(DataSource.CPIC, "amitriptyline", 1);
+    testWrapper.testMessageCountForDrug(DataSource.CPIC, ObjectType.GUIDELINE, "amitriptyline", 1);
   }
 
   /**
@@ -744,14 +745,14 @@ void testCyp2c19_s1s2(TestInfo testInfo) throws Exception {
     testWrapper.testPrintCpicCalls( "CYP2C19", "*1/*2");
 
     testWrapper.testMatchedAnnotations("amitriptyline", 2);
-    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.DPWG, ObjectType.GUIDELINE);
     testWrapper.testMatchedAnnotations("citalopram", 2);
-    testWrapper.testAnyMatchFromSource("citalopram", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("citalopram", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("citalopram", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("citalopram", DataSource.DPWG, ObjectType.GUIDELINE);
     testWrapper.testMatchedAnnotations("clomipramine", 3);
-    testWrapper.testAnyMatchFromSource("clomipramine", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("clomipramine", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("clomipramine", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("clomipramine", DataSource.DPWG, ObjectType.GUIDELINE);
     testWrapper.testMatchedAnnotations("ivacaftor", 0);
 
     GeneReport cyp2c19report = testWrapper.getContext().getGeneReport(DataSource.CPIC, "CYP2C19");
@@ -768,9 +769,9 @@ void testCyp2c19_s1s2(TestInfo testInfo) throws Exception {
             Objects.requireNonNull(m.getMatches().getVariant()).equals("rs58973490"))
         .count());
 
-    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.CPIC);
+    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.CPIC, ObjectType.GUIDELINE);
     // the variant is hom, so the ambiguity message should not apply and, thus, no matching messages
-    testWrapper.testMessageCountForDrug(DataSource.CPIC, "amitriptyline", 0);
+    testWrapper.testMessageCountForDrug(DataSource.CPIC, ObjectType.GUIDELINE, "amitriptyline", 0);
 
     // CYP2C19 reference is *38, not *1, so should not have a reference message
     testWrapper.testMessageCountForGene(DataSource.CPIC, "CYP2C19", 0);
@@ -789,37 +790,37 @@ void testClomipramineCall(TestInfo testInfo) throws Exception {
     testWrapper.testPrintCpicCalls( "CYP2C19", "*2/*2");
 
     testWrapper.testMatchedAnnotations("amitriptyline", 2);
-    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.DPWG, ObjectType.GUIDELINE);
     testWrapper.testMatchedAnnotations("clomipramine", 3);
-    testWrapper.testAnyMatchFromSource("clomipramine", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("clomipramine", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("clomipramine", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("clomipramine", DataSource.DPWG, ObjectType.GUIDELINE);
     testWrapper.testMatchedAnnotations("desipramine", 1);
-    testWrapper.testAnyMatchFromSource("desipramine", DataSource.CPIC);
+    testWrapper.testAnyMatchFromSource("desipramine", DataSource.CPIC, ObjectType.GUIDELINE);
     testWrapper.testMatchedAnnotations("doxepin", 2);
-    testWrapper.testAnyMatchFromSource("doxepin", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("doxepin", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("doxepin", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("doxepin", DataSource.DPWG, ObjectType.GUIDELINE);
     testWrapper.testMatchedAnnotations("imipramine", 3);
-    testWrapper.testAnyMatchFromSource("imipramine", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("imipramine", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("imipramine", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("imipramine", DataSource.DPWG, ObjectType.GUIDELINE);
     testWrapper.testMatchedAnnotations("nortriptyline", 2);
-    testWrapper.testAnyMatchFromSource("nortriptyline", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("nortriptyline", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("nortriptyline", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("nortriptyline", DataSource.DPWG, ObjectType.GUIDELINE);
     testWrapper.testMatchedAnnotations("trimipramine", 1);
 
     testWrapper.testMatchedAnnotations("clopidogrel", 5);
-    testWrapper.testAnyMatchFromSource("clopidogrel", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("clopidogrel", DataSource.DPWG);
-    testWrapper.testAnyMatchFromSource("clopidogrel", DataSource.FDA);
+    testWrapper.testAnyMatchFromSource("clopidogrel", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("clopidogrel", DataSource.DPWG, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("clopidogrel", DataSource.FDA, ObjectType.LABEL);
 
     testWrapper.testMatchedAnnotations("lansoprazole", 2);
-    testWrapper.testAnyMatchFromSource("lansoprazole", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("lansoprazole", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("lansoprazole", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("lansoprazole", DataSource.DPWG, ObjectType.GUIDELINE);
 
     // voriconazole has 2 populations with recommendations so should have 2 matching annotations from CPIC
     // and 1 from DPWG
-    testWrapper.testMatchedAnnotations("voriconazole", DataSource.CPIC, 2);
-    testWrapper.testMatchedAnnotations("voriconazole", DataSource.DPWG, 1);
+    testWrapper.testMatchedAnnotations("voriconazole", DataSource.CPIC, ObjectType.GUIDELINE, 2);
+    testWrapper.testMatchedAnnotations("voriconazole", DataSource.DPWG, ObjectType.GUIDELINE, 1);
   }
 
   @Test
@@ -832,10 +833,10 @@ void testCyp2c19noCall(TestInfo testInfo) throws Exception {
 
     testWrapper.testNotCalledByMatcher("CYP2C19");
 
-    testWrapper.testNoMatchFromSource("citalopram", DataSource.CPIC);
-    testWrapper.testNoMatchFromSource("citalopram", DataSource.DPWG);
-    testWrapper.testNoMatchFromSource("ivacaftor", DataSource.CPIC);
-    testWrapper.testNoMatchFromSource("ivacaftor", DataSource.DPWG);
+    testWrapper.testNoMatchFromSource("citalopram", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testNoMatchFromSource("citalopram", DataSource.DPWG, ObjectType.GUIDELINE);
+    testWrapper.testNoMatchFromSource("ivacaftor", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testNoMatchFromSource("ivacaftor", DataSource.DPWG, ObjectType.GUIDELINE);
   }
 
   @Test
@@ -852,11 +853,11 @@ void testCyp2c19s4bs17rs28399504missing(TestInfo testInfo) throws Exception {
     testWrapper.testPrintCpicCalls("CYP2C19", "*4/*4", "*4/*17", "*17/*17");
 
     testWrapper.testMatchedAnnotations("citalopram", 7);
-    testWrapper.testMatchedAnnotations("citalopram", DataSource.CPIC, 3);
-    testWrapper.testMatchedAnnotations("citalopram", DataSource.DPWG, 3);
-    testWrapper.testMatchedAnnotations("citalopram", DataSource.FDA, 1);
-    testWrapper.testAnyMatchFromSource("citalopram", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("citalopram", DataSource.DPWG);
+    testWrapper.testMatchedAnnotations("citalopram", DataSource.CPIC, ObjectType.GUIDELINE, 3);
+    testWrapper.testMatchedAnnotations("citalopram", DataSource.DPWG, ObjectType.GUIDELINE, 3);
+    testWrapper.testMatchedAnnotations("citalopram", DataSource.FDA, ObjectType.LABEL, 1);
+    testWrapper.testAnyMatchFromSource("citalopram", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("citalopram", DataSource.DPWG, ObjectType.GUIDELINE);
   }
 
   @Test
@@ -913,8 +914,8 @@ void testCyp2c19s1s4missingS1(TestInfo testInfo) throws Exception {
         .filter(m -> m.getExceptionType().equals(MessageAnnotation.TYPE_AMBIGUITY))
         .count());
 
-    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.CPIC);
-    testWrapper.testMessageCountForDrug(DataSource.CPIC, "amitriptyline", 2);
+    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testMessageCountForDrug(DataSource.CPIC, ObjectType.GUIDELINE, "amitriptyline", 2);
   }
 
   @Test
@@ -1081,8 +1082,8 @@ void testAmitriptylineCallWoCyp2c19(TestInfo testInfo) throws Exception {
     testWrapper.testRecommendedDiplotypes("CYP2D6", "*1", "*4");
 
     testWrapper.testMatchedAnnotations("amitriptyline", 2);
-    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("amitriptyline", DataSource.DPWG, ObjectType.GUIDELINE);
   }
 
 
@@ -1102,7 +1103,7 @@ void testSlco1b1HomWild(TestInfo testInfo) throws Exception {
 
     testWrapper.testMatchedAnnotations("simvastatin", 2);
 
-    DrugReport dpwgReport = testWrapper.getContext().getDrugReport(DataSource.DPWG, "simvastatin");
+    DrugReport dpwgReport = testWrapper.getContext().getDrugReport(DataSource.DPWG, ObjectType.GUIDELINE, "simvastatin");
     assertNotNull(dpwgReport);
     assertNotNull(dpwgReport.getGuidelines());
     assertEquals("No recommendation", dpwgReport.getGuidelines().first().getAnnotations().first().getClassification());
@@ -1126,8 +1127,8 @@ void testSlco1b1HomVar(TestInfo testInfo) throws Exception {
     testWrapper.testRecommendedDiplotypes(DataSource.CPIC, "SLCO1B1", expectedCallsToRecommendedDiplotypes(expectedCalls));
     testWrapper.testPrintCalls(DataSource.CPIC, "SLCO1B1", expectedCalls);
 
-    testWrapper.testMatchedAnnotations("simvastatin", DataSource.CPIC, 1);
-    testWrapper.testMatchedAnnotations("simvastatin", DataSource.DPWG, 1);
+    testWrapper.testMatchedAnnotations("simvastatin", DataSource.CPIC, ObjectType.GUIDELINE, 1);
+    testWrapper.testMatchedAnnotations("simvastatin", DataSource.DPWG, ObjectType.GUIDELINE, 1);
 
     Document document = readHtmlReport(vcfFile);
     htmlChecks(document, "SLCO1B1", expectedCalls, "simvastatin", RecPresence.YES, RecPresence.YES);
@@ -1170,8 +1171,8 @@ void testSlco1b1Test3(TestInfo testInfo) throws Exception {
     testWrapper.testRecommendedDiplotypes(DataSource.CPIC, "SLCO1B1", expectedCallsToRecommendedDiplotypes(expectedCalls));
     testWrapper.testPrintCalls(DataSource.CPIC, "SLCO1B1", expectedCalls);
 
-    testWrapper.testMatchedAnnotations("simvastatin", DataSource.CPIC, 1);
-    testWrapper.testMatchedAnnotations("simvastatin", DataSource.DPWG, 1);
+    testWrapper.testMatchedAnnotations("simvastatin", DataSource.CPIC, ObjectType.GUIDELINE, 1);
+    testWrapper.testMatchedAnnotations("simvastatin", DataSource.DPWG, ObjectType.GUIDELINE, 1);
 
     Document document = readHtmlReport(vcfFile);
     htmlChecks(document, "SLCO1B1", expectedCalls, "simvastatin", RecPresence.YES, RecPresence.YES);
@@ -1305,7 +1306,7 @@ void testUgt1a1s28s80phased(TestInfo testInfo) throws Exception {
 
     // the guideline should not have an ambiguity message
     testWrapper.testMatchedAnnotations("atazanavir", 1);
-    testWrapper.testMessageCountForDrug(DataSource.CPIC, "atazanavir", 0);
+    testWrapper.testMessageCountForDrug(DataSource.CPIC, ObjectType.GUIDELINE, "atazanavir", 0);
 
     testWrapper.testMessageCountForGene(DataSource.CPIC, "UGT1A1", 2);
     testWrapper.testGeneHasMessage(DataSource.CPIC, "UGT1A1", "reference-allele");
@@ -1666,15 +1667,15 @@ void testHlab(TestInfo testInfo) throws Exception {
     testWrapper.testSourcePhenotype(DataSource.DPWG, "HLA-B", "*15:02 positive");
 
     // *57:01 guideline
-    testWrapper.testMatchedAnnotations("abacavir", DataSource.CPIC, 1);
-    testWrapper.testMatchedAnnotations("abacavir", DataSource.DPWG, 1);
+    testWrapper.testMatchedAnnotations("abacavir", DataSource.CPIC, ObjectType.GUIDELINE, 1);
+    testWrapper.testMatchedAnnotations("abacavir", DataSource.DPWG, ObjectType.GUIDELINE, 1);
     // *58:01 guideline
-    testWrapper.testMatchedAnnotations("allopurinol", DataSource.CPIC, 1);
+    testWrapper.testMatchedAnnotations("allopurinol", DataSource.CPIC, ObjectType.GUIDELINE, 1);
     // *15:02 guideline (along with CYP2C9)
     testWrapper.testMatchedAnnotations("phenytoin", 5);
-    testWrapper.testMatchedAnnotations("phenytoin", DataSource.CPIC, 2);
-    testWrapper.testMatchedAnnotations("phenytoin", DataSource.DPWG, 2);
-    testWrapper.testMatchedAnnotations("phenytoin", DataSource.FDA, 1);
+    testWrapper.testMatchedAnnotations("phenytoin", DataSource.CPIC, ObjectType.GUIDELINE, 2);
+    testWrapper.testMatchedAnnotations("phenytoin", DataSource.DPWG, ObjectType.GUIDELINE, 2);
+    testWrapper.testMatchedAnnotations("phenytoin", DataSource.FDA, ObjectType.LABEL, 1);
   }
 
   @Test
@@ -1698,17 +1699,17 @@ void testSingleHlabAllele(TestInfo testInfo) throws Exception {
     testWrapper.testSourcePhenotype(DataSource.DPWG, "HLA-B", "*58:01 negative");
     testWrapper.testSourcePhenotype(DataSource.DPWG, "HLA-B", "*15:02 positive");
 
-    testWrapper.testMatchedAnnotations("abacavir", DataSource.CPIC, 1);
-    testWrapper.testMatchedAnnotations("allopurinol", DataSource.CPIC, 1);
+    testWrapper.testMatchedAnnotations("abacavir", DataSource.CPIC, ObjectType.GUIDELINE, 1);
+    testWrapper.testMatchedAnnotations("allopurinol", DataSource.CPIC, ObjectType.GUIDELINE, 1);
     testWrapper.testMatchedAnnotations("phenytoin", 5);
-    testWrapper.testMatchedAnnotations("phenytoin", DataSource.CPIC, 2);
-    testWrapper.testMatchedAnnotations("phenytoin", DataSource.DPWG, 2);
-    testWrapper.testMatchedAnnotations("phenytoin", DataSource.FDA, 1);
+    testWrapper.testMatchedAnnotations("phenytoin", DataSource.CPIC, ObjectType.GUIDELINE, 2);
+    testWrapper.testMatchedAnnotations("phenytoin", DataSource.DPWG, ObjectType.GUIDELINE, 2);
+    testWrapper.testMatchedAnnotations("phenytoin", DataSource.FDA, ObjectType.LABEL, 1);
 
     // carbamazepine-CPIC is a two gene lookup, let's test to make sure only specifying HLA-B will still return results
-    testWrapper.testMatchedAnnotations("carbamazepine", DataSource.CPIC, 3);
+    testWrapper.testMatchedAnnotations("carbamazepine", DataSource.CPIC, ObjectType.GUIDELINE, 3);
     // carbamazepine-DPWG is a single gene lookup so it will be a "normal" lookup
-    testWrapper.testMatchedAnnotations("carbamazepine", DataSource.DPWG, 1);
+    testWrapper.testMatchedAnnotations("carbamazepine", DataSource.DPWG, ObjectType.GUIDELINE, 1);
   }
 
   @Test
@@ -1728,16 +1729,16 @@ void testHlabPhenotype(TestInfo testInfo) throws Exception {
     testWrapper.testReportable("CYP2C9");
     testWrapper.testReportable("HLA-B");
     testWrapper.testMatchedAnnotations("abacavir", 3);
-    testWrapper.testMatchedAnnotations("abacavir", DataSource.CPIC, 1);
-    testWrapper.testMatchedAnnotations("abacavir", DataSource.DPWG, 1);
-    testWrapper.testMatchedAnnotations("abacavir", DataSource.FDA, 1);
+    testWrapper.testMatchedAnnotations("abacavir", DataSource.CPIC, ObjectType.GUIDELINE, 1);
+    testWrapper.testMatchedAnnotations("abacavir", DataSource.DPWG, ObjectType.GUIDELINE, 1);
+    testWrapper.testMatchedAnnotations("abacavir", DataSource.FDA, ObjectType.LABEL, 1);
     // allopurinol relies on a different allele for recs so no matches
     testWrapper.testMatchedAnnotations("allopurinol", 0);
     // phenytoin also relies on a different allele, but there will be a match for DPWG since the recommendations are
     // split between the two genes on that side
     testWrapper.testMatchedAnnotations("phenytoin", 1);
-    testWrapper.testNoMatchFromSource("phenytoin", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("phenytoin", DataSource.DPWG);
+    testWrapper.testNoMatchFromSource("phenytoin", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("phenytoin", DataSource.DPWG, ObjectType.GUIDELINE);
   }
 
   /**
@@ -1781,22 +1782,24 @@ void testRecommendationExamples(TestInfo testInfo) throws Exception {
 
     testWrapper.testReportable("CYP2C19", "CYP2C9", "HLA-A", "HLA-B");
     testWrapper.testMatchedAnnotations("celecoxib", 1);
-    testWrapper.testAnyMatchFromSource("celecoxib", DataSource.CPIC);
-    testWrapper.testMatchedAnnotations("citalopram", 3);
-    testWrapper.testMatchedAnnotations("clomipramine", DataSource.CPIC, 1);
-    testWrapper.testMatchedAnnotations("clomipramine", DataSource.DPWG, 1);
-    testWrapper.testMatchedAnnotations("clopidogrel", 5);
-    testWrapper.testMatchedAnnotations("clopidogrel", DataSource.CPIC, 3);
-    testWrapper.testMatchedAnnotations("clopidogrel", DataSource.DPWG, 1);
-    testWrapper.testNoMatchFromSource("flucloxacillin", DataSource.CPIC);
-    testWrapper.testMatchedAnnotations("flucloxacillin", DataSource.DPWG, 1);
-    testWrapper.testNoMatchFromSource("fluvoxamine", DataSource.CPIC);
-    testWrapper.testNoMatchFromSource("fluvoxamine", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("celecoxib", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testMatchedAnnotations("citalopram", 4);
+    testWrapper.testMatchedAnnotations("clomipramine", DataSource.CPIC, ObjectType.GUIDELINE, 1);
+    testWrapper.testMatchedAnnotations("clomipramine", DataSource.DPWG, ObjectType.GUIDELINE, 1);
+    testWrapper.testMatchedAnnotations("clopidogrel", 6);
+    testWrapper.testMatchedAnnotations("clopidogrel", DataSource.CPIC, ObjectType.GUIDELINE, 3);
+    testWrapper.testMatchedAnnotations("clopidogrel", DataSource.DPWG, ObjectType.GUIDELINE, 1);
+    testWrapper.testMatchedAnnotations("clopidogrel", DataSource.FDA, ObjectType.LABEL, 1);
+    testWrapper.testMatchedAnnotations("clopidogrel", DataSource.FDA, ObjectType.ASSOCIATION, 1);
+    testWrapper.testNoMatchFromSource("flucloxacillin", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testMatchedAnnotations("flucloxacillin", DataSource.DPWG, ObjectType.GUIDELINE, 1);
+    testWrapper.testNoMatchFromSource("fluvoxamine", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testNoMatchFromSource("fluvoxamine", DataSource.DPWG, ObjectType.GUIDELINE);
     testWrapper.testMatchedAnnotations("siponimod", 1);
-    testWrapper.testAnyMatchFromSource("siponimod", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("siponimod", DataSource.DPWG, ObjectType.GUIDELINE);
 
-    testWrapper.testMatchedAnnotations("carbamazepine", DataSource.CPIC, 3);
-    testWrapper.testMatchedAnnotations("carbamazepine", DataSource.DPWG, 1);
+    testWrapper.testMatchedAnnotations("carbamazepine", DataSource.CPIC, ObjectType.GUIDELINE, 3);
+    testWrapper.testMatchedAnnotations("carbamazepine", DataSource.DPWG, ObjectType.GUIDELINE, 1);
   }
 
   @Test
@@ -1953,8 +1956,8 @@ void testCyp2d6AlleleWithNoFunction(TestInfo testInfo) throws Exception {
     testWrapper.testSourcePhenotype(DataSource.CPIC, "CYP2D6", "n/a");
 
     // this nonsense allele will still match to "Indeterminate" phenotypes in guidelines for CYP2D6
-    testWrapper.testMatchedAnnotations("atomoxetine", DataSource.CPIC, 2);
-    DrugReport atoReport = testWrapper.getContext().getDrugReport(DataSource.CPIC, "atomoxetine");
+    testWrapper.testMatchedAnnotations("atomoxetine", DataSource.CPIC, ObjectType.GUIDELINE, 2);
+    DrugReport atoReport = testWrapper.getContext().getDrugReport(DataSource.CPIC, ObjectType.GUIDELINE, "atomoxetine");
     assertNotNull(atoReport);
     assertNotNull(atoReport.getGuidelines());
     assertEquals(1, atoReport.getGuidelines().size());
@@ -2203,7 +2206,7 @@ void testPartialCallInTwoGene(TestInfo testInfo) throws Exception {
 
     // We don't expect to get a match since 2C19 is a partial call even when 2D6 has a call.
     // Currently, partials will not be visible past the phenotyper so recommendation matches are not visible.
-    testWrapper.testMatchedAnnotations("amitriptyline", DataSource.CPIC, 0);
+    testWrapper.testMatchedAnnotations("amitriptyline", DataSource.CPIC, ObjectType.GUIDELINE, 0);
   }
 
 
@@ -2296,7 +2299,7 @@ void testOutsideCallPhenotypeOverridesDiplotype(TestInfo testInfo) throws Except
     Diplotype diplotype = geneReport.getRecommendationDiplotypes().first();
     assertThat(diplotype.getPhenotypes(), contains("Poor Metabolizer"));
 
-    DrugReport drugReport = testWrapper.getContext().getDrugReport(DataSource.CPIC, "clomipramine");
+    DrugReport drugReport = testWrapper.getContext().getDrugReport(DataSource.CPIC, ObjectType.GUIDELINE, "clomipramine");
     assertNotNull(drugReport);
     assertEquals(1, drugReport.getGuidelines().size());
     GuidelineReport guidelineReport = drugReport.getGuidelines().first();
@@ -2416,8 +2419,8 @@ void testF5OutsideCallPhenotype(TestInfo testInfo) throws Exception {
     testWrapper.testReportable(gene);
     testWrapper.testPrintCalls(DataSource.DPWG, gene, displayedCalls);
 
-    testWrapper.testNoMatchFromSource("hormonal contraceptives for systemic use", DataSource.CPIC);
-    testWrapper.testMatchedAnnotations("hormonal contraceptives for systemic use", DataSource.DPWG, 1);
+    testWrapper.testNoMatchFromSource("hormonal contraceptives for systemic use", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testMatchedAnnotations("hormonal contraceptives for systemic use", DataSource.DPWG, ObjectType.GUIDELINE, 1);
 
     Document document = readHtmlReport(outsideCallFile);
     htmlChecks(document,
@@ -2451,8 +2454,8 @@ void testF5OutsideCallDiplotype(TestInfo testInfo) throws Exception {
     testWrapper.testReportable(gene);
     testWrapper.testPrintCalls(DataSource.DPWG, gene, expectedCalls);
 
-    testWrapper.testNoMatchFromSource("hormonal contraceptives for systemic use", DataSource.CPIC);
-    testWrapper.testMatchedAnnotations("hormonal contraceptives for systemic use", DataSource.DPWG, 1);
+    testWrapper.testNoMatchFromSource("hormonal contraceptives for systemic use", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testMatchedAnnotations("hormonal contraceptives for systemic use", DataSource.DPWG, ObjectType.GUIDELINE, 1);
 
     Document document = readHtmlReport(outsideCallFile);
     htmlChecks(document, gene, expectedCalls, "hormonal contraceptives for systemic use", RecPresence.NO, RecPresence.YES);
diff --git a/src/test/java/org/pharmgkb/pharmcat/PipelineWrapper.java b/src/test/java/org/pharmgkb/pharmcat/PipelineWrapper.java
index 84c88fb35..ec34b1713 100644
--- a/src/test/java/org/pharmgkb/pharmcat/PipelineWrapper.java
+++ b/src/test/java/org/pharmgkb/pharmcat/PipelineWrapper.java
@@ -13,7 +13,6 @@
 import java.util.TreeSet;
 import java.util.stream.Collectors;
 import com.google.common.base.Preconditions;
-import com.google.common.collect.Lists;
 import org.checkerframework.checker.nullness.qual.Nullable;
 import org.junit.jupiter.api.TestInfo;
 import org.opentest4j.AssertionFailedError;
@@ -21,7 +20,9 @@
 import org.pharmgkb.pharmcat.reporter.TextConstants;
 import org.pharmgkb.pharmcat.reporter.handlebars.ReportHelpers;
 import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
 import org.pharmgkb.pharmcat.reporter.model.MessageAnnotation;
+import org.pharmgkb.pharmcat.reporter.model.ObjectType;
 import org.pharmgkb.pharmcat.reporter.model.result.Diplotype;
 import org.pharmgkb.pharmcat.reporter.model.result.DiplotypeTest;
 import org.pharmgkb.pharmcat.reporter.model.result.DrugReport;
@@ -39,7 +40,7 @@
 class PipelineWrapper {
   // controls to support running PipelineTest from SyntheticBatchTest
   private static boolean m_compact = true;
-  private static List<DataSource> m_sources = Lists.newArrayList(DataSource.CPIC, DataSource.DPWG, DataSource.FDA);
+  private static List<DataSourceType> m_sources = DataSourceType.listValidDataSourceTypes();
 
   private final Env m_env;
   private final Path m_outputPath;
@@ -55,7 +56,7 @@ static void setCompact(boolean compact) {
     m_compact = compact;
   }
 
-  static void setSources(List<DataSource> sources) {
+  static void setSources(List<DataSourceType> sources) {
     m_sources = sources;
   }
 
@@ -393,31 +394,31 @@ void testMatchedAnnotations(String drugName, int expectedCount) {
         drugName + " has " + numMatched + " matching recommendation(s) instead of " + expectedCount);
   }
 
-  void testMatchedAnnotations(String drugName, DataSource source, int expectedCount) {
-    DrugReport drugReport = getContext().getDrugReport(source, drugName);
+  void testMatchedAnnotations(String drugName, DataSource source, ObjectType type, int expectedCount) {
+    DrugReport drugReport = getContext().getDrugReport(source, type, drugName);
     assertNotNull(drugReport);
     assertEquals(expectedCount, drugReport.getMatchedAnnotationCount(),
         drugName + " has " + drugReport.getMatchedAnnotationCount() + " matching " + source +
             " recommendation(s) instead of " + expectedCount);
   }
 
-  void testAnyMatchFromSource(String drugName, DataSource source) {
-    DrugReport drugReport = getContext().getDrugReport(source, drugName);
+  void testAnyMatchFromSource(String drugName, DataSource source, ObjectType type) {
+    DrugReport drugReport = getContext().getDrugReport(source, type, drugName);
     assertNotNull(drugReport);
-    assertTrue(drugReport.getGuidelines().stream().anyMatch((g) -> g.getSource() == source && g.isMatched()),
+    assertTrue(drugReport.getGuidelines().stream().anyMatch((g) -> g.getSource().getDataSource() == source && g.isMatched()),
         drugName + " does not have matching recommendation from " + source);
   }
 
-  void testNoMatchFromSource(String drugName, DataSource source) {
-    DrugReport drugReport = getContext().getDrugReport(source, drugName);
+  void testNoMatchFromSource(String drugName, DataSource source, ObjectType type) {
+    DrugReport drugReport = getContext().getDrugReport(source, type, drugName);
     if (drugReport != null) {
-      assertTrue(drugReport.getGuidelines().stream().noneMatch(r -> r.getSource() == source && r.isMatched()),
+      assertTrue(drugReport.getGuidelines().stream().noneMatch(r -> r.getSource().getDataSource() == source && r.isMatched()),
           drugName + " has a matching recommendation from " + source + " and expected none");
     }
   }
 
-  void testMessageCountForDrug(DataSource source, String drugName, int messageCount) {
-    DrugReport drugReport = getContext().getDrugReport(source, drugName);
+  void testMessageCountForDrug(DataSource source, ObjectType type, String drugName, int messageCount) {
+    DrugReport drugReport = getContext().getDrugReport(source, type, drugName);
     assertNotNull(drugReport);
     assertEquals(messageCount, drugReport.getMessages().size(),
         drugName + " expected " + messageCount + " messages and got " + drugReport.getMessages());
diff --git a/src/test/java/org/pharmgkb/pharmcat/Ryr1Test.java b/src/test/java/org/pharmgkb/pharmcat/Ryr1Test.java
index 035d9374e..a702ff429 100644
--- a/src/test/java/org/pharmgkb/pharmcat/Ryr1Test.java
+++ b/src/test/java/org/pharmgkb/pharmcat/Ryr1Test.java
@@ -14,6 +14,7 @@
 import org.pharmgkb.pharmcat.reporter.TextConstants;
 import org.pharmgkb.pharmcat.reporter.handlebars.ReportHelpers;
 import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.ObjectType;
 
 import static org.pharmgkb.pharmcat.PipelineTest.*;
 
@@ -174,8 +175,8 @@ void cacna1sMissing_ryr1Ref(TestInfo testInfo) throws Exception {
     testWrapper.testRecommendedDiplotypes(DataSource.CPIC, "RYR1", List.of(TextConstants.REFERENCE, TextConstants.REFERENCE));
     testWrapper.testPrintCalls(DataSource.CPIC, "RYR1", expectedCalls);
 
-    testWrapper.testMatchedAnnotations("desflurane", DataSource.CPIC, 1);
-    testWrapper.testNoMatchFromSource("desflurane", DataSource.DPWG);
+    testWrapper.testMatchedAnnotations("desflurane", DataSource.CPIC, ObjectType.GUIDELINE, 1);
+    testWrapper.testNoMatchFromSource("desflurane", DataSource.DPWG, ObjectType.GUIDELINE);
 
     Document document = readHtmlReport(vcfFile);
     htmlChecks(document,
diff --git a/src/test/java/org/pharmgkb/pharmcat/SyntheticBatchTest.java b/src/test/java/org/pharmgkb/pharmcat/SyntheticBatchTest.java
index 99cb058c0..3446891cb 100644
--- a/src/test/java/org/pharmgkb/pharmcat/SyntheticBatchTest.java
+++ b/src/test/java/org/pharmgkb/pharmcat/SyntheticBatchTest.java
@@ -6,6 +6,7 @@
 import java.nio.file.Files;
 import java.nio.file.Path;
 import java.text.SimpleDateFormat;
+import java.util.ArrayList;
 import java.util.Date;
 import java.util.List;
 import java.util.stream.Collectors;
@@ -18,12 +19,14 @@
 import org.junit.platform.launcher.listeners.SummaryGeneratingListener;
 import org.pharmgkb.common.util.CliHelper;
 import org.pharmgkb.common.util.PathUtils;
-import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.DataSourceType;
+import org.pharmgkb.pharmcat.reporter.model.ObjectType;
 import org.pharmgkb.pharmcat.util.CliUtils;
 import org.slf4j.Logger;
 import org.slf4j.LoggerFactory;
 
 import static org.junit.platform.engine.discovery.DiscoverySelectors.selectClass;
+import static org.pharmgkb.pharmcat.reporter.model.DataSource.*;
 
 
 /**
@@ -41,7 +44,7 @@ class SyntheticBatchTest {
   private static final Path sf_outsideCYP2D6G6PDFile
       = PathUtils.getPathToResource("org/pharmgkb/pharmcat/reporter/outside_CYP2D6_G6PD.tsv");
   private final boolean m_compact;
-  private final List<DataSource> m_sources;
+  private final List<DataSourceType> m_sources;
 
 
   public static void main(String[] args) {
@@ -49,8 +52,10 @@ public static void main(String[] args) {
         .addOption("o", "output-dir", "directory to output to", false, "o")
         .addOption("a", "all-tests", "run all tests for Katrin")
         .addOption("re", "reporter-extended", "output extended report")
-        .addOption("cpic", "cpic", "CPIC reports")
-        .addOption("dpwg", "dpwg", "DPWG reports")
+        .addOption("cpic", "cpic", "CPIC guideline annotation reports")
+        .addOption("dpwg", "dpwg", "DPWG guideline annotation reports")
+        .addOption("fdaLabel", "fda-label", "FDA label annotation reports")
+        .addOption("fdaAssoc", "fda-assoc", "FDA PGx association reports")
         .addOption("mega", "mega", "generate all variations in one run")
         ;
 
@@ -69,26 +74,34 @@ public static void main(String[] args) {
           System.exit(1);
         }
 
-        List<DataSource> sources = Lists.newArrayList(DataSource.CPIC, DataSource.DPWG);
+        List<DataSourceType> sources = DataSourceType.listValidDataSourceTypes();
         doRun(dir.resolve("default"), true, sources, true);
         doRun(dir.resolve("extended"), false, sources, true);
-        doRun(dir.resolve("cpic"), true, Lists.newArrayList(DataSource.CPIC), true);
-        doRun(dir.resolve("cpic-extended"), false, Lists.newArrayList(DataSource.CPIC), true);
-        doRun(dir.resolve("dpwg"), true, Lists.newArrayList(DataSource.DPWG), true);
-        doRun(dir.resolve("dpwg-extended"), false, Lists.newArrayList(DataSource.DPWG), true);
+        for (DataSourceType dataSource : sources) {
+          doRun(dir.resolve(dataSource.toCompactString()), true, Lists.newArrayList(dataSource), true);
+          doRun(dir.resolve(dataSource.toCompactString() + "-extended"), false, Lists.newArrayList(dataSource), true);
+        }
 
 
       } else {
-        List<DataSource> sources = Lists.newArrayList(DataSource.CPIC, DataSource.DPWG);
+        List<DataSourceType> sources = DataSourceType.listValidDataSourceTypes();
         boolean cpic = cliHelper.hasOption("cpic");
         boolean dpwg = cliHelper.hasOption("dpwg");
-        if (cpic || dpwg) {
-          sources.clear();
+        boolean fdaLabel = cliHelper.hasOption("fdaLabel");
+        boolean fdaAssoc = cliHelper.hasOption("fdaAssoc");
+        if (cpic || dpwg || fdaLabel || fdaAssoc) {
+          sources = new ArrayList<>();
           if (cpic) {
-            sources.add(DataSource.CPIC);
+            sources.add(new DataSourceType(CPIC, ObjectType.GUIDELINE));
           }
           if (dpwg) {
-            sources.add(DataSource.DPWG);
+            sources.add(new DataSourceType(DPWG, ObjectType.GUIDELINE));
+          }
+          if (fdaLabel) {
+            sources.add(new DataSourceType(FDA, ObjectType.LABEL));
+          }
+          if (fdaAssoc) {
+            sources.add(new DataSourceType(FDA, ObjectType.ASSOCIATION));
           }
         }
         Path dir = null;
@@ -103,7 +116,7 @@ public static void main(String[] args) {
     }
   }
 
-  private static void doRun(@Nullable Path dir, boolean compact, List<DataSource> sources, boolean allTests)
+  private static void doRun(@Nullable Path dir, boolean compact, List<DataSourceType> sources, boolean allTests)
       throws Exception {
     if (dir != null) {
       System.out.println("Saving results to " + dir);
@@ -533,7 +546,7 @@ private void execute() throws Exception {
   }
 
 
-  private SyntheticBatchTest(boolean compact, List<DataSource> sources) throws IOException {
+  private SyntheticBatchTest(boolean compact, List<DataSourceType> sources) throws IOException {
     m_compact = compact;
     m_sources = sources;
 
@@ -546,7 +559,7 @@ private SyntheticBatchTest(boolean compact, List<DataSource> sources) throws IOE
         Style: %s
             """, new SimpleDateFormat("MMMMM dd, yyyy").format(new Date()), CliUtils.getVersion(),
         (compact ? "Compact" : "Full"),
-        sources.stream().map(DataSource::toString).collect(Collectors.joining(", "))
+        sources.stream().map(DataSourceType::toString).collect(Collectors.joining(", "))
 
     );
     Files.writeString(TestUtils.createTestFile(getClass(), "README.md"), readmeContent);
diff --git a/src/test/java/org/pharmgkb/pharmcat/ToxicGenesTest.java b/src/test/java/org/pharmgkb/pharmcat/ToxicGenesTest.java
index 2de616d49..1b4adbfae 100644
--- a/src/test/java/org/pharmgkb/pharmcat/ToxicGenesTest.java
+++ b/src/test/java/org/pharmgkb/pharmcat/ToxicGenesTest.java
@@ -15,6 +15,7 @@
 import org.pharmgkb.pharmcat.reporter.TextConstants;
 import org.pharmgkb.pharmcat.reporter.handlebars.ReportHelpers;
 import org.pharmgkb.pharmcat.reporter.model.DataSource;
+import org.pharmgkb.pharmcat.reporter.model.ObjectType;
 import org.pharmgkb.pharmcat.reporter.model.result.DrugReport;
 import org.pharmgkb.pharmcat.reporter.model.result.GeneReport;
 import org.pharmgkb.pharmcat.reporter.model.result.Genotype;
@@ -94,8 +95,8 @@ void cacna1sRef_ryr1Ref(TestInfo testInfo) throws Exception {
     testWrapper.testPrintCalls(DataSource.CPIC, "RYR1", expectedCalls);
 
     // each gene has its own annotation which means there should be 2 CPIC annotations matched, one for each gene
-    testWrapper.testMatchedAnnotations("desflurane", DataSource.CPIC, 1);
-    testWrapper.testNoMatchFromSource("desflurane", DataSource.DPWG);
+    testWrapper.testMatchedAnnotations("desflurane", DataSource.CPIC, ObjectType.GUIDELINE, 1);
+    testWrapper.testNoMatchFromSource("desflurane", DataSource.DPWG, ObjectType.GUIDELINE);
 
     Document document = readHtmlReport(vcfFile);
     htmlChecks(document, new ImmutableSortedMap.Builder<String, List<String>>(Ordering.natural())
@@ -346,11 +347,11 @@ void testNudt15Ref(TestInfo testInfo) throws Exception {
 
     testWrapper.testMatchedAnnotations("azathioprine", 2);
     testWrapper.testMatchedAnnotations("mercaptopurine", 2);
-    testWrapper.testAnyMatchFromSource("mercaptopurine", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("mercaptopurine", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("mercaptopurine", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("mercaptopurine", DataSource.DPWG, ObjectType.GUIDELINE);
     testWrapper.testMatchedAnnotations("thioguanine", 2);
-    testWrapper.testAnyMatchFromSource("thioguanine", DataSource.CPIC);
-    testWrapper.testAnyMatchFromSource("thioguanine", DataSource.DPWG);
+    testWrapper.testAnyMatchFromSource("thioguanine", DataSource.CPIC, ObjectType.GUIDELINE);
+    testWrapper.testAnyMatchFromSource("thioguanine", DataSource.DPWG, ObjectType.GUIDELINE);
   }
 
   @Test
@@ -366,7 +367,7 @@ void testNudt15S2(TestInfo testInfo) throws Exception {
     testWrapper.testPrintCpicCalls("NUDT15", "*1/*2");
     testWrapper.testRecommendedDiplotypes("NUDT15", "*1", "*2");
 
-    DrugReport azaReport = testWrapper.getContext().getDrugReport(DataSource.CPIC, "azathioprine");
+    DrugReport azaReport = testWrapper.getContext().getDrugReport(DataSource.CPIC, ObjectType.GUIDELINE, "azathioprine");
     assertNotNull(azaReport);
     GuidelineReport azaCpicGuideline = azaReport.getGuidelines().iterator().next();
     List<Genotype> genotypes = Genotype.makeGenotypes(azaCpicGuideline.getGeneReports());